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 Abstract 
 
Exploring the binding of corrin-based intermediates to enzymes of the 
cobalamin biosynthetic pathway  
 
Cobalamin, commonly known as vitamin B12, is the most complex small molecule 
created in nature. The biosynthesis is carried out in microorganisms and requires around 
thirty enzyme catalysed steps. Understanding its synthesis is of interest, as potentially more 
new analogues may be created. These would be non-toxic, water-soluble molecules, which 
are beginning to show promise as drug delivery systems in medical treatment.  
 
The thesis focuses on a selection of enzymes located halfway through the aerobic 
cobalamin biosynthetic pathway. This includes six canonical methyltransferases as well as 
CobK, CobH and CobB. The structures of CobK and CobH have recently been solved and 
show product trapping activity. This unusual behaviour of an enzyme binding its product 
tightly raises two main questions. Firstly, why do these enzymes hold on to their product, a 
feature which may potentially help or hinder the production of cobalamin biosynthesis, and 
secondly, how does the subsequent enzyme in the pathway obtain its substrate? 
 
To probe these questions a number of techniques have been explored. In Chapter 3, X-
ray crystallography is used to attempt to solve the structures of CobL and CobB. Chapter 4 
demonstrates the unusual product binding activity of CobK using UV-VIS spectroscopy, NMR 
and ITC. This work led on to the investigation of how CobL obtains its substrate which was 
studied using enzyme kinetics. The chapter concludes with the surprising discovery of an 
incorrect cobalamin intermediate binding out of turn in the pathway. This prompted an 
analysis of in silico docking data of the canonical methyltransferases in Chapter 5, to 
attempt to determine how the specificity of highly similar intermediates is coordinated and 
distinguished in enzymes with such similar architecture.    
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Chapter 1: Introduction 
 
1.1 What is cobalamin and how is it used in nature? 
Cobalamin, more commonly known as vitamin B12 is the most complex small molecule 
synthesised in nature, which typically requires around thirty biosynthetic enzymes1,2. Figure 1 shows 
the structure of this organometallic co-factor where cobalt is coordinated via  a 
dimethylbenzimidazole (DMB) base, four nitrogens and an upper axial ligand, in which the chemistry 
of this carbon-cobalt bond is essential and unique in the reactions it facilitates3,4. The ability of 
cobalamin to coordinate different upper axial ligands allows it to carry out a diverse range of 
reactions4. Despite being such a well-studied co-factor, ongoing research still shows there is a vast 
amount to continue learning about its reactivity and the functions of cobalamin containing proteins4. 
Regarding its own biosynthesis these include ongoing structure-function studies of cobalamin 
biosynthetic enzymes and the exploration of protein-protein interactions in what appear to be the 
formation of multiprotein complexes, which are explored in this thesis, as well as wider applications 
on prokaryotic physiology and how cobalamin is regulated and involved in cobalamin dependent 
pathways5.  
 15 
 
Figure 1: Shows the full structure of cobalamin where a cobalt ion is coordinated in an octahedral 
fashion via a dimethylbenzimidazole (DMB) base, four nitrogen atoms located in the corrin ring 
and an upper axial ligand labelled X. Alternative forms of cobalamin, where the upper axial ligand 
of cobalt, indicated by X can be substituted for a 5’-deoxyadenosyl-, methyl-, cyano- or hydroxy- 
chemical group. Adapted from Froese et al, 20196. 
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Vitamins and minerals are micronutrients and defined as a compound that a living organism 
requires but cannot synthesise itself in the required amount. Vitamins are different to minerals in 
that they are organic and can therefore be broken down by heat, air or acid, whereas minerals are 
inorganic and retain their chemical structures. The word vitamin was originally derived from the 
Latin ‘vita’, meaning vital, and the chemical functional group ‘amine’, resulting in the name vitamine. 
This therefore signified that vitamins were small organic amines found in nature which were vital for 
healthy (human) growth, metabolism, development and body function. However, the ‘e’ was later 
dropped when it was discovered this definition did not hold true, as not all vitamins turned out to be 
amines, resulting in vitamins being defined by their solubility and importance to living organisms7. 
The continued reassignment of organic molecules over time additionally led to the originally defined 
vitamins F-J being either reassigned or removed as they were no longer classified as vitamins. This 
explains why the numerical and alphabetical sequences no longer hold true in some classes of 
vitamins7. For example, vitamin B7, biotin, was originally called vitamin H. Figure 2 shows an 
overview of all the vitamins and their solubilities.  
 17 
 
Figure 2: An overview of the chemical structures of vitamins and their respective solubilities in 
water or fats. Image taken from www.compoundchem.com  
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The in-depth study of vitamins has always been difficult, due to their involvement in enzyme 
catalysis as co-factors. This has meant organisms only require them to be present in low quantities 
resulting in the use of classical techniques such as enzyme assays being difficult to use when 
monitoring their activity. As a consequence the study of intermediates involved in vitamin synthesis 
has proved difficult to investigate, as they are typically labile or controlled by negative feedback 
loops8. It is therefore not surprising in this case that the study of cobalamin has proved to be a 
challenging one, involving decades of research and it has been interesting to observe in the 
literature how advances and improvements in science have continued to deepen our understanding 
of cobalamin biosynthesis and its importance in nature9,10,11. In fact, the research of cobalamin has 
resulted in two Nobel prizes being awarded. The first Nobel prize was awarded to Minot and Murphy 
in 1934, for discovering that vitamin B12 cured pernicious anaemia12, and the second Nobel prize 
was awarded in 1964 to Dorothy Hodgkin for solving the structure of vitamin B12 using X-ray 
crystallography13.  
When investigating cobalamin metabolism and biosynthesis in nature there are different 
categories to consider; (i) organisms which do not synthesise or require cobalamin; (ii) organisms 
which synthesise cobalamin and require it and; (iii) organisms which require it but cannot synthesise 
it. There is no evidence, including from genome sequencing, to suggest that eukaryotes can 
synthesise cobalamin14. This means that humans fall into the third category, while other eukaryotes 
such as plants and fungi fall into the first category14,15. Interestingly about half of all algae also 
require cobalamin and differences in cobalamin availability and cobalamin independent metabolic 
pathways are presumed to have contributed to heterogenous occurrences of cobalamin-dependent 
enzymes in algae16.  
In fact, cobalamin dependence has resulted in varying symbiotic relationships. These include 
bacteria colonising the extracellular mucous layer of algae where photosynthetic products and 
bacterial cobalamin are exchanged 16. Caenorhabditis elegans fed with cobalamin producing bacteria 
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resulted in accelerated development and reduced mortality due to a change in gene expression 17,18, 
while legume plants contain cobalamin dependant bacteria and when grown under cobalamin 
deficient conditions resulted in an inhibition of growth, due to a lack of nitrogen fixation 19.  
As humans cannot synthesise cobalamin it is therefore classified as an essential vitamin in our 
diet. Despite having a gut flora which contains cobalamin producing microbes Degan et al, 2014 
argue that these would be unlikely to provide sufficient supplies of cobalamin exceeding their own 
demands16. This therefore means our cobalamin intake is obtained from our diet and typically 
includes animal products such as red meat, fish and dairy produce 20. In a similar fashion to 
prokaryotes our bodies have developed their own specific means to absorb and salvage cobalamin 
from our diets. This is summarised concisely in Figure 3. As humans ingest food containing 
cobalamin, which is typically present bound to cobalamin binding proteins, it is released when these 
are digested in the stomach. The three essential proteins involved in cobalamin binding and 
subsequent absorption are haptocorrin, intrinsic factor and transcobalamin. Haptocorrin is found in 
many bodily fluids such as saliva and bile where it serves to protect cobalamin during passage 
through the acidic environment in the stomach. This allows for the succeeding transfer of cobalamin 
to intrinsic factor, which can be absorbed via receptor mediated endocytosis in the ileum. As 
cobalamin enters the blood stream it binds to transcobalamin which is responsible for delivering 
cobalamin to cells, again via receptor mediated endocytosis, with the majority of cobalamin stored 
in the liver21.   
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Figure 3: Taken from Green et al, 2017 21. A) Shows how cobalamin is absorbed into the 
bloodsteam via the cobalamin binding proteins haptocorrin, intrinsic factor and transcobalamin. 
B) Shows how cobalamin is taken up by cells, from the bloodstram, via receptor mediated 
endocytosis and the essential reactions methycobalamin and adenosylcobalamin are involved in 
for the production of methionine and succinyl-CoA respectively.  
 
Cobalamin deficiency can arise in a number of ways including inadequate intake, inadequate 
bioavailability or malabsorption21. Green et al, 2017 provides a comprehensive summary of the 
different forms and reasons that cobalamin deficiency may arise due to disruption of cobalamin 
uptake and transport through the body21. Pernicious anaemia is the most well known outcome of   
cobalamin deficiency and is more typically seen in those living in affluent areas, where it develops as 
an autoimmune response, caused by a lack of intrinsic factor. Those living in low income countries 
are more likely to have a low intake of cobalamin due to a lack of cobalamin rich food of animal 
origin. Surprisingly a study by Yajnik et al, 2006 found that those living in slums with poorer hygiene 
in fact had a higher cobalamin intake than urban dwellers due to a higher exposure and ingestion of 
cobalamin containing microorganisms22.  
A B 
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Humans are able to use both adenosylcobalamin and methylcobalamin for vital cellular 
metabolism as summarised in Figure 3B. These include DNA, amino acid and fatty acid synthesis as 
well as in mitochondrial metabolism23,24. Methylcobalamin is essential for the methylation of the 
amino acid cysteine into methionine.  It is also involved in the formation of S-adenosylmethionine 
(SAM) from S-adenosylhomocysteine (SAH) which is an essential methyl donor for numerous cellular 
reactions including the production of the nucleotide thymine, neurotransmitters, proteins as well as 
epigenetic reactions such as the methylation of DNA, histones and other gene expression 
regulators21,24,25. Therefore, a lack of methylcobalamin can result in high levels of SAH, which leads to 
cellular stress and apoptosis. If thymine synthesis is prevented this leads to the incorrect 
incorporation of dUTP into DNA which has a large impact on areas of the body with high turnover 
such as the haematopoietic systems in bone marrow, resulting in anaemia from abnormally large 
blood cells. Adenosylcobalamin is involved in the formation of succinyl-CoA, an essential component 
of respiration in the mitochondria21.  
Overall cobalamin can be summarised as essential for the following three classes of reactions in 
nature:  
1) Methyl transfer reactions occur via methylcobalamin and typically are carried out by a 
methyl-cation transfer. This involves  a heterolytic cleavage of the carbon-cobalt bond, 
where the cobalt shuffles between Co(III) and Co(I)4. Examples include; methionine synthase 
and O-demethylases26–28. 
2) Isomerase reactions occur via adenosylcobalamin. This is by the formation of a highly 
reactive transient adenosyl radical by a homolytic cleavage of the carbon-cobalt bond4. The 
most notable example would be methylmalonyl-CoA mutase29,30. 
3) Reduction reactions via dehalogenation are unique in nature and have allowed 
microorganisms to live in unusual locations, as it allows them to use organohalides as the 
final electron acceptor in respiration4,31. This class of reaction has led to further study of 
catalysis as a means to minimise waste and disposal methods of organic halides which have 
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negative impacts on the environment and health4,32. Some examples include the enzymes 
CprA and haloalkane dehalogenases, which are involved in reductive dehalogenation of 
halogenated aromatic and aromatic hydrocarbons in microbes33–35. 
1.2 Applications of cobalamin-based molecules 
 
A very recent study by Lawrence et al, 2018 has described how they created fluorescent 
analogues of cobalamin which they were then able to detect in bacteria, worms and plants36. This 
was achieved by replacing a SAM molecule with an allyl analogue in the biosynthetic pathway, upon 
which a fluorescent tag could be attached. Through careful tailoring of subsequent biosynthetic 
enzymes after this step, including site directed mutagenesis to accommodate the allyl intermediate, 
an incomplete cobalamin analogue was produced. Bacteria could salvage this corrinoid compound 
and successfully convert it into fluorescent cobalamin for metabolism. Humans are unable to salvage 
incomplete corrinoids therefore making this a promising application for observing and targeting 
cobalamin dependent infections such as Tuberculosis. Another surprising finding of this study was 
demonstrating the uptake of cobalamin in plants, despite them having no dependence for it, 
showing that nutrient-enriched plants could be grown to help tackle cobalamin deficiency in some 
countries.  
Rapidly growing cells, such as cancer cells, have an increased demand for nutrients and 
vitamins37. This makes cobalamin an attractive therapeutic target as it is water soluble with no 
known toxicity and as it is an essential vitamin, it is therefore unlikely that mutations involved in 
uptake will arise. This has allowed radiolabelled 57Co and 111In forms of cobalamin to be used to 
image and locate tumours37–39. Waibel et al, 2008 went one step further to edit the radiolabelled 
cobalamin in such a way to minimise undesirable radio-accumulation in the kidneys. This was 
achieved by interrupting how it interacted specifically with transcobalamin II, while maintaining 
normal interaction with transcobalamin I, typically present in higher amounts in tumours37,40.  
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Lodowski et al, 2018 described the use of antivitamins, which are a class of cobalamin analogues 
gaining recent interest in several research areas, as their photo-properties offer opportunities to 
explore the chemistry and metabolism of vitamin B12 alongside further applications41. Examples of 
these include photocatalysis of iridium(III) B12 complexes for reductive dehalogenation reactions32, 
photolytic cleavage to permit drug-release of cob(III)alamins and ferric porphyrins42,43 and 
photopolymerisation of B-12-mediated hydrogels44.  
By studying the biosynthetic enzymes of cobalamin, not only a greater understanding of its 
synthesis can be gained, but also the biosynthetic pathway could be altered, using mutations, to 
allow the creation of new molecules based on cobalamin. The advantage of such molecules is that 
they would be non-toxic and water soluble. Such molecules have been shown to have applications in 
therapeutics such as trojan horse drug delivery systems and imaging or various light inducing 
applications, all offering exciting potentials in many aspects of society.  
1.3 How cobalamin is synthesised 
 
Cobalamin is unique to the B series of vitamins as it is in a family of molecules known as 
tetrapyrroles, in which four pyrrole groups are joined together to form a conjugated carbon ring. The 
most well-known examples of these molecules are haem and chlorophyll. These molecules contain a 
planar carbon ring which is able to chelate a metal ion in the centre, via the nitrogen atom from 
each of the four pyrrole groups which forms the ring. Typically, this conjugated tetrapyrrole ring 
contains twenty carbon atoms, except in the case of cobalamin where it has a contracted ring of 
nineteen carbon atoms. Different tetrapyrroles chelate different metals and in the case of cobalamin 
the metal is cobalt, which can change its oxidation state between +1 to +3 and is essential for the 
reactions it helps catalyse. Tetrapyrroles are all derived from a precursor known as 
uroporphyrinogen III, highlighted in Figure 4, which serves as a key branch point in the biosynthesis 
of these various tetrapyrrole molecules. 
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Figure 4: Tetrapyrrole derivatives which can be formed from the precursor uroporphyrinogen III. 
Figure adapted from Raux, et al, 2000 1. 
 
The structure of cobalamin can be split into three parts based on how the cobalt is coordinated 
via its octahedral geometry. The lower axial ligand is coordinated via a nitrogen on a ribonucleotide 
dimethylbenzimidazole group which loops down from the tetrapyrrole ring at carbon number 17 
(C17). The four planar co-ordinations result from the afore mentioned pyrrole nitrogen atoms in the 
tetrapyrrole ring. Finally, the upper axial coordination varies depending on the type of cobalamin. 
Two naturally occurring biological forms exist where the upper coordination is either via a methyl- or 
adenosyl- group, named methylcobalamin or adenosylcobalamin respectively15. A synthetic 
cyanocobalamin and hydroxycobalamin also exists where the upper axial ligands are cyanide or 
hydroxy- groups respectively, in which the cyano- form is used in vitamin supplements. The structure 
of cobalamin is summarised in Figure 1 where the X can be substituted for the various upper axial 
ligands.  
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The complete de novo biosynthesis of cobalamin typically involves around thirty enzymes and 
can be carried out either anaerobically or aerobically1,2. The enzymes involved in aerobic synthesis 
are typically coined Cob proteins, while those involved in the anaerobic pathway are coined Cbi.  
Interestingly these two pathways are remarkably similar with the stepwise chemical modifications 
occurring in the same order, due to genetically and structurally similar proteins45. The only major 
difference between the two pathways, excluding oxygen usage, is that the cobalt is inserted into the 
corrin ring early in anaerobic synthesis and later during the aerobic pathway. The stepwise 
modifications of cobalamin biosynthesis are summarised in Figure 5. This allowed a wider study of 
how the cobalamin biosynthetic pathway proceeds and in some cases has provided excellent 
structural homology for proteins when one side of the pathway has been unknown. Interestingly 
Thermes et al, 1996 attempted using cobalt containing intermediates from the anaerobic pathway 
on the aerobic enzymes but found cobalamin biosynthesis was not possible by interchanging these 
pathways46. Alternatively a more cost-effective method for bacteria and archaea is to salvage 
cobalamin from corrinoid molecules in their local environment and transform these into 
adenosylcobalamin47. This is mediated by the Btu proteins, where BtuB is an essential transport 
protein and controlled by a cobalamin riboswitch16,48,49.  
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Figure 5: A) A comprehensive summary of how microorganisms synthesise or salvage cobalamin. 
The branch points for other tetrapyrrole intermediates are also shown as well as the alternative 
enzymes involved in the aerobic or anaerobic pathways. Figure taken from Fang et al, 201747 
B) Highlights more closely the similarities and differences of the aerobic and anaerobic synthesis 
of cobalamin, taken from Warren et al, 20022. The chemical changes are summarised down the 
middle while the substrates and gene names flow down the outer edges of the two columns. The 
sections highlighted in grey signify major genetic differences between the two pathways.  
B 
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To understand the naming conventions which describe the enzymatic reaction steps of the 
cobalamin biosynthetic pathway, it is important to know how the tetrapyrrole ring is labelled. The 
four pyrrole rings are assigned uppercase letters from A-D, which are assigned in a clockwise fashion 
as shown in Figure 6A. The carbon atoms of the tetrapyrrole ring are subsequently numbered from 
one to twenty where the numbering begins and ends at the first pyrrole group A, Figure 6B. Finally, 
the outer ethanoic and propanoic sidechains are labelled using lowercase letters a-g in a clockwise 
fashion, again beginning with pyrrole A, Figure 6C, where one of the side chains is ignored between 
d and e, as it is removed during cobalamin biosynthesis. 
 
 
Figure 6: A guide on how to understand the naming convention used when describing the 
intermediates of cobalamin synthesis. A) Shows how the pyrrole rings are labelled in a clockwise 
fashion. B) Shows how the carbon atoms are named in a clockwise fashion. C) Shows how the 
carboxylic acid side chains are labelled in a clockwise fashion.  
 
 Cobalamin contains a nineteen membered heterocyclic carbon ring known as a corrin ring, 
Figure 1. This distinguishes corrin based molecules from porphyrins which are twenty membered 
heterocyclic carbon rings, found in all other tetrapyrrole based molecules1. The name of the 
intermediate uroporphyrinogen III contains ‘uro-‘ which comes from the Greek meaning ‘combined’ 
indicating a combined porphyrin structure derived from pyrrole groups. The roman numeral ‘III’ 
identifies the third isomeric form, based on how the carboxyl side chains are arranged, with the third 
form found exclusively in nature11,50. Subsequently many of the cobalamin intermediates are called 
precorrin-x. This refers to the intermediates of corrin ring biosynthesis between uroporphyrinogen 
A B C 
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III and cobyrinic acid, with the x indicating the number of methyl groups which have been attached5. 
Finally, in the aerobic pathway a name change to hydrogenobyrinic acid occurs after precorrin-8, 
because it is the hydrogen (cobalt-free) form of cobyrinic acid from the equivalent stage of the 
anaerobic pathway, signifying no further methylation reactions take place51. 
For the purpose of this project the work involved on biosynthesis focuses only on the aerobic 
pathway. The biosynthesis of cobalamin can be broken down into three sections based on the 
enzymes involved in relation to the project; (i) the synthesis of the precursor uroporphyrinogen III 
via Hem proteins52; (ii) the Cob enzymes used in the laboratory for the synthesis of cobalamin 
intermediates up to hydrogenobyrinic acid-a,c-diamide and (iii) the remaining Cob proteins involved 
in cobalamin synthesis (which is beyond the scope of this project).  
The initial genes involved in the synthesis of uroporphyrinogen III produce the Hem proteins. 
The initial precursor for any tetrapyrrole is 5-aminolevulinic acid (ALA). There are two separate 
pathways, which vary in different organisms, coined the C4 and C5 pathway based on the number of 
carbons present in the substrate for ALA synthesis. Each pathway contains a HemA protein and 
these are briefly summarised in the top right corner of Figure 5A. Once ALA has been produced the 
protein HemB subsequently combines two molecules of ALA to form a pyrrole molecule. The 
remaining Hem proteins HemC and HemD then combine the four pyrrole groups together and close 
the tetrapyrrole ring to form uroporphyrinogen III, as shown in Figure 7. The precursor 
uroporphyrinogen III acts as a major branch point for other tetrapyrrole derivatives as shown in the 
top right corner Figure 5A. Despite Escherichia coli (E. coli) being unable to produce cobalamin, it 
could be used in the laboratory for this project by hijacking the existing Hem genes involved in 
siroheme synthesis and subsequently introducing the Cob genes on a plasmid vector, which would 
produce the enzyme to act upon uroporphyrinogen III. 
 
 30 
 
 
Figure 7: The initial steps involved in the formation of cobalamin in which uroporphyrinogen III, 
the precursor for tetrapyrrole derivatives, is formed from 5-aminolevulinic acid via the enzymes 
HemB, HemC and HemD. 
 
 
The second part of the cobalamin synthesis focuses on the initial Cob proteins and covers the 
main enzymes which are the focus of this project. The stepwise enzymatic reactions of different 
cobalamin intermediates are shown in Figure 8. These include contraction of the tetrapyrrole carbon 
ring, via the removal of carbon-20, and a number of smaller modifications, including several 
methylations via S-adenosylmethionine (SAM). These eight methylation reactions to the corrin ring 
are carried out by six canonical methyltransferases and one non-canonical methyltransferase, upon 
which the precorrin intermediates are named and identified50. For example, precorrin-4 indicates 
the addition of four methyl-groups, while precorrin-8 indicates eight methyl-group additions. In 
some cases, the precorrin intermediate ends in the letter A or B, as in the case of precorrin-3 and 
precorrin-6, which indicates no additional methyl-groups have been added but rather signify an 
alternative reaction has taken place.  
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Figure 8: The step by step synthesis of cobalamin intermediates from uroporphyrinogen III to 
hydrogenobyrinic acid-a,c-diamide. Figure adapted from Deery et al53. 
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The final section of the cobalamin biosynthetic pathway includes the insertion of cobalt into the 
corrin ring and the synthesis and addition of the lower and upper axial coordinated ligands. This 
involves connecting the ribonucleotide dimethylbenzimidazole group via a linker arm on C17 and 
attaching a methyl- or adenosyl- group above depending on the final form of cobalamin produced, 
Figure 9.   
 
 
Figure 9: The final Cob enzymes inovoled in the biosynthesis of cobalamin biosynthesis that 
follows on from hydrogenobyrinic acid-a,c-diamide. These enzymes include the insertion of cobalt 
into the corrin ring, the synthesis and attachment of the dimethylbenzimidazole group via a linker 
arm on C17 and the attachment of an upper axial ligand labelled X, which can be a methyl- or 
adenosyl- group.  
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1.4 Enzymes of interest 
 
1.4.1 Canonical methyltransferases  
The biosynthesis of cobalamin requires eight methylation reactions to the corrin ring. The order 
of these methylations was discovered to be C2>C7>C20>C17>C12>C1>C15>C5 using pulse-labelling 
techniques52. Once molecular cloning became a more established technique in the nineteen nineties, 
this allowed the specific enzymes to be assigned including the option to overproduce the precorrin 
intermediates, which had been initially difficult to isolate due to their instability or low 
concentrations2,52.  These are summarised in Table 1 and include the enzymes CobA, CobI, CobJ, 
CobM and CobF. CobL is also included but described in more depth below in section 1.4.3.  
 
Aerobic methyltransferase 
(PDB code) 
Addition of 
methyl-group to 
Ancillary reaction 
catalysed 
Anaerobic equivalent 
(PDB code) 
CobA  
(not solved) 
C2 & C7 None SUMT (1S4D) 
CysG (1PJQ) 
CobI 
(not solved) 
C20 None CbiL  
(2QBU) 
CobJ 
(3NUT) 
C17 Ring contraction CbiH  
(not solved) 
CobM 
(3NDC) 
C11 None CbiF  
(1CBF) 
CobF 
(3ND1) 
C1 C1 Acetic acid 
extrusion 
CbiD  
(1SR8) 
CobLc 
(3NjR) 
C15 Decarboxylation of 
C12 
CbiT  
(2YXD) 
CobLN 
(not solved) 
C5 None  CbiE  
(2BB3) 
Full length CobL 
(not solved) 
C5 & C15 Decarboxylation of 
C12 
CbiET 
(to be published) 
Table 1: A summary of the aerobic methyltransferases involved in cobalamin biosynthesis, the 
reaction(s) they carry out and anaerobic equivalents. If a structure has been solved the Protein 
Data Bank codes are in brackets. 
 
 
All cobalamin methyltransferases are canonical (have the same fold) except CobLc which is a 
non-canonical methyltransferase and does not fit into the classification of a Class III 
methyltransferase like the rest. The Class III canonical methyltransferases are defined by a sequence 
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motif GXGXG located after the first b-strand and an active site located in a cleft between two aba 
domains, in which each contains five b-strands and are parallel in the first and a mixture of parallel 
and antiparallel in the second, Figure 1054. In the aerobic pathway all of the methyltransferases are 
canonical with similar architecture, except one. CobL has both a canonical (N-terminus) and non-
canonical (C-terminus) methyltransferase domain, where each adds one methyl group during the 
cobalamin biosynthetic pathway.  
The first methyltransferase in the pathway CobA, adds two methyl-groups using the same 
canonical domain to catalyse both methylations to uroporphyrinogen III at C2 and C7 to form 
precorrin-2 (PC2)55. CobI is the second methyltransferase and carries out the third methylation at 
C20, forming precorrin-3A (PC3A)56. This is followed by CobG, which is not a methyltransferase and 
unique in the aerobic pathway because it requires oxygen to oxidise PC3A into precorrin-3B57. This 
oxidation is the set up for ring contraction and removal of C20, which is an ancillary reaction carried 
out after CobJ has methylated at C17, where both of these reactions result in the formation of 
precorrin-4 (PC4)57. The penultimate methyltransferase described in this section is CobM, which 
methylates PC4 at C11 to form precorrin-5 (PC5)58. Finally, CobF is the second methyltransferase of 
three to carry out an additional ancillary reaction, where the corrin ring decoration at C1 is removed 
as acetic acid, which then allows the subsequent methylation of C1 to form precorrin-6A (PC6A)59,60. 
The remaining Cob enzymes in this second phase of cobalamin biosynthesis are discussed below 
in more depth, including the final methyltransferase CobL. The double methylation action of CobA 
and CobL therefore allows the overall attachment of eight methyl-groups via only six 
methyltransferase enzymes. The order of these methylation reactions is important for the 
biochemical pathway. For example, the failure of CobI to act on C20 does not lead to successful ring 
contraction and the C11 methylation of CobM is vital for the isomerase action of CobH only three 
steps further along in the reaction pathway56. 
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Figure 10: A) Shows a summary of the secondary structure components of Class III 
methyltransferases. B) Shows a simplified representation of the tertiary structure which defines 
Class III methyltransferases via two aba domains in which the first domains contain five parallel 
b-strands. Figure adapted from Schubert et al, 2003 54. C) Crystal structure of CobJ monomer in 
green (3NUT.pdb) with S-adenosylhomocysteine (SAH) bound in purple to signify the location of 
the active site. D) Three methyltransferase monomers overlapped: CobJ in green 3NUT.pdb), 
CobM in yellow (3NDC.pdb) and CobF in blue (3ND1.pdb). Figures C and D where made via PyMOL, 
the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC.  
 
 
  
A B 
C 
D 
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1.4.2 CobK 
Of the four Cob proteins routinely synthesised and purified in the laboratory for this project, 
CobK is the first in the section of the biosynthetic pathway before cobalt is inserted. Interestingly 
this enzyme was accidently discovered via the unexpected formation of precorrin-6B, when 
nicotinamide adenine dinucleotide phosphate (NADPH) was omitted in a routine conversion of 
uroporphyrinogen III to HBA59. CobK converts precorrin-6A (PC6A) into precorrin-6B (PC6B) via a 
reduction reaction of the carbon-18/19 double bond, in the presence of NADPH 60,61. The numbering 
of this precorrin intermediate does not change as the tetrapyrrole still has six methyl groups 
attached and therefore two forms of precorrin-6 exist and are differentiated using A and B in the 
order they are respectively formed in the synthetic pathway. The crystal structure of this protein 
was only recently solved by the Pickersgill group and published in the Protein Data Bank (PDB)62. 
Three structures were solved; the native form and two ligand bound structures where one contained 
NADPH and the other contained both NADPH and the product precorrin-6B, Figure 11A. The enzyme 
has aroused interest as the crystal structure indicates extremely tight binding of its product via the 
closure of a flexible loop region over the active site. This flexible loop region was not present in the 
apoenzyme (5C4R.pdb) and holoenzyme structure with only NADPH bound (5C4N.pdb) but was 
observed closed over the active site in the structure with both NADPH and PC6B bound (5N0G.pdb). 
This highlights the flexibility of this post b2 loop region which is only detected clamping over the 
precorrin-6B ligand.  
The protein structure of CobK is monomeric and can be described as two Rossmann fold 
domains, typically observed for nucleotide binding cofactors such as NADP+ where each fold 
represents half of the protein63. Unusually these folds exchange strands between one another and 
are connected via a hinge like region in the middle in which the active site is located62. Upon 
substrate binding a flexible loop region closes over the active site pulling the two halves together, 
facilitated predominantly via conserved basic residues such as arginine and lysine. The NADPH/PC6B 
crystal structure shows complete encasing of the precorrin substrate/product via many binding 
 37 
interactions to the ethanoic and propanoic groups of the tetrapyrrole ring, Figure 11B. The NADPH is 
located adjacent to the precorrin-6B but is more exposed upon binding, compared to the more 
complete encapsulation of precorrin-6B, as shown in Figure 11C.  
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Figure 11: A) Shows a structural comparison of CobK holoenzyme (5C4R.pdb), apoenzyme 
(5C4N.pdb) and ligand bound form (4X7G.pbd),N.B. the PC6B was in fact methylated at C5, which 
is discussed in more depth later in chapter 4. B) Shows a view of the active site, where the b2/b3 
loop is again highlighted in pink and key binding residues for loop closure and ligand docking are 
labelled with PC6B coloured in green and NADPH coloured purple. C) Shows a surface view of 
CobK in grey where the b2/b3 loop is highlighted in pink. This view shows how encapsulated PC6B 
ligand (green) is upon binding and when rotated around the active site only NADPH (purple)  and a 
small portion of PC6B are exposed. Figures made via PyMOL, the PyMOL Molecular Grapics 
System, Version 2.0 Schrodinger, LLC. 
  
B 
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1.4.3 CobL 
CobL is the next enzyme in the cobalamin biosynthetic pathway after CobK. It is responsible for 
the conversion of PC6B into precorrin-8 (PC8), via two methylations at carbon five (C5) and carbon 
fifteen (C15) using s-adenosylmethionine (SAM) and a decarboxylation at carbon twelve (C12)64. 
Currently only the crystal structure of the C-terminal domain (CobLc) has been solved (PDB-3NJR)53. 
The C-terminus is responsible for the first modification where the decarboxylation of C12 acts in 
tandem with the methylation, as proposed in Figure 12. This produces precorrin-7 (PC7), which is 
subsequently methylated at C-5 in a second active site located in the N-terminus (CobLN).  
The crystal structure of CobLc shows that it forms a tetramer, by way of the formation of a 
central b-barrel via an extended b-hairpin from each monomer53.  The original crystal structure 
shows a dimer in the crystal unit cell, formed via the b-hairpin, but upon generating the crystal 
symmetry and protein packing in the crystal the tetramer becomes apparent, Figure 13. A 
remarkable structural comparison of CobLc with its anaerobic equivalent CbiT  is demonstrated in  
Figure 14, highlighting the high degree of structural similarity between these non-canonical 
methyltransferases65.  
The anaerobic equivalent of CobL consists of the proteins CbiE and CbiT, which in some cases 
exists as a single protein CbiET, which is thought to have occurred via a gene fusion65. Individually 
both CbiE and CbiT have had their structures solved (PDB 1KXZ and 2BB3 respectively)65. CbiT shows 
a very strong structural similarity with CobLc, Figure 14, while CbiE is thought to be an appropriate 
structural analogue to the unsolved N-terminus of CobL (CobLN), as it carries out the same reaction 
of a C5 methylation. Of the methyltransferase structures solved they indicate much weaker binding 
affinity for tetrapyrrole binding, whereas the binding of SAM or unmethylated form S-
adenosylhomocysteine (SAH) appears to be much more buried into the binding clefts. A structural 
comparison of the N- and C-termini of an unpublished CbiET structure is demonstrated in Figure 15. 
This highlights the similarity of the N-terminus to CobJ, a canonical methyltransferase in the aerobic 
pathway, and the C-terminus to CobLC a non-canonical methyltransferase of the aerobic pathway.   
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Figure 12: Proposed sequential mechanism of CobL, where the C-terminus first methylates C15 via 
the decarboxylation of C12. This is followed by the methylation of C5 via the N-terminal active 
site. Figure taken from Deery et al, 2012 53.  
 
 
 
Figure 13: Shows how CobLc monomers assemble to form a dimer or dimers. SAH is coloured in 
purple and signifies the location of the active site. Each monomer has a large b-hairpin present 
which come together to form a central b-barrel upon tetramer formation. Figure made via PyMOL, 
the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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Figure 14: A structural comparison of CobLc monomer in green (3NJR.pdb) with the anaerobic 
equivalent CbiT monomer in yellow (2YXD.pdb), which show a large similarity in overall tertiary 
structure. Figure made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, 
LLC. 
 
 
 
 
 
 
Figure 15: A structural comparison of the N- and C-termini of CbiET (unpublished) with CobJ 
(3NUT.pdb), a canonical methyltransferase, as described in section 1.4.1 which closely mirrors the 
N-terminus of CbiET (or CbiE) and also CobLc (3NJR.pdb) which closely mirrors the C-terminus of 
CbiET (or CbiT). S-adenosylhomocysteine (SAH) is present in CbiET and coloured in purple, 
signifying the location of the two active sites present in the enzyme. Figure made via PyMOL, the 
PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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CobL is believed to be structurally similar to CbiET, which forms a homo-tetramer, via a 
dimerisation of dimers65. Two CbiET monomers dimerise in a longitudinal fashion along the full 
length of the CbiE portion of the protein. This dimer then dimerises laterally via the CbiT portion of 
the protein where each individual monomer features two long b-strand regions which come 
together to form a b-barrel holding the tetramer together, where this final double dimerisation is 
identical to CobLc in Figure 13. There does appear to be a groove between the active sites of the C- 
and N-terminals, as highlighted in red in Figure 16, which may facilitate the progression of the PC7 
into the second active site without loss of substrate, acting as a form of substrate channelling. This 
groove is purely speculative when looking at CbiET in surface view, however it is lined with charged 
residues such as arginine, lysine, aspartic acid and glutamic acid which would interact well with the 
carboxylic acid side chains of PC7 between transfer. 
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Figure 16: A structure of the unpublished CbiET tetramer. Each chain is highlighted in a different 
colour with SAH and cobalt-precorrin-6B both highlighted in purple, to indicate the locations of 
the active sites. Below is a surface view of the CbiET dimer in blue and green in which a groove 
highlighted in red can be observed between the active sites of the N- and C-termini of separate 
protein chains. Figure made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 
Schrodinger, LLC. 
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1.4.4 CobH 
CobH is the third enzyme of interest in the biosynthetic pathway, following on from CobL. In a 
similar fashion to CobK it has aroused interest due to unusual product binding. CobH catalyses the 
isomeric rearrangement of precorrin-8 into hydrogenobyrinic acid (HBA), by moving the methyl-
group located at C11 to C12 via a sigmatropic rearrangement reaction66,67. Figure 17A shows a 
proposed mechanism for CobH via a catalytic histidine residue. This reaction causes a highly visible 
colour change from yellow to pink/red of the cobalamin intermediate.  
CobH is a homodimer where the two active sites are formed between the two monomers. The 
crystal structures have been solved (PDB 1I1H and 1F2V)67, where again the structure supports 
product binding. Tight binding is a result of the complete burial of ligand and numerous binding 
interactions, via basic residues, such as charged arginine or uncharged polar groups such as serine, 
asparagine and glutamine, Figure 17B.  
To support the observed product binding activity Thibaut et al, 1992 also observed that CobH 
had an extremely slow catalytic turnover with a Kcat of 5.1h-1 which corresponded to a Vmax of          
230nmolh-1mg-1. They took this one step further and showed that when CobH is in the presence of 
HBA it is inhibited through competitive means. This is not surprising given CobH is a mutase and 
simply rearranges the substrate into a slightly altered isomeric form. An interesting side study from 
this paper found that HBA was able to inhibit the production of the anaerobic equivalent cobyrinic 
acid, whereas hydrogenobyrinic acid-a,c-diamide produced by the subsequent enzyme CobB does 
not, highlighting that the a- and c- chains must play a role in dictating specificity in CobH binding. 
The protein face around the active sites appears to have a rather flat edge, when viewed in surface 
mode, which may provide a protein-protein interaction site for assisting in correctly delivering PC8 
or removal of HBA. 
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Figure 17: A) Proposed mechanism taken from Shipman et al,2001 67 showing the simatropic 
rearrangement involved for the formation of HBA via a catalytic histidine residue. B) Shows how 
CobH (4FDV.pdb) dimer formation comes about, with HBA coloured in purple, and includes a close 
up of the active site, to highlight interacting binding residues and a surface view to show almost 
complete burial of HBA. Figure B made via PyMOL, the PyMOL Molecular Grapics System, Version 
2.0 Schrodinger, LLC. 
A 
B 
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1.4.5 CobB 
CobB is the final enzyme of interest in this study and catalyses the reaction after CobH, where 
hydrogenobyrinic acid is amidated to hydrogenobyrinic acid-a,c-diamide (HBAD). The di-amidation 
takes place on two of the seven carboxyl groups, designated a and c on the porphyrin ring 51. CobB 
currently has not had its crystal structure solved. Galperin and Grishin68 carried out an in-depth 
sequence analysis of CobB and concluded that it belongs to a family of enzymes known as class I 
glutamine-dependent amidotransferases. This class of enzymes typically have a low sequence 
identity however they do exhibit a strong structural conservation68,69,70. These enzymes contain a 
glutamine binding domain and an ATP binding domain. Class I glutamine-dependent 
amidotransferases are identified via their catalytic triad consisting of cysteine, histidine and glutamic 
acid, which are required for glutamine binding. The glutamic acid and histidine residues assist in the 
activation of the cysteine thiol, which cleaves the amine group from the glutamine substrate71. 
Surprisingly CobB lacks the glutamic acid residue of the catalytic triad, however this is thought to be 
the least important of the three catalytic residues70. ATP binding occurs in the ATP binding domain 
which can be typically defined by the well-defined P-loop fold72. The P-loop contains two conserved 
sequence motifs, the Walker A motif which is responsible for positioning the triphosphate, which 
typically has the pattern GXXXXGK, and the Walker B motif which is normally an aspartate (or 
glutamate) residue involved in the binding of a water-bridged magnesium ion73,74. 
The mechanism of action in class I amidotransferases occurs through a coupled mechanism 
between the separate active sites. The glutaminase activity only occurs when all substrates are 
bound, thus avoiding any wasteful hydrolysis and loss of substrates73,75. In CobB the substrate HBA is 
phosphorylated via ATP twice where it has been shown that the carboxyl chain assigned c is 
amidated before the carboxyl chain assigned a on the corrin ring51.  The amine group is donated via 
glutamine in the form of ammonia, which then travels through an intramolecular tunnel. This avoids 
protonation into ammonium, where it can then amidate the substrate via nucleophilic attack76. 
Figure 18 shows the mechanism of how class I glutamine-dependent amidotransferases bind 
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glutamine and how a basic residue, typically histidine activates the thiol group of the catalytic 
cysteine. Thereafter the cleaved ammonia is transferred to a separate site upon which it amidates a 
separate substrate via an SN1 reaction76,77.  
 
 
 
 
Figure 18: A) Shows the mechanism of action of the glutamine binding domain of CobB, where it 
can be seen that an activated cysteine residue carries out a nucleophilic attack to cleave the amine 
group of glutamine. Figure taken from Massiere et al, 1995 70. B) Shows the reaction sequence of 
the ATP binding domain of CobB, where ATP first phosphorylates the C7 c-chain of HBA followed 
by a nucleophilic substitution by ammonia. Figure taken from Fresquet et al, 2004 78.  
  
A 
B 
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Many amidotransferases have been shown to contain molecular tunnels, typically ranging 
between 20-30Å, which serve to protect intermediates, enhance catalysis or reduce transient 
time77,79–81. Figure 19 shows varying representations of CobB. Figure 19B Is the crystal structure of 
CTP synthase, which carries out the regulation of pyrimidine levels by converting UTP to CTP via an 
amidation reaction82. CTP synthase is a good comparison as it is a full-length protein containing both 
a class I glutamine amidotransferase domain and an ATP binding domain required for CTP 
production. Other protein models include glutamate synthase, GMP synthetase, MinD and 
dethiobiotin synthetase to name a few, but these only contain one of the domains found in 
CobB70,71,73,83,84. Finally, Figure 19C shows a predicted model of the ATP binding domain of CobB by 
Galperin and Grishin, 200068. 
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Figure 19: A) Shows a simplified model of CobB showing the glutamine and ATP binding domains, 
created using Biorender.com. B) Shows CTP synthase (5TKV.pdb) with the substrates glutamine 
and CTP coloured in purple. CTP is associated with a Mg ion (green sphere). The ATP domain also 
contains two sulphate ions which is most likely where ATP binds. C) Shows a computational model 
of the ATP binding domain taken from Galperin and Grishin, 200068. Figure B made via PyMOL, the 
PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
 
A 
B 
C 
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The anaerobic equivalent of CobB is CbiA, which has had an in-depth study on it carried out by 
Fresquet et al, 2004 78 who summarised that CbiA acts as a monomer, whereas CobB is a dimer. 
Unsurprisingly their study of CbiA found it has a 500-fold higher affinity for its substrate cobyrinic 
acid, than the aerobic equivalent substrate HBA from the aerobic pathway. They also demonstated 
that ammonia can be substituted as a nitrogen source which was also observed originally by 
Debussche et al 199051. However, Fresquet et al, 200478 demonstated that glutamine hydrolysis can 
occur in the absence of other substrates but is enhanced in the presence of ATP or cobyrinic acid. 
This is assumed to be coordinated by a conformational change that is transmitted allosterically upon 
substrate binding. Both active sites can act independently either phosphorylating cobyrinic acid or 
glutamine cleavage but CbiA works best when all active sites are occupied. Surprisingly even at 
saturating concentrations it was found that these two active sites were not completely coupled to 
each other, with the rate of glutamine hydrolysis being around eight times faster than ADP 
production. However, Fresquet et al, 2004 were unable to explain how the sequential order of the 
amidations is co-ordinated, given the cobyrinic acid needs to leave the active site and re-binds after 
rotating.  
 
1.5 Purpose of thesis 
The biosynthesis of cobalamin has been studied for decades. The recent crystal structure of 
CobK62 solved in the Pickersgill group and the enzyme trap study53 have prompted the idea of 
product binding activity in both of the enzymes CobK and CobH. This activity raises questions such 
as: (i) Does this activity help or hinder the pathway? (ii) How are the products released? (iii) How is 
selectivity for such similar substrates brought about?  
With a particular focus on looking at how the subsequent enzyme in the pathway receives its 
substrate, an understanding of this unusual product binding activity may help to further clarify some 
of the complexity and coordination involved in the biosynthesis of cobalamin. Within this thesis a 
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number of approaches are described that have been used to attempt to probe product trapping 
activity of cobalamin biosynthetic enzymes further. In Chapter 3, the individual protein purifications 
for X-ray crystallography are described for CobL, CobB and co-crystallography attempts of the 
enzyme pairs CobK/L and CobH/B. In Chapter 4, product binding activity of PC6B to CobK is 
demonstrated using UV spectroscopy, isothermal calorimetry (ITC) and nuclear magnetic resonance 
(NMR) and concludes with techniques including X-ray crystallography and fluorescence spectroscopy 
which show incorrect cobalamin intermediates binding to CobK. This prompted an in-depth analysis 
of the canonical methyltransferase structures in Chapter 5, where their structures are described and 
ligand docking is explored to try and elucidate how specific precorrin binding is brought about. To 
probe these research questions further the main aims of the project were: 
 
 
1. To solve the structures of full length CobL and CobB using crystallography to provide 
further insights on how these enzymes obtain their substrates from the product binding 
enzymes CobK and CobH. 
 
2. To further explore the product binding activity and release of PC6B to CobK so as to 
determine why CobK may do this and how CobL, the subsequent enzyme in the 
pathway, obtains its substrate. 
 
 
3. To provide a possible explanation into how the stereo-specificity of the cobalamin 
biosynthetic enzymes are able to differentiate between different cobalamin 
intermediates, with a particular focus on the canonical methyltransferases, due to a 
large amount of structural data available on these enzymes.  
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Chapter 2: Materials and Methods 
 
2.1 Chemicals 
Unless otherwise stated all chemicals and reagents were purchased from Sigma-Aldrich, which is 
now Merck. Cobalamin intermediates were made in the laboratory as described in section 2.3.4. 
2.2 Genes 
The five main proteins of interest produced in the laboratory for this project were CobK, CobL 
(full length), CobLc (the C-terminal domain of CobL), CobH and CobB. These enzymes are present in 
the aerobic production of cobalamin and listed in the sequential order required for cobalamin 
biosynthesis. The gene sequences used were all sourced from Rhodobacter capsulatus.   
For the methyltransferase sequence review in Chapter 5, sequences came from proteins that 
already have known structures and are available in the Protein Data Bank. A summary of all the 
protein sequences used in this project are listed in Table 2, alongside the protein data bank codes 
used for structural studies. 
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Protein Organism PDB Code 
CobA Rhodobacter capsulatus - 
CysG Salmonella typhimurium 1PJQ 
SUMT Sinorhizobium 1S4D 
CobI Rhodobacter capsulatus - 
CbiL Methanothermobacter 
thermautotrophicus 
2QBU 
CobJ Rhodobacter capsulatus 3NUT 
CbiH Bacillis megaterium - 
CobM Rhodobacter capsulatus 3NDC 
CbiF Bacillis megaterium 1CBF 
CobF Rhodobacter capsulatus 3ND1 
CbiD Archaeoglobus fulgidus 1SR8 
CobK Rhodobacter capsulatus 4X7G 
CobL 
(C-terminus) 
Rhodobacter capsulatus 3NJR 
CbiE Archaeoglobus fulgidus 2BB3 
CbiT Methanothermobacter 
thermautotrophicus 
1L3I 
CobH Rhodobacter capsulatus 4FDV 
CobB Rhodobacter capsulatus - 
Table 2: A summary of all the cobalamin biosynthetic proteins used in this project, along with the 
Protein Data Bank code if they have had their structure solved. 
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2.3 Microbiology techniques 
 
2.3.1 Media for microbial growth 
Different media and antibiotics were used throughout the project and their compositions are 
described in Table 3. 
Chemical  Chemical components  Chemical  Chemical components 
 
 
LB media 
 
 
10g/L Trypton 
5g/L Yeast Extract 
5g/L NaCl 
Autoclaved 
  
 
 
100x Stock trace 
elements 
(200ml) 
1g EDTA 
166mg FeCl3.6H2O 
3mg ZnCl2 
3mg CuCl2.2H2O 
2mg H3BO3 
2mg CoCl2.6H2O 
0.32mg MnCl2.6H2O 
Adjusted pH to 7.5 with NaOH 
Added dH2O to 200ml 
 
LB Agar 
LB media 
15g/L Agar 
Autoclaved 
 Chloramphenicol 
stock 
34mg/ml in ethanol 
Filter sterilised  
Stored at -200C 
 
2TY media 
16g/L Trypton 
10g/L Yeast Extract 
5g/L Sodium Chloride 
Autoclaved 
  
Ampicillin stock 
100mg/ml in dH2O 
Filter sterilised  
Stored at -200C 
 
 
 
 
Minimal Media 
(1L) 
100ml of M9 Salts 
10ml of 100x stock 
trace elements 
840ml of autoclaved 
dH2O 
50ml of filtered sterile 
additives 
Add appropriate 
antibiotics 
  
 
 
Filtered Sterile 
Additives 
(200ml) 
4ml of 1mg/ml thiamine 
4ml of 1mg/ml biotin 
1.2ml of autoclaved 1M CaCl2 
4ml of autoclaved 1M 
MgSO4.7H2O 
80ml of 20% w/v glucose 
4g of NH4Cl 
Added dH2O to 200ml 
Filter sterilise through 0.02µm 
filter 
 
10x M9 Salts 
30g/L KH2PO4 
120g/L Na2HPO4 
5g/L NaCl 
Autoclaved 
  
- 
 
- 
Table 3: Summary media and related chemical components required for protein production in this 
project. 
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2.3.2 Cloning and isolation of plasmid DNA 
At the start of this project all individual proteins were already present within pET14b plasmids, 
which encoded an N-terminal histidine tag; they were ready to transform for laboratory use. These 
constructs had been prepared by Dr Evelyne Deery who is currently based at the University of 
Kent53.  
Fresh plasmid stocks of CobK, CobL, CobLc, CobH and CobB were prepared by transforming into 
DH5a™ Competent Cells. This was undertaken by adding 5-10ng of plasmid DNA to 50µl of DH5a™ 
Competent Cells which were then left on ice for thirty minutes. After this time the cells were then 
heat shocked in a water bath set at 420C for forty-five seconds before being placed back on ice for 
two minutes. Following this 950µl of LB media was then added to the cells which were then 
incubated at 370C and shaken at 200 rotations per minute (rpm) for one hour. The 1ml of DH5a™ 
competent cell culture was then centrifuged for two minutes at 12,000g. This resulted in the cells 
being pelleted and 700µl of supernatant was removed before resuspending the pellet. To allow for a 
tenfold dilution 200µl and 20µl of cells were spread out on to separate LB agar plates which 
contained 100µg/ml of the antibiotic ampicillin. These plates were left overnight in an incubator at 
370C. After twenty-four hours a single cell colony was picked and inoculated to a 5ml LB culture 
which contained 100µg/ml of ampicillin and this was left to grow at 370C overnight. After twelve 
hours a QIAprep® Miniprep was carried out using the solutions and instructions provided: 
1. Resuspend pelleted bacterial cells in 250µl Buffer P1 and transfer to a microcentrifuge 
tube. 
2. Add 250µl Buffer P2 and mix thoroughly by inverting the tube 4-6 times. 
3.  Add 350µl Buffer N3. Mix immediately and thoroughly by inverting the tube 4-6 times. 
4. Centrifuge for 10 mins at 13,000rpm in a table top microcentrifuge. 
5. Apply 800µl of the supernatant from step 4 to the QIAprep 2.0 spin column by pipetting. 
6. Centrifuge for 30-60s. Discard the flow-through. 
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7. (Recommended) Wash the QIAprep 2.0 spin column by adding 0.5ml Buffer PB and 
centrifuging for 30-60s. Discard the flow-through. 
8. Wash QIAprep 2.0 spin column by adding 0.75ml Buffer PE and centrifuge for 30-60s. 
9. Discard the flow-through and centrifuge at full speed for an additional 1 min to remove 
residual wash buffer. 
10. Place the QIAprep 2.0 column in a clean 1.5ml microcentrifuge tube. To elute DNA, add 
50µl Buffer EB or water to each QIAprep 2.0 spin column, leave to stand for 1 min and 
centrifuge for 1 min. 
11. The pure plasmid DNA was stored at -200C until required.  
To prepare plasmid stocks of tetrapyrrole producing cells the same method as above was 
followed but it typically required a longer incubation on agar plates to produce cell colonies, due to 
the large size of the plasmids, Figure 20. These constructs were again made by Dr Evelyne Deery via 
the link and lock method53. These plasmids consist of all the aerobic Cob proteins up to the Cob 
protein able to synthesise the desired tetrapyrrole product, in which the final enzyme in the 
sequence contained a histidine tag. These constructs include; a precorrin-6B producing plasmid (all 
Cob proteins up to CobK), a hydrogenobyrinic acid producing plasmid (all Cob proteins up to CobH) 
and hydrogenobyrinic acid-a,c-diamide producing plasmid (all Cob proteins up to CobB). 
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Figure 20: The different plasmids used for Cob protein and cobalamin intermediate production. A) 
Shows a pET3a plasmid used for the production of individual Cob proteins. These plasmids 
contained a T7 RNA promoter, TEV cleavage site and an N-terminal His-tag on the protein of 
interest as well as an ampicillin resistance gene. B) Showed the pET14b plasmid produced by Dr 
Evelyne Deery containing all the Cob biosynthetic proteins up to the desired cobalamin 
intermediate shown in the brackets, where the final protein also contained an N-terminal histidine 
tag. Figure was created using Biorender.com. 
 
2.3.3 Production of recombinant proteins 
For production of an individual Cob protein, plasmid DNA was transformed into One Shot™ BL21 
(DE3) Chemically Competent E. coli cells. The transformation procedure was identical to section 
2.3.2 above, but after cells were grown overnight on agar plates, colonies were picked and 
inoculated into 10ml LB cultures containing 100µg/ml ampicillin and grown at 370C shaken overnight 
at 200rpm. After twelve to sixteen hours the 10ml cultures were inoculated into one litre LB media 
batches, which again contained 100µg/ml of ampicillin. The one litre cultures were then grown at 
370C and shaken at 220 rpm until an OD600 reading of 0.6-0.8AU was obtained, which typically took 
around three hours. At this point 0.4mM isopropyl b-D-1-thiogalactopyranoside (IPTG) was added to 
induce protein expression. Cell cultures were then grown for a further eighteen hours at 180C before 
the cells were harvested by centrifugation at 8,000g for fifteen minutes. The supernatant was 
poured off and the cell pellets were collected and stored at -200C. 
  
CobK/L/H/B
CobL
AMPR
pET3a plasmid
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2.3.4 Growth of cobalamin intermediate producing cells 
The cobalamin intermediate producing plasmids: precorrin-6B (PC6B), hydrogenobyrinic acid 
(HBA) and hydrogenobyrinic acid-a,c-diamide (HBAD) were transformed into One Shot™ BL21 (DE3) 
pLysS chemically competent cells as described in section 2.3.2 above. However, the agar plates 
required the addition of 34µg/ml chloramphenicol in addition to 100µg/ml ampicillin due to the 
pLysS host cells to reduce basal protein expression. Cell colonies were picked and inoculated into 
10ml 2TY cultures, which contained 34µg/ml and 100µg/ml chloramphenicol and ampicillin 
respectively and grown overnight at 370C and shaken at 200rpm. After twelve to sixteen hours the 
10ml cultures were transferred into one litre 2TY media batches, which again contained 34µg/ml 
chloramphenicol and 100µg/ml ampicillin and grown at 370C until an OD600 reading of 0.6-0.8AU was 
obtained, which typically took around three hours. At this point 0.4mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) was added to induce protein expression. After induction the 
temperature was lowered to 180C and the batches were shaken at 220rpm for 24-36hrs. Typically 
this would produce a greyish-green coloured culture for PC6B producing cells and pink coloured 
cultures for HBA and HBAD producing cells. Cells were harvested by centrifugation at 8,000g for 
fifteen minutes. The supernatant was removed, and the cell pellets collected and stored at -200C.  
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2.4 Purification of recombinant proteins 
 
2.4.1 Protein purification buffers 
All individual Cob proteins contained a histidine tag, so a nickel column followed by a size 
exclusion chromatography using Superdex 200 Increase column a was used in tandem for protein 
purification. Depending on the protein being purified the purification buffers used varied and are 
summarised in Table 4.  
 
Cob 
Protein 
Loading buffer 
(Buffer A) 
Wash buffer 
(Buffer B) 
 Elution buffer 
(Buffer C) 
Desalting buffer 
(Buffer D) 
 
CobK 
100mM NaCl 
20mM HEPES pH7.5 
5mM imidazole 
100mM NaCl 
20mM HEPES 
pH7.5 
40mM imidazole 
100mM NaCl 
20mM HEPES 
pH7.5 
400mM imidazole 
100mM NaCl 
20mM HEPES 
pH7.5 
 
 
CobL 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
5mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
60mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
400mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
 
 
CobLc 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
5mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
60mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
400mM imidazole 
500mM NaCl 
20mM Tris-HCl 
pH8.0 
 
 
CobH 
100mM NaCl 
20mM Hepes 
pH7.5 
5mM imidazole 
100mM NaCl 
20mM Hepes 
pH7.5 
60mM imidazole 
100mM NaCl 
20mM Hepes 
pH7.5 
400mM imidazole 
100mM NaCl 
20mM Hepes 
pH7.5 
 
 
 
CobB 
100mM NaCl 
20mM Hepes 
pH7.5 
5mM imidazole 
2mM TCEP 
Kept on ice 
100mM NaCl 
20mM Hepes 
pH7.5 
60mM imidazole 
2mM TCEP 
Kept on ice 
100mM NaCl 
20mM Hepes 
pH7.5 
400mM imidazole 
2mM TCEP 
Kept on ice 
100mM NaCl 
20mM Hepes 
pH7.5 
 
2mM TCEP 
Kept on ice 
Table 4: Summary of protein purification buffers used for each Cob protein. 
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2.4.2 Lysis of cells 
Typically, 1-2 cell pellets (~5-10g) were used for each protein purification, where each pellet had 
originally come from a one litre cell culture. The cell pellets were left on ice to thaw for thirty 
minutes before being resuspended in 30ml of buffer A. The resuspended cells were then lysed by 
sonication on ice for six minutes with thirty second intervals at 25-30 watts. The cell lysate was then 
centrifuged at 25,000g for thirty minutes at 40C and the supernatant was collected and stored on ice. 
 
2.4.3 Purification of His-tagged proteins 
The supernatant from the previous steps was then loaded on to a nickel column, which had been 
washed with five column volumes of loading buffer (buffer A). Once all the supernatant had been 
passed through the column, five column volumes of buffer A was washed through the nickel column. 
This was then followed by a second wash of five column volumes of wash buffer (buffer B). Finally, 
two column volumes of elution buffer (buffer C) were added to the nickel column and collected, as 
this elution contained the protein of interest. 
 
2.4.4 Protein buffer exchange 
The nickel column elution was concentrated down to 2.5ml in a Vivaspin® 20 centrifugal 
concentrator with an appropriate molecular weight cut off (MWCO), depending on the protein being 
purified. This was typically a 10kDa MWCO or 30kDa MWCO and spun at 4000g for 30-60 minutes. 
Once concentrated the nickel eluted protein was passed down a PD10 desalting column, which had 
been washed with 25mls of desalting buffer (buffer D). The initial elution was discarded but when a 
further 3.5mls of buffer D was passed through the PD10 column the elution was collected, as it 
contained imidazole free protein. 
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2.4.5 Size exclusion chromatography (SEC) 
The PD10 elution was concentrated down to 0.5ml before being loaded onto a Superdex 200 
Increase size exclusion column by injection, which had already been washed with two column 
volumes of buffer D. Typically 1.5 column volumes of 1ml fractions were collected running at a flow 
rate of 0.5ml/min. The AKTA FPLC provided a UV trace of the size exclusion column collection at A280, 
allowing protein containing fractions to be identified.  
 
2.4.6 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The success of the protein purification was monitored by taking samples throughout and 
carrying out a sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. Samples were 
mixed with an equal volume of 2x SDS loading buffer (100mM Tris-HCl pH6.8, 4% SDS, 0.2% 
bromophenol blue, 15% glycerol and 200mM Dithiothreitol) and boiled for ten minutes. These were 
then loaded onto a 12% SDS PAGE gel (where a 10ml separating solution contained: 3.35ml dH2O, 
2.5mls 1.5M Tris-HCl pH8.0, 4.0ml 30% acrylamide, 100µl 10% SDS, 50µl 10% APS, 15µl TEMED and a 
5ml 4% stacking gel solution contained: 1.68ml dH2O, 1.25ml 0.5M Tris-HCl pH6.8, 2mls 30% 
acrylamide, 50µl 10% SDS, 25µl 10% APS and 15µl TEMED). The SDS PAGE gel was loaded into a gel 
tank carried out in SDS-PAGE running buffer (25mM Tris-base, 192mM glycine and 0.1% SDS) at 
200V for forty-five minutes. The gel was then stained by shaking gently in Coomassie stain for ten 
minutes (1gL-1 Coomassie Brilliant Blue, methanol 50% v/v, glacial acetic acid 10% v/v and H2O 40% 
v/v) which was then removed and replaced with a destaining solution (10% acetic acid, 30% 
methanol and 60% distilled water) and shaken gently for 1-2 hours. 
 
2.4.7 Native polyacrylamide gel electrophoresis (Native-PAGE) 
Precast NativePAGE Novex 4-16% Bis-Tris gradient gels were used to separate and monitor 
potential protein interactions and conformations in their native state. Protein samples were mixed 
with an equal volume of 2x native loading buffer (100mM Tris-HCl pH6.8, 02% bromophenol blue, 
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15% glycerol). Cold running buffer (25mM Tris-base, 192mM glycine) was added to the gel tank and 
samples loaded onto the precast gradient gels 4%-16%, purchased from BioRad, in which the gel 
tank had been placed in ice. The gel was run at a fixed current of 20mA for 3-6hours. The gel was 
then stained in Coomassise stain for ten minutes, which was then removed and replaced with a 
distaining solution and shaken gently for two hours.   
 
2.4.8 Thrombin cleavage  
A thrombin cleavage was used to remove the hexahistidine tag of the protein. First the protein 
of interest was buffer exchanged into PBS buffer (137mM NaCl, 10mM Na2HPO4, 2.7mM KCl pH 7.4) 
as described in section 2.4.3. Having measured the protein concentration 1 unit of thrombin was 
added per mg of protein. The cleavage was initially trialled by splitting the protein stock and 
thrombin mixture into 4 equal aliquots which were left shaking at 40C, 160C, 300C and 370C. Samples 
were taken after 1, 2, 3 and 16 hours and run on an SDS-PAGE to confirm the optimal temperature 
and time for successful thrombin cleavage.  
2.5 Preparation of cobalamin intermediates 
 
2.5.1 Lysis of cells 
As the tetrapyrrole purification relies on the product trapping activity of a histidine tagged 
enzyme, an additional cell pellet which contained an individual Cob protein was also mixed with a 
tetrapyrrole containing pellet. (For example, 1-2 resuspended cell pellets of PC6B containing cells 
would also be mixed with one resuspended pellet of CobK containing cells). Each pellet was thawed 
on ice for thirty minutes and then resuspended in 30ml of buffer A, see Table 4. The resuspended 
cells were then lysed by sonication on ice for twelve minutes with thirty second intervals of 25-30 
watts of sonication. The cell lysate was then centrifuged at 25,000g for thirty minutes at 40C and the 
supernatant was collected and stored on ice. 
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2.5.2 Purification of His-tagged protein 
The supernatant was passed through a nickel column, which had been washed with five column 
volumes of buffer A. Once all the supernatant had been passed through the column, five column 
volumes of buffer A were washed through the nickel column. This was then followed by a second 
wash of five column volumes of buffer B. Finally, two column volumes of buffer C were added to the 
nickel column and collected as this elution contained the protein and cobalamin intermediate of 
interest as summarised in Figure 21.  
 
Figure 21: Example of a nickel column purification of the tetrapyrrole HBA where (A) is a pre-
prepared nickel column (B) is a post-loaded nickel column and (C) shows 1ml aliquots of nickel 
column elution.  
 
2.5.3 Protein buffer exchange 
       The nickel column elution was concentrated down to 2.5ml in a Vivaspin® 20 centrifugal 
concentrator with an appropriate molecular weight cut off (MWCO), depending on the protein being 
purified. This was typically a 10kDa MWCO or 30kDa MWCO, and spun at 4000g for 30-60 minutes. 
Once concentrated the nickel eluted protein and tetrapyrrole was passed down a PD10 desalting 
column, which had been washed with 25mls of buffer D. The initial elution was discarded but when a 
further 3.5mls of buffer D was passed through the PD10 column the elution was collected as it 
contained imidazole free protein and tetrapyrrole. At this stage if protein and cobalamin 
intermediate were required together then size exclusion chromatography was carried out as 
described in section 2.4.4 above. 
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2.5.4 Reverse phase chromatography 
If the cobalamin intermediate was to be purified, then the pH of the PD10 elution was lowered 
to pH4 and any protein precipitation removed by centrifugation. The pH was then increased back to 
pH7.5 causing a second occurrence of protein precipitation which was removed by centrifugation. 
Finally, it was important to lower the pH again to pH4, otherwise the cobalamin intermediate would 
not bind to the reverse phase column in the next step. The pH4 cobalamin intermediate solution was 
then passed down a Telos® C18 reverse phase column. This column was initially washed with 5ml 
methanol, followed by 10ml ethanol and finally 5ml 1% acetic acid. The cobalamin intermediate was 
then passed through the column, which was then washed with 1.3ml 1% acetic acid. To elute the 
cobalamin intermediate 2ml of 50% ethanol was passed through the column and this elution was 
collected, Figure 22. This solution was then lyophilized for twelve hours and the powder of the 
cobalamin intermediate was stored at -800C until required. 
 
 
Figure 22: Example of a RP18 column purification of the tetrapyrroles PC6B (yellow) and HBA 
(pink) where (A) shows PC6B bound to the RP18 column (B) shows HBA bound to the RP18 column 
and (C) shows the elution collections of PC6B and HBA.  
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2.5.5 Mass spectrometry (MS) 
The presence of the cobalamin intermediate could be monitored throughout both visibly, due to 
its colour, or by carrying out a UV-VIS wavelength scan between 300-500nm, where each 
tetrapyrrole gives a distinctive absorbance trace. The tetrapyrrole was confirmed by carrying out 
high resolution mass spectrometry and compared to the known molecular weight53. The mass 
spectrometry was kindly provided by Dr Roberto Buccafusca who is the Analytical Services Facility 
Manager at Queen Mary University. 
 
2.6 Spectroscopy and biochemistry techniques 
 
2.6.1 UV-VIS spectroscopy 
UV-VIS spectroscopy was undertaken to monitor absorbance in both the ultraviolet (UV) region, 
200-400nm, and the visible region, 400-800nm. The machine was zeroed before each run with an 
appropriate buffer solution and then the sample was loaded using a Quartz cuvette. Typically, a 
wavelength scan was performed to determine protein concentration or monitor the presence of 
tetrapyrroles.  
Protein concentration was calculated using the Beer-Lambert Law, Equation 1, where A is the 
absorbance measured at 280nm, c is the protein concentration, e is the protein’s extinction 
coefficient and 	𝑙 is the length of the cuvette was 1cm. The protein’s extinction coefficient was 
obtained by uploading the gene sequence into the ProtParam tool at 
https://web.expasy.org/protparam/.  
 
Equation 1 
𝐴 = 𝑐	𝜀	𝑙 
Where: A=Absorbance (AU), C= concentration (moldm-3), e=protein extinction coefficient            
(mol-1dm3cm-1), l= length of cuvette (cm). 
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 To follow the turnover reaction of tetrapyrrole enzyme modification, an appropriate 
wavelength was selected via an initial wavelength scan. The absorbance at this wavelength was then 
measured every three seconds for a set amount of time once the reaction had been initiated. 
 
2.6.2 Enzyme kinetics using UV-VIS spectroscopy 
The catalytic turnover of PC6B by the enzyme CobL was measured using UV-VIS spectroscopy. 
PC6B has an absorption maximum of 348nm when in the presence of CobK, whereas PC8 shows a 
decrease and shift with an absorbance maximum of 390nm. Due to the stronger absorption signal 
observed at 348nm this was chosen as the wavelength to measure absorption. PC6B concentrations 
were selected at 50µM intervals between concentrations of 50µM to 400µM. Initial studies were 
only carried out in the presence of CobL with a concentration of 5µM throughout. All reactions were 
initiated by adding 1mM SAM where absorption measurements were taken every three seconds for 
ten minutes. The second investigation of PC6B turnover was carried out in equimolar concentrations 
of CobK and NADPH to ensure that product binding occurred. A concentration of 5µM CobL was 
maintained and each run was initiated by the addition of 1mM SAM. All experiments were repeated 
three times to ensure that averages could be measured during the analysis which was carried out 
using GraphPad Prism version 7.0a for Mac OS X, GraphPad Software, La Jolla California USA, 
www.graphpad.com. 
  
2.6.3 Fluorescence spectroscopy 
Fluorescence spectroscopy was used to observe the presence of a fluorophore such as HBA and 
typically relies on a molecule having conjugated p-electrons present in the structure. This technique 
relies on a particular wavelength to excite electrons from a ground state to a higher energy level, 
which upon returning to the ground state emit light radiation, which is measured at a perpendicular 
angle to the beamline. An appropriate excitation wavelength was selected based on the UV-VIS 
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wavelength scan of the fluorophore to identify where maximum absorbance/excitation occurs. 
Detection was measured using a wavelength scan at higher wavelengths to the selected excitation 
wavelength.  
 
2.6.4 Real-time PCR thermal melts 
A real-time PCR instrument was used to screen the thermal shift profiles of proteins with and 
without ligands in a 96-well format. Temperature profiles were generated by averaging results 
measured across three repeats. The well conditions were always made to a final volume of 20µl 
upon which a 1x solution of the dye SYPRO® Orange was added. The 96 well tray was sealed with 
SealPlate® film and the thermal shift assay was carried out at 20-950C, where the temperature was 
increased by 10C every minute.  
 
2.6.5 Isothermal calorimetry (ITC) 
Isothermal calorimetry is a sensitive technique that is able to measure the heat that is either 
released or absorbed during a protein binding event. As CobK protein was less precious and easier to 
produce than PC6B, the protein was added to the cell of the ITC machine while PC6B was added to 
the syringe, as the volume required for the cell was 280µl compared to 60µl in the syringe. Initially a 
10x concentration of ligand: protein was trialled using CobK with a concentration of 30µM and a 
PC6B concentration of 300µM. Initial runs were trialled where PC6B was injected across 13 
injections of 3µl into CobK in the presence and absence of NADPH (30µM). As ligand saturation 
occurred too quickly the number of injections was increased to 19 with a volume of 2µl and the 
concentration of protein was increased to 45µM to increase the signal and the temperature lowered 
to 150C given the reaction observed was endothermic.    
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2.7 Structural biology 
 
2.7.1 X-ray crystallography background and methodology 
 
2.7.1.1 Introduction to X-ray crystallography 
X-ray crystallography is the most powerful tool to determine the atomic resolution structure of 
proteins of any size, provided that high-quality crystals and diffraction data can be collected. The 
crystallography pipeline is summarised in Figure 23A, highlighting the key stages involved in solving a 
protein structure. Initially this is begun by cloning the protein of interest into a vector, expressing 
the protein in high amounts and subsequently purifying said protein, as described above in Section 
2.4.  
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Figure 23 A) Show an overview of the stages involved in the crystallography pipeline when trying to 
solve a structure. B) Shows the two methods used to grow and produce crystals using either the 
hanging drop or sitting drop method, upon which a sample of protein solution is mixed with reservoir 
solution and left so that water vapour can evaporate and concentrate the protein. C) Shows a diagram 
of how protein solubility is linked to concentration of the protein and precipitant within the solution. 
D) Shows a simplified diagram of how diffraction is collected from a crystal at a synchrotron, where X-
rays are shone onto the crystal at different angles and diffraction data collected on a detector, figure 
taken from Taylor 2010 85. E) Shows the relationship between Bragg’s equation to determine the 
distance d, between the lattice planes of a crystal during a diffraction data collection.  
A 
B C 
D E 
Protei
n Crystal 
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2.7.1.2 X-ray crystallography screening and optimisation 
Once pure protein was obtained it was concentrated to 10-20mg/ml and used to screen for 
successful crystal conditions. Screening was carried out using 96-well plates using either the hanging 
drop or sitting drop method as shown in Figure 23B. For protein crystals to form the protein needs to 
initially be undersaturated and soluble in a screening solution. Figure 23B and C show that as the 
reservoir of the screening solution draws water from the protein drop, this leads to an increase in 
the concentration of the protein and precipitant in the protein drop, allowing nucleation of protein 
crystals to form86. If nucleation is successful, the concentration of the protein in solution will 
decrease and crystal growth favoured if the solubility lies within the metastable zone.  
Crystal trays were prepared by trialling crystal screening solutions which were purchased from 
Molecular Dimensions Limited and included; Structure Screen 1+2 HT-96 (MD1-30), JCSG-plus™ HT-
96 (MD1-40), MemGold 2™ (MD1-63), PACT premier™ (HT-96) and Morpheus® HT-96 (MD1-47). 
These trays were prepared by mixing pure protein with crystal screening solutions using ttplabtech 
mosquito®. Trays were sealed and left at 190C and were checked regularly for two weeks. 
If any screen conditions looked promising these were optimised. This can involve altering 
physical, chemical and biochemical factors87. Typically, chemical factors were changed by altering 
the salt or precipitant concentration across a small range. This was undertaken using a Celltrat 24 
Well Cell Culture Plate, where 1µl of crystal reservoir solution was mixed with 1µl protein solution, 
placed on a cover slip and sealed above the respective reservoir with vacuum grease using the 
hanging drop method. These trays were again left at 190C and checked regularly for two to three 
weeks.  
2.7.1.3 Picking crystals 
 
Protein crystals were picked using appropriately sized Mounted Round LithoLoops down a 
microscope. Unless the Morpheus screen condition had been used, the protein crystals were then 
transferred into a cryo-solution which contained the crystallisation solution and 10-20% glycerol. 
The loops were then transferred into a Uni-Puck which was cooled under liquid nitrogen. Once all 
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the crystal samples had been loaded, the Uni-Puck was closed and transferred to a Dewar that had 
been cooled using liquid nitrogen. Through a collaboration with Birkbeck University the Dewar was 
shipped off to Diamond Light Source synchrotron based in Oxfordshire ready for data collection. 
Crystal samples were uploaded on to https://ispyb.diamond.ac.uk and crystal diffraction data was 
usually collected remotely by logging into the Diamond beamline via the software NoMachine. 
 
2.7.1.4 Collecting crystal diffraction data 
Diffraction data of protein crystals are obtained by illuminating with X-rays, where a single 
oscillation image is obtained by rotating the crystal through a small degree of rotation, Figure 
23D85,88. These images are combined to form a data set that samples the entire three-dimensional 
diffraction pattern for said sample. Interactions of X-rays with crystals are described using the 
Bragg’s model, in which the diffraction images are a result of reflections within the lattice planes of 
the crystal89. Every atom within the repeating unit of a protein crystal contributes to the intensity of 
every reflection in a diffraction pattern and these reflections are related to the planes from which 
they have arisen by the use of the crystal lattice indices h,k and l. Bragg’s law explains that two 
beams with identical wavelength and phase are scattered off two different atoms within it, Figure 
23E. The lower beam in Figure 23E travels an extra length of 2dsinq and constructive interference 
occurs when this length is equal to whole number integer of the wavelength giving rise to Bragg’s 
equation, Equation 2, thus allowing the amplitude to be measured on the detector via the intensity 
of the diffraction spots 88,89. This equation shows the relationship between the interplanar distances 
of the reflecting planes dhkl and the angle of reflection qhkl is reciprocal, where for example closely 
spaced planes give rise to large diffraction angles89.  
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Equation 2 
𝑛𝜆 = 2𝑑+,-𝑠𝑖𝑛𝜃+,- 
Bragg’s equation where l is the wavelength of the X-ray radiation, n is a whole number integer, d 
is the spacing of the interatomic planes between the lattice planes of the crystal hkl and q the 
angle of reflection.  
 
2.7.1.5 Calculating the electron density map 
In order to generate an electron density map of the structure both the amplitude of the 
diffracted X-ray waves and their phase angles are required. During a diffraction experiment the 
intensities of reflected waves from the lattice planes hkl from the crystal are measured via a 
detector, Figure 23D. The amplitude of the reflected wave |Fhkl| is proportional to the square root of 
the measured intensity. Within the unit cell of the crystal the electron density at a given position 
(xyz) can be calculated using Fourier transformation shown in Equation 3, in which the electron 
density at (xyz) is the sum of contributions to the point (xyz) of waves scattered from the crystal 
planes (hkl), where the amplitude relies on the number of electrons in the plane, added with the 
correct relative phase of the wave (ahkl). The amplitudes are measured during diffraction of the 
crystal however the phases are lost during the experiment and this is typically coined the phase 
problem88,90. When phase information is available a Fourier transformation can be used to construct 
an electron density map in reciprocal space. Phases can be obtained either by using the structure of 
a homologous protein in a process known as molecular replacement or via the incorporation of a 
heavy atom88. 
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Equation 3 
 
𝑝(𝑥𝑦𝑧) =
1
𝑉
	9|𝐹+,- | exp(𝑖𝛼+,-)exp	(−2𝜋𝑖ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧) 
 
Fourier transformation equation used in X-ray crystallography to calculate the coordinates of 
electron density, p(xyz), in a given unit cell with volume (V). hkl represent the lattice planes of the 
crystal, |Fhkl| is the structure-factor amplitude of the X-ray beam and ahkl is the phase associated 
with the amplitude90.  
 
To determine a crystal diffraction collection strategy, crystals were loaded and centred in the 
synchrotron beamline and three images were taken at a 450 oscillation. A successful crystal screen 
would result in an appropriate strategy being generated and applied, which allowed for a thorough 
diffraction data collection. Crystal diffraction images were processed using Dials or Mosflm, via the 
CCP4 Suite91. Protein phases were determined and refined using molecular replacement through 
Phaser via the Phenix suite92.  
To solve the phases molecular replacement was used and relies on a Patterson function, where a 
Patterson map can be calculated from the same Fourier summation that is used to calculate the 
electron density map85. A Patterson map is also produced from the atomic coordinates of a 
structurally similar model and rotated over the calculated Patterson map obtained from the 
structure-factor amplitudes of the protein crystal structure to determine the orientation of the 
model in a new unit cell85 . A Patterson function is a Fourier summation that can be calculated 
directly from the measured intensities 93.  The translation of the correctly oriented model can also be 
measured via a translational function z-score (number of standard deviations above the mean 
value), in which a score above 8.0 means the structure of interest can definitely be solved. 
Phases can also be solved experimentally by incorporation of heavy atoms into the crystal 
lattice88. This method relies on anomalous scattering of X-rays which give rise to measurable 
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intensity changes which allow the position of the heavy atom to be determined85. This method was 
attempted to solve the structure of CobB exploiting the incorporation of selenomethionine (SeMet) 
residues. To obtain phase information from the incorporation of selenium multiple anomalous 
diffraction (MAD) phasing was carried out. This technique requires the presence of a heavy atom 
which has an X-ray absorption edge in the energy range of the X-ray wavelength used (~1Å) 93. Three 
different wavelengths were applied around the heavy atom’s absorption edge and the change in 
wavelength causes a change in the measured intensities of the individual reflections allowing these 
differences to be used to directly calculate the phase angle for each reflection 93.   
This was undertaken using the SelenoMet™ Medium Complete (MD12-500) purchased from 
Molecular Dimensions Limited. A 100ml LB culture was inoculated with a single cell colony and 
grown overnight for 12-16 hours at 370C with the appropriate antibiotics. The cells were centrifuged 
at 4000g for fifteen minutes and the pellets washed three times with sterile water. The pellets were 
resuspended in 1ml of sterile water and inoculated into a litre of prewarmed (300C) minimal media 
which contained selenomethionine. These cultures were grown for two hours at 370C at 220rpm 
before the addition of 1mM IPTG was added to induce protein production, at which stage the 
temperature was lowered to 180C and then left to grow for a further 12-16 hours. Cells were 
harvested by centrifugation at 8,000g for fifteen minutes and stored at -200C. The protein 
purification was identical to section 2.4 described above. 
The selenomethionine medium was prepared by dissolving 21.6g of SelenoMet Medium Base in 
one litre of dH2O and autoclaved. Subsequently 5.1g of SelenoMet Nutrient mix was dissolved in 
50ml dH2O and filter sterilised before being added to the autoclaved SelenoMet Medium Base 
solution. A further 4ml of 250x selenomethionine and appropriate antibiotics were added before the 
grow up. 
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2.7.1.6 Structure validation 
Initial estimates of phases typically have large errors which makes the electron density map 
noisy and ill defined88. Therefore, structure refinement and validation are carried out. This relies on 
model refinement programs and graphic displays such as COOT and Molprobity to help provide 
validation to interpret many unexplained difference peaks in the electron density Fourier map 94,95. 
Furthermore calculated phases are also prone to model bias and these errors can be measured using 
R-factors and R-free 96,97. The R-free is a useful validation as it is calculated by removing a random 
sample of reflections and used to compare to the refinement R-factors to provide a more objective 
quality criterion as standard R values can easily be abused 97,98. Additionally cycles of refinement 
involve manual rebuilding of the model until a good agreement can be seen between the model and 
the calculated electron density map and these cycles include further validation of stereochemical 
quality indicators, such as acceptable deviations in bond length, amino acid rotamer orientations 
and torsion angles via the Ramachandran plot 95,98.  
 
2.7.2 Nuclear magnetic resonance (NMR) 
 
2.7.2.1 N15 labelled media 
Isotopically labelled 15N proteins were produced by growing cells in minimal media in which 15N 
labelled NH4Cl replaced regular ammonium chloride. A method described by Marley et al99 was 
followed as it argued that higher protein yields could be obtained by initially growing cells in 
unlabelled rich media to produce all the cell machinery required for protein production. Once the 
cells were in the exponential growth phase they were transferred into 15N labelled minimal media 
and protein production was induced. 
This was achieved by initially growing cells to an optical density of OD600 ~0.7 in one litre batches 
of LB media as described above in section 2.3.3. These cells were then pelleted by centrifugation at 
5000g for thirty minutes. The cells were washed in M9 salt solution (Table 3) and then resuspended 
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in isotopically labelled minimal media and inoculated into 1L batches of 15N labelled minimal media. 
The cells were grown for a further hour at 370C so as to allow for growth recovery and any 
unlabelled metabolites to be cleared, before protein expression was induced by the addition of 
0.8mM IPTG. The temperature was then lowered to 180C at 220rpm and the cells left to grow for a 
further eighteen hours. Cells were harvested by centrifugation at 8000g for fifteen minutes and cell 
pellets stored at -200C until required. N15 labelled protein was purified as normal as described in 
section 2.4 above.  
 
2.7.2.2 NMR data collection 
Pure 15N labelled protein was used for 2D HSQC experiments on the Bruker 700MHz NMR 
machine at the Francis Crick Institute. The data collection and results output were facilitated under 
the supervision of Dr Shuang Gu, from Queen Mary of London University. Protein concentrations no 
lower than 0.2mM were used and protein was kept in buffer D solution throughout.   
2.8 Bioinformatics  
Docking data of precorrin intermediates and products had been carried out by members of the 
Pickersgill group before this project was undertaken, as a number of methyltransferase crystal 
structures had been solved lacking precorrin ligands. Multiple models of different conformations in 
which precorrin substrates/product bind to their respective methyltransferase were generated using 
AutoDock Vina webserver100. In some cases the cleft opening was too tight on currently solved 
structures so certain amino acids were made more flexible using the elNemo web server for normal 
mode analysis to generate new protein data bank templates for docking101.  Some structures of the 
ligands were energy-minimized by Avogadro: an open-source molecular builder and visualization 
tool. Version 1.XX. http://avogadro.cc/ 102. 
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Chapter 3: Crystallography of Cob 
proteins 
 
3.1 Introduction, aims and objectives 
The Cob proteins produced in the laboratory during this project included CobK, CobL, CobLc (C-
terminal domain of CobL), CobH and CobB. Three of these have had their protein structure solved 
using X-ray crystallography: CobK, CobLc and CobH53,62,67. The crystal structures of CobK and CobH 
provide evidence of product binding activity based on the sequestration of their respective products 
PC6B and HBA. This unusual behaviour was first observed visually in the laboratory due to these 
brightly coloured cobalamin intermediates accompanying the enzymes during purification as shown 
in Chapter 2. Based on this product trapping by CobK and CobH these proteins can be grouped into 
the pairs CobK-CobL and CobH-CobB as the second enzyme in the pair must obtain its substrate for 
the cobalamin biosynthetic pathway to proceed. As the enzymes CobL and CobB are both proteins 
larger than 30kDa, X-ray crystallography studies would be able to determine their structures. 
Therefore, to explore these pairs further and help understand how they work and provide guidance 
on future mutagenesis studies, the aims were to: 
 
1. Solve the structure of full length CobL using X-ray crystallography. 
2. Solve the structure of CobB using X-ray crystallography. 
3. Co-crystallise and solve the structure of the enzyme pairs CobK-CobL and CobH-CobB 
using X-ray crystallography. 
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3.2 CobL crystallography 
 
3.2.1 CobL protein purification 
The first step in attempting to solve the crystal structure of CobL was to purify the protein. The 
purification of CobL became a fairly routine procedure, as all the Cob proteins were purified in a 
highly similar fashion using a nickel column followed by size exclusion chromatography. However, it 
was found that CobL was far more prone to insolubility during purification and therefore the buffers 
used required a much higher sodium chloride concentration of 500mM compared to the typical 
100mM for the other Cob proteins to maintain solubility. Despite this small set back the purification 
of CobL did produce pure protein as seen in Figure 24. Once pure protein was obtained it was 
concentrated typically to concentrations between 10-20mg/ml ready for crystallography. 
 
 
Figure 24: Purification of CobL (~42kDa). A) SDS-PAGE analysis of the protein purification process. 
B) UV profile of the S200 size exclusion column elution where the peak is from the fractions 11 to 
14mls.  
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3.2.2 CobL crystal screening and optimisation 
A thermal melt study carried out on a real time PCR machine of 150µM CobL with an excess of 
20x substrates PC6B, SAH and SAM was carried out a real-time PCR machine and shown in Figure 25. 
When CobL was in the presence of one ligand only Figure 25A, the addition of SAM caused an 
increase in melting temperature (Tm) from 380C to 490C while the addition of SAH had an even 
greater effect causing an increase in Tm from 380C to 560C, while PC6B had no effect on Tm. The 
addition of two ligands, Figure 25B, resulted in the same respective Tm when one ligand was used 
demonstrating that PC6B has no overall effect on the increased stability of CobL and this increase in 
Tm is solely due to SAH and SAM binding only.  
Therefore, for CobL crystal screening a 20x times excess of SAH and SAM was added separately 
to CobL samples before crystal trays were set up. The Molecular Dimensions screening conditions 
‘Structure Screen I & II’ (SSI/II) and ‘JCSG+’ were trialled and after a few days small crystals were 
observed as summarised in Figure 26. From these initial screens the conditions that yielded the best 
looking crystals were selected for optimisation. These were SSI-C8, SSI-C10 and SSII-E12. Crystals 
were picked and soaked in a cryogenic solution containing the addition of 20% glycerol where they 
were sent off to the Diamond Synchrotron.  
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Figure 25: A real time PCR thermal melt study of CobL in the presence of one (A) or two (B) ligands 
which included PC6B, SAM and SAH. The melting temperature (Tm) can be calculated by recording 
the temperature at which the negative first derivative occurs and has been labelled on each curve.  
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Figure 26: CobL crystal screening and optimisation with crystallography conditions summarised 
below. Structure Screen I (SSI) and Structure Screen II (SSII) were used.  
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3.2.3 CobL crystal data processing 
Data were collected at Diamond Light Source using an X-ray wavelength of 0.97628Å on 
beamline I04. The highest resolution reflection observation was 3.6 Å. These images were integrated 
using iMosflm and scaled using Aimless through the CCP42i Suite. The crystallographic statistics of 
the data processing are summarised in Table 5. The most probable space group was P42 2 2 based on 
the Rpim and trials of numerous space groups. The point group summary had a space group 
confidence score of 0.711, with a Laue group confidence and probability of 0.989 and 0.992 
respectively. The data continued to be confirmed as highly twinned, even when analysed in space 
group P1, Figure 27. Molecular replacement was attempted using phaser via the Phenix Suite. 
Models which were used included CobLc, CbiET and as the N-terminus does not have a structure a 
CobL sequence identical model based on CbiE was generated via the phyre2 server, which is a 
protein fold recognition server. However molecular replacement solutions were not convincing with 
the best TFZ score of 5.1. So, the search models could not be placed in the unit cell satisfactorily and 
molecular replacement was therefore unsuccessful.   
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CobL data collection statistics 
 
Space group P 42 2 2 
Cell edges (Å) 141.750 141.750 114.880 
90.000 90.000 90.000 
Wavelength (Å) 0.97628 
 Overall Inner shell Outer shell 
Resolution (Å) 3.60-89.25 8.82-89.25 3.60-3.94 
Number of observations 102,591 6944 23,638 
Number of unique reflections 13,990 1039 369 
Multiplicity 7.3 6.9 7.2 
Rmerge 0.239 0.078 0.681 
Rpim 0.087 0.031 0.251 
Rmeas 0.256 0.085 0.729 
Mean I/s 5.7 13.3 2.6 
CC1/2 0.99 0.993 0.865 
Completeness (%) 98.7 97.4 98.9 
Wilson B estimate (Å2) 64.21   
Table 5: Summary of data collection statistics for CobL crystals where Rmerge = Σ hkl Σ i |Ii–< I>| 
/− Σ hkl Σ Ii, where Ii is the intensity of the ith observation, <I> is the mean intensity of the 
reflection and the summations extend over all unique reflections (hkl) and all equivalents (i), 
respectively and Rpim is a measure of the quality of the data after averaging the multiple 
measurements and Rpim = Σ hkl [n/(n-1)]1/2 Σ i |Ii(hkl)–< I(hkl) > |/Σ hkl Σ i Ii(hkl), where n is the 
multiplicity, other variables as defined for Rmerge62,103.  
 
 
 
Figure 27: L-test showing that the CobL crystals were highly twinned, with a twin fraction of 0.45, 
where the CobL data (black line) is almost completely overlapping with the twinned function (red 
line). Graph generated by CCP42i. 
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3.2.4 CobL co-crystallisation with CobK 
A co-crystallisation of CobL with CobK was attempted in the hope that if these proteins interact, 
they may be trapped and observed in a crystal structure. CobK was purified as described in Chapter 
2 section 2.4 and a typical purification profile is shown in Figure 28. Once pure CobK and CobL 
proteins were obtained they were mixed in equal molar concentrations of 20mg/ml with a 10x 
excess of substrates PC6B, NADPH and SAH present to encourage product trapping by CobK and 
prevent PC6B turnover by CobL.  
Protein crystals were observed, Figure 29, in a screen tray of Structure Screen II-F4, which was 
composed of 1M sodium acetate trihydrate, 0.1M sodium HEPES pH7.5 and 0.05M cadmium 
sulphate 8/3-hydrate. These crystals were picked straight from the sitting drop of the screen tray and 
sent off to collect diffraction data at the Diamond Synchrotron. A summary of the crystal data 
statistics are reported in Table 6, where the diffraction images were integrated using Dials in the 
CCP4-2i suite followed by molecular replacement using Phaser in the Phenix suite. 
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Figure 28: Purification of CobK (~26kDa). A) SDS-PAGE analysis of the protein purification process. 
B) UV profile of the S200 size exclusion column elution where the peak is from the fractions 15 to 
18mls. 
 
 
 
 
 
Figure 29: Crystals obtained from screening attempts of CobK mixed with CobL using Structure 
Screen II containing 1M sodium acetate trihydrate, 0.1M sodium HEPES pH7.5 and 0.05M 
cadmium sulphate 8/3-hydrate. 
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CobK data collection statistics 
 
Space group P 1 21 1 
Cell edges (Å) 33.645 113.113 58.340 
90.000 93.293 90.000 
Wavelength (Å) 0.91587 
 Overall Inner shell Outer shell 
Resolution (Å) 2.00-58.24 8.94-58.24 2.00-2.05 
Number of observations 148,346 1873 10,984 
Number of unique reflections 29,413 351 2,162 
Multiplicity 5.0 5.3 5.1 
Rmerge 0.114 0.059 0.75 
Rpim 0.056 0.028 0.408 
Rmeas 0.127 0.066 0.408 
Mean I/s 7.7 16.9 2.1 
CC1/2 0.995 0.998 0.663 
Completeness (%) 100 99.5 100 
Wilson B estimate (Å2) 28.15   
 
Refinement statistics 
 
Resolution (Å) 2.00-58.24 
Number of reflections 25100 
R-work/R-free 0.24/0.31 
Number of atoms 
(protein chains/ligand/water) 
2/0/284 
Rmsd bond length  0.08 
Rmsd bond angle 0.923 
Mol Probability  1.87 
Residues in most favoured regions (%) 96.65 
Outliers (%) 0 
Table 6: Data collection and refinement statistics for CobK and CobL co-crystallisation, which upon 
using molecular replacement the unit cell only contained CobK. Rmerge = Σ hkl Σ i |Ii–< I>| /− Σ hkl 
Σ Ii, where Ii is the intensity of the ith observation, <I> is the mean intensity of the reflection and 
the summations extend over all unique reflections (hkl) and all equivalents (i), respectively and 
Rpim is a measure of the quality of the data after averaging the multiple measurements and Rpim 
= Σ hkl [n/(n-1)]1/2 Σ i |Ii(hkl)–< I(hkl) > |/Σ hkl Σ i Ii(hkl), where n is the multiplicity, other 
variables as defined for Rmerge R-factor = Σ hkl |Fo–Fc |/Σ hkl Fo, where Fo 
and Fc represent the observed and calculated structure factors, respectively. The R-Factor is 
calculated using 95% of the data included in refinement and R-free the 5% excluded62,103. 
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Upon solving the diffraction data using molecular replacement, it became apparent that the 
protein crystals only contained the protein CobK. The crystals were obtained in a different 
crystallisation condition to the already solved structure and was in a different space group, with 
much tighter crystal packing in the unit cell. No ligands were present in the CobK structure meaning 
a higher resolution structure of the apoenzyme was obtained to 2.00Å. This was a significant 
improvement compared to the current structure of the apoenzyme which has a resolution of 3.17Å.  
Upon refining the crystal structure three features were observed. Firstly, the disulphide bond 
present in the known published structure was not actually present, Figure 30. Secondly a metal ion 
was observed in the structure of both protein chains due to the octahedral geometry between the R-
groups of threonine 72 and serine 80, the backbone of proline 74 and alanine 76 and two additional 
water molecules, located near the NADPH binding site, as shown in Figure 31 where the sodium-
oxygen distances are too short for this to be a water molecule. Finally in chain A, one of the two 
protein chains present in the unit cell, it was possible to partially model the loop region of the 
apoenzyme, which has not been observed in the current published structure of the apoenzyme, 
Figure 32. The reason the dynamic loop region was observed and could be modelled was due to the 
tight crystal packing present which resulted in crystal contacts between separate protein chains 
which somewhat restrained the flexible loop region to some degree. The two protein chains in this 
data collection were back to back, where one was inverted, and a large number of water molecules 
bridge the protein-protein interface.  
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Figure 30: Electron density map of CobK showing that the disulphide bond does not occur as 
highlighted in red during pre- and post-refinement in (A) and (B) respectively. Figure produced via 
COOT94. 
 
 
Figure 31: Octahedral coordination of a sodium ion (green) binding in CobK crystal data, which was 
an artefact of the crystallisation conditions where 1M of sodium acetate was also present. Figure 
made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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Figure 32: A) Shows the two CobK protein chains (chain A-green, chain B- blue) modelled in the 
asymmetric unit, with each containing a sodium ion coloured in red. Chain A has the flexible loop 
region highlighted in purple, while this loop could not be modelled in chain B, due to its flexible 
nature. B) Shows the close proximity of a neighbouring protein chain (yellow) which due to crystal 
contacts (pink) allowed this flexible loop region (purple) to be modelled. Figure made via PyMOL, 
the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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3.3 CobB crystallography 
 
3.3.1 CobB protein purification 
Initially purification of CobB typically resulted in low yields of protein which would subsequently 
degrade over a 24-hour period. To resolve this a number of steps were introduced. This included 
keeping all buffers on ice throughout the purification. The addition of 2mM TCEP to the purification 
buffers was included as the protein contained an active site cysteine, in which TCEP would prevent 
its oxidation. While these changes did result in slightly better yields it was concluded that purifying 
the protein in the presence of ligands would assist in stability and lead to improved yields. To 
achieve this CobB was purified from cell pellets obtained from HBAD tetrapyrrole producing cells as 
described in section 2.3.4 and this did result in greater protein yields as shown in Figure 33. 
Furthermore, as these cells were grown over a 24-hour period it was concluded that there was 
probably more HBAD present than protein. Therefore, an additional cell pellet containing histidine 
tagged CobB was also mixed into the purification during the sonication step so that any free 
HBA/HBAD present in the cell lysate could be mopped up and assist in increased protein yields. CobB 
could visibly be observed binding HBAD during the purification protocol exhibiting product binding 
activity similar to CobH as shown in Chapter 2 section 2.5.2 Figure 21. 
To determine if the presence of substrates assisted in the protein stability of CobB thermal melt 
studies were carried out using a real time PCR instrument. These are summarised in Figure 34 in 
which one, two or three substrates were present in an excess of 20x to CobB. Each experiment was 
repeated three times and an average plotted to determine the melting temperature (Tm).  Native 
CobB gave a Tm of 58oC and in the presence of one, two or three substrates the measured Tm 
remained the same as shown in Figure 34.   
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Figure 33: Purification of CobB (~45kDa) in presence and absence of ligand HBAD. A) SDS-PAGE 
analysis of the protein purification process with no ligands present. B) SDS-PAGE analysis of CobB 
with HBAD present C) UV profile of the S200 size exclusion column elution where the peak is from 
the fractions 11 to 16mls. 
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Figure 34: Real time PCR thermal melt studies of CobB in the presence of (A) one substrate only (B) 
two substrates (C) three substrates. These substrates included HBA, glutamine, ATP and non-
hydrolysable ATP. The melting temperature (Tm) has been labelled on each curve. 
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3.3.2 CobB crystal screening and optimisation 
Pure CobB protein was concentrated to 20mg/ml and put down for crystal screening conditions. 
Initial screening gave spherulites in multiple conditions, and any promising looking conditions were 
optimised further. Early optimisations were unsuccessful but when a microseeding technique 
described by Till et al, 2013 was used, crystals were obtained104. The best looking crystals were in the 
condition JCSG+ G2, in which the optimisation conditions ranged between 25%-30% w/v poly(acrylic 
acid sodium salt) 5100, 0.02M magnesium chloride hexahydrate and 0.1M HEPES pH7.5. These 
crystals are shown in Figure 35.   
 
Figure 35: Crystals obtained of CobB from optimisation trays. The upper images show a large 
amount of precipitation, but red crystals have been highlighted. The lower images were from 
subsequent optimisation trays and despite adding HBAD the red colour was not observed and 
instead more crystals were produced, but they were smaller in size. The final image shows a 
loaded CobB crystal at the Diamond Synchrotron.   
 
  
 94 
3.3.3 CobB crystal data processing  
Diffraction data were collected at the Diamond Synchrotron to 3.0Å resolution from multiple 
trips and about 70 crystals, with collection strategies provided from the initial diffraction screens. 
From the processed data files, the best collection had a resolution of 3.0Å. These images were 
integrated using DIALS and scaled through AIMLESS in the CCP4 suite, as shown in Table 7. The space 
group selected for this reduction was P2 with a space group confidence score and Laue group 
confidence score of both 1.0.  
Molecular replacement was unable to be used to solve the structure of CobB. Molecular 
replacement was carried out using the Phenix Suite with models which had been generated via the 
Phyre2 webserver. Despite generating 120 models all with a confidence score >98.7% the phases 
were unable to be solved and so a structure of CobB could not be generated.  
 
CobB data collection statistics 
 
Space group P1 2 1 
Cell edges (Å) 55.090 113.725 67.194 
90.000 103.183 90.000 
Wavelength (Å) 0.97625 
 Overall Inner shell Outer shell 
Resolution (Å) 3.00-113.72 9.00-113.72 3.0-3.18 
Number of observations 107,199 4,130 17,608 
Number of unique reflections 16,241 633 2630 
Multiplicity 6.6 6.5 6.7 
Rmerge 0.327 0.228 0.845 
Rpim 0.138 0.093 0.358 
Rmeas 0.335 0.247 0.92 
Mean I/s 4.9 6.4 3.3 
CC1/2 0.936 0.96 0.763 
Completeness (%) 100 99.9 100 
Wilson B estimate (Å2) 25.72   
Table 7: Data collection statistics for CobB where Rmerge = Σ hkl Σ i |Ii–< I>| /− Σ hkl Σ Ii, where Ii is 
the intensity of the ith observation, <I> is the mean intensity of the reflection and the summations 
extend over all unique reflections (hkl) and all equivalents (i), respectively and Rpim is a measure 
of the quality of the data after averaging the multiple measurements and Rpim = Σ hkl [n/(n-1)]1/2 
Σ i |Ii(hkl)–< I(hkl) > |/Σ hkl Σ i Ii(hkl), where n is the multiplicity, other variables as defined for 
Rmerge R-factor = Σ hkl |Fo–Fc |/Σ hkl Fo, where Fo and Fc represent the observed and calculated 
structure factors, respectively62,103. 
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3.3.4 CobB selenomethionine crystals 
As it was not possible to solve the CobB structure by molecular replacement using diffraction 
data from four separate Synchrotron visits, an attempt was made to try and solve the phases using 
anomalous dispersion from incorporated selenium atoms. To do this CobB was produced and 
purified in minimal media where the amino acid methionine was substituted with selenomethionine 
(SeMet). HBA and ATP were added to the protein elution steps after the nickel column and size 
exclusion chromatography, to help stabilise the protein, since purifying CobB from HBAD producing 
cells had been shown to increase protein yields. As the protein was produced in cells grown in 
minimal media this did result in the expected lower yields and purity which is likely due to stress 
additional stress proteins synthesised in E.coli, Figure 36. However enough protein was purified and 
concentrated for setting up crystal trays with a concentration of 20mg/ml. The purification and 
crystal trays were set up in an identical fashion to a regular CobB purification in section 3.3.2 and 
produced small square plate crystals as shown in Figure 37. These crystals were extremely small and 
difficult to pick with a size no greater than 0.5mm. They were not red suggesting that HBAD was not 
present unlike the previous CobB crystals observed in section 3.3.2.   
 
   
Figure 36:. Purification of CobB labelled with selenomethionine (~45kDa). A) SDS-PAGE analysis of 
the protein purification process. B) UV profile of the S200 size exclusion column elution where the 
peak is from the fractions 12 to 16mls. 
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Figure 37: A selection of CobB SeMet crystal optimisations showing small flat square crystals.  
 
During the diffraction data collection, the presence of selenium in the protein crystals was clear 
from the CHOOCH fluorescence scan that was carried out during the crystal screen process, Figure 
38. The best diffraction data collected were from 1440 images generated from 720o rotation with 
0.5o oscillations and gave a resolution up to 3.03Å. The space group and unit cell dimensions were 
identical to those obtained for non-labelled CobB crystals and the data reduction statistics are 
summarised in Table 8.  
In an attempt to solve the phases via the selenium incorporation Parrot via CCP4-2i and AutoSol 
via Phenix were both trialled. The electron density maps generated were not of sufficient quality to 
attempt to trace the protein backbone. This was highlighted by a mid-slope of anomalous probability 
of 0.882, which was less than 1 meaning the location of selenium atoms in the crystal diffraction 
data could not be accurately placed. 
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Figure 38: CHOOCH fluorescence scan showing the presence of selenium in CobB crystals labelled 
with selenomethionine.    
 
 
SeMet CobB data collection statistics 
 
Space group P 1 2 1 
Cell edges (Å) 55.947 113.734 68.076 
90.000 103.365 90.000 
Wavelength (Å) 0.97925 
 Overall Inner shell Outer shell 
Resolution (Å) 3.03-113.73 9.09-113.73 3.03-3.21 
Number of observations 212,673 7,743 34,370 
Number of unique reflections 16,226 629 2,626 
Multiplicity 13.1 12.3 13.1 
Rmerge 0.577 0.107 2.262 
Rpim 0.165 0.029 0.647 
Rmeas 0.601 0.041 0.647 
Mean I/s 5.2 14.2 2.0 
CC1/2 0.981 0.995 0.531 
Completeness (%) 100 99.9 100 
Anomalous multiplicity 6.5 6.4 6.5 
Anomalous completeness (%) 99.9 99.6 100 
DelAnom CC1/2 0.01 0.048 0.038 
Mid-slope of Anom Probability 0.882   
Wilson B estimate (Å2) 44.73   
Table 8: Data collection statistics for CobB labelled with selenomethionine where Rmerge = Σ hkl Σ 
i |Ii–< I>| /− Σ hkl Σ Ii, where Ii is the intensity of the ith observation, <I> is the mean intensity of 
the reflection and the summations extend over all unique reflections (hkl) and all equivalents (i), 
respectively and Rpim is a measure of the quality of the data after averaging the multiple 
measurements and Rpim = Σ hkl [n/(n-1)]1/2 Σ i |Ii(hkl)–< I(hkl) > |/Σ hkl Σ i Ii(hkl), where n is the 
multiplicity, other variables as defined for Rmerge R-factor = Σ hkl |Fo–Fc |/Σ hkl Fo, where Fo 
and Fc represent the observed and calculated structure factors, respectively 62,103. 
 98 
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0.0 5.0 10.0 15.0 20.0 25.0
UV
 ab
so
rb
an
ce
 (m
AU
) 
Elution volume (mls)
SEC purification of CobH using an S200 column
3.3.5 CobB co-crystallisation with CobH 
As CobH exhibits product trapping activity, it was envisaged that CobH and CobB could be co-
crystallised together showing a trapped interaction which initiates the release of HBA. To attempt 
this CobH and CobB were purified and put down together for crystal screens in the presence of 10x 
excess non-hydrolysable ATP, adenosine 5’-(b,y-imido)triphosphate lithium salt hydrate, to prevent 
HBA turnover. A typical CobH protein purification is shown in Figure 39. The crystal screening 
resulted in multiple conditions yielding red/orange square like crystals, as shown in Figure 40. These 
crystals were numerous and large enough to be picked directly from the screen droplets, without 
the need for optimisation. Cryo-solutions were made by using the existing well conditions and 
diluting with 20% glycerol if a cryogenic agent was not already present, before being sent off to 
Diamond Synchrotron for diffraction data collection.  
 
 
  
Figure 39: Purification of CobH (~25kDa). A) SDS-PAGE analysis of the protein purification process. 
B) UV profile of the S200 size exclusion column elution where the peak is from the fractions 13 to 
16mls. 
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Figure 40: A selection of crystals observed when CobB and CobH were put down together from a 
range of crystallisation screen conditions, with a neighbouring table summarising the conditions.  
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During the diffraction data collection, the automated collection strategies showed a smaller unit 
cell and different space group to previously described CobB data collections. Molecular replacement 
confirmed that the only protein present in the crystals was CobH. The best collection was solved to 
1.5Å and the crystal data statistics are summarised in Table 9. The diffraction images were scaled 
using Dials via CCP4-2i suite and molecular replacement carried out using Phaser in the Phenix suite, 
with CobH (PDB 4FDV) as a model.  
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CobH data collection statistics 
 
Space group C 1 2 1 
Cell edges (Å) 70.062 65.622 48.453 
90.000 99.297 90.000 
Wavelength (Å) 0.91587 
 Overall Inner shell Outer shell 
Resolution (Å) 1.50-47.82 8.22-47.82 1.50-1.53 
Number of observations 97,975 735 3,901 
Number of unique reflections 34,370 224 1,663 
Multiplicity 2.9 3.3 2.3 
Rmerge 0.056 0.045 0.73 
Rpim 0.069 0.028 0.574 
Rmeas 0.069 0.053 0.932 
Mean I/s 8.5 23.5 1.2 
CC1/2 0.997 0.998 0.52 
Completeness (%) 99.2 98.6 97.7 
Wilson B estimate (Å2) 18.77   
 
Refinement statistics 
 
Resolution (Å) 1.50-47.82 
R-work/R-free 0.19/0.21 
Number of atoms 
(protein/ligand/water) 
1/1/212 
Rmsd bond length  0.08 
Rmsd bond angle 1.514 
Mol Probability  0.96 
Residues in most favoured regions (%) 98.54 
Outliers (%) 0 
Table 9: Crystal data collection and refinement statistics for CobH & CobB co-crystallisation, which 
ended up being just CobH. Rmerge = Σ hkl Σ i |Ii–< I>| /− Σ hkl Σ Ii, where Ii is the intensity of the 
ith observation, <I> is the mean intensity of the reflection and the summations extend over all 
unique reflections (hkl) and all equivalents (i), respectively and Rpim is a measure of the quality of 
the data after averaging the multiple measurements and Rpim = Σ hkl [n/(n-1)]1/2 Σ i |Ii(hkl)–< 
I(hkl) > |/Σ hkl Σ i Ii(hkl), where n is the multiplicity, other variables as defined for Rmerge  R-factor 
= Σ hkl |Fo–Fc |/Σ hkl Fo, where Fo and Fc represent the observed and calculated structure factors, 
respectively. The R-Factor is calculated using 95% of the data included in refinement and R-free 
the 5% excluded62,103. 
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The structure of CobH was refined with HBA bound and solved to 1.5 Å which is a small 
improvement in the resolution on five of the six existing structures available in the Protein Data 
Bank, in which only one has been solved to a higher resolution of 1.45Å36,53,67. The degree to which 
this structure of CobH compares to the existing HBA product bound structure 4FDV.pdb is identical 
as highlighted by overlaying the two structures in Figure 41, with a root-mean-square-deviation 
(RMSD) of 0.071 when the alpha carbons of the protein backbone where aligned.  
 
 
 
Figure 41: The CobH structure obtained with HBA bound (blue) overlaid with the existing CobH 
with HBA structure 4FDV.pdb (green), showing little difference between the two. Figure made via 
PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. When 209 residues 
were aligned on Pymol using the function ‘align Prot1////CA, Prot2, object=alignment’ a RMSD of 
0.071 was generated from 200 of these residues.  
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3.4 Discussion and future work 
 
3.4.1 CobL crystallography 
During the course of this project it has not been possible to solve the structure of CobL from the 
present series of experiments undertaken. Crystals were obtained during screening and 
optimisations were carried out. However, despite multiple crystallisation conditions trialled, they 
continued to result in a large number of very small low-quality crystals. These crystals proved 
difficult to physically pick and troublesome to centre on the synchrotron beamline.    
A number of suitable models for molecular replacement of CobL were available and these 
included the C-terminal domain of CobL (PDB 3NJR)53 and the anaerobic equivalent enzyme CbiT 
(PDB 1KXZ)65. Given the high degree of similarity of the C-terminus, therefore it could be concluded 
that the full length structure of CobL is structurally very similar to the anaerobic enzymes CbiET, of 
which the laboratory group currently also has an unpublished structure. Alternatively, given the 
similarity of the N-terminus of CbiET to CbiE it could be concluded that other canonical 
methyltransferases which have already had their structures solved would also be appropriate 
models as they are all Class III methyltransferases.  
Upon the reduction of CobL diffraction data the multiplicity and completeness were good. 
However, the limitations of the data collection arose from the high resolution of the outer shell of 
3.6 Å. Despite an overall Rpim score of 0.087 this is misleading as the outer shell had a very high 
Rpim of 0.251, which despite containing a correction for redundancy is still similar to Rmerge 
indicating a poor signal-to-noise ratio105. Finally, the L-test indicated that the CobL crystals were 
highly twinned, with an almost perfect twin fraction score of 0.45. This meant that it was not 
possible to solve the full-length structure of CobL using molecular replacement, despite having many 
promising models readily available. 
During the crystallisation process of CobL it was observed that more crystals were produced 
when CobL was in the presence of the ligand SAH, which supported the thermal melt studies of CobL 
stability with various ligands. Based on the crystal structures of CobLc and CbiET, these observations 
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agree with the binding and docking interactions present in these structures. SAH is present in both 
of these structures and is buried deep in the active site, Figure 42. The unpublished structure of 
CbiET also contains the anaerobic equivalent tetrapyrrole cobalt-PC6B, which does not appear to 
bind as tightly, which is in further agreement with the thermal melt studies where PC6B had no 
effect on the melting temperature (Tm) and therefore protein stability of CobL. 
Clearly more time needs to be spent on producing larger and better-quality crystals. This could 
be achieved by further screening trials and continued optimisation. Attempting to produce crystals 
of CobL protein from a different species of bacteria may result in better crystals, as existing efforts 
have already been pursued. Given that small crystals can be produced it is possible that the XP 
Screen: Protein Crystal Glue produced by MiTeGen may assist in crystal production and quality, as 
summarised in Figure 43. This screen contains Anderson-Evans polyoxotungstate [TeW6O24]6-, which 
also offers the option to carry out anomalous dispersion diffraction data collections for phasing due 
to the presence of six tungsten atoms.  
 
 
Figure 42: The protein structure of CobLc dimer in green (3NJR.pdb) overlaid the CbiET dimer in 
blue (unpublished) to show the structural homology. SAH (purple) can be seen buried in the active 
site, whereas cobalt-PC6B (yellow) is more exposed when bound at the C-terminus when a surface 
view is applied to CbiET and rotated 900. Figure made via PyMOL, the PyMOL Molecular Grapics 
System, Version 2.0 Schrodinger, LLC. 
 
 
 
 105 
 
 
 
 
Figure 43: A simplified explaination of how XP Screen: The Protein Crystal Glue-96 solutions 
MiTeGen works from their website.  
 
 
3.4.2 CobK crystallography (CobL co-crystallisation with CobK) 
A higher resolution structure of the native form of CobK was obtained in an attempt to co-
crystallise a CobK-CobL complex. Three new features were observed during the refinement process. 
This included the lack of the disulphide bond presented in the known published structure. Given 
CobK is a bacterial cytoplasmic enzyme it is unlikely a disulphide bond would be able to form in a 
reducing environment. A metal ion was observed in the structure via the octahedral geometry 
between neighbouring amino acids and nearby water molecules. However, it was concluded that it 
was likely to be a sodium atom and was observed as an artefact of the crystallisation conditions 
which contained 1M sodium acetate. As this occurred in the NADPH binding site it could also explain 
why no substrate binding was observed when excess ligands were added to the screening process. 
Finally, this structure was in a different space group of P21 compared to the current PDB structures 
which are in P21 21 21. The crystal packing present was much denser with two protein chains 
orientated back to back and inverted with respect to one another in the asymmetric unit. This could 
have potentially come about due to a transisent interaction between CobK and CobL resulting in 
different contacts present during crystal packing and growth. With no ligands present there was an 
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improvement in the resolution reported of the already existing apoenzyme. It was interesting that 
the flexible loop region of CobK could be observed in one of the protein chains due to crystal 
contacts trapping it and allowing this dynamic loop to be modelled. When this protein chain was 
overlaid with the holoenzyme available in the Protein Data Bank, there was little difference between 
these structures as shown in Figure 44. When this structure is overlaid with existing CobK structures 
it bears a closer resemblance to the apoenzyme (5C4R.pdb) with an RMSD of 0.534 and includes the 
active site loop residues. The degree of variation in the flexible loop region, compared to the 
product structure, and lack of electron density in the apoenzyme highlights just how flexible this 
region is. For a structure solved to 2.0Å an R-free value of 0.31 is higher than expected given an R-
work value of 0.24. Clearly the apoenzyme is more flexible in nature than the product-bound form, 
which may have resulted in more variation within the crystal packing and flexible loop regions. 
Despite this the model is in good agreement with existing structures.  
 
Figure 44: The CobK in blue is the structure solved within this project, where the flexible loop 
region and sodium ion have been coloured purple. The blue CobK has been overlaid with the 
existing apoenzyme (green) with an RMSD of 0.534 between 211 alpha carbon atoms. The product 
bound CobK (green with PC6B in yellow and NADPH in blue) gave an RMSD of 1.228 between 235 
alpha carbons. Figure made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 
Schrodinger, LLC.The Pymol alignment function was ‘align Prot1////CA, Prot2, object=alignment’. 
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3.4.3 CobB crystallography 
During the purification of CobB in the presence of HBAD, product binding was visibly observed 
by the pink pigmentation co-migrating during nickel column chromatography, size exclusion 
chromatography and concentration steps. This also happens with CobK and CobH protein 
purifications with their respective products. HBAD binding to CobB appeared to show an increase in 
protein stability and yield but when this was measured using a thermal melt study surprisingly there 
was no change in the melting temperature of CobB.  
In a similar way to the CobL crystallography, the structure of CobB remains unsolved despite 
crystals being obtained. The highest resolution data obtained was limited to only 3.0Å, but given 
models were generated with extremely high confidence scores, it still was not possible to solve the 
structure of CobB using molecular replacement. As was the case with CobL, a high Rpim of 0.138 was 
obtained despite a good multiplicity and completeness score, but once again the outer shell Rpim 
was similar to Rmerge highlighting poor signal-to-noise ratio105.  The quality of the crystals was 
insufficient as indicated by the CC1/2 of 0.763 in the outer shell. The models generated for molecular 
replacement were from a varied range of existing PDB structures available, combined with 
extremely high confidence scores, which were in line with the ATP and glutamine binding domains 
present in class I glutamine-dependent amidotransferases. The Matthews coefficient estimated that 
two protein chains would likely occupy the unit cell, which is in agreement with the literature of 
CobB forming a dimer51. There was also the presence of non-crystallographic symmetry in the 
asymmetric unit cell which may also have hindered molecular replacement strategies.   
Despite producing additional crystals containing selenium labelled methionine, which were 
successfully picked for data collection, the structure of CobB could still not be solved. The selenium 
anomalous crystal data was again restricted to a high resolution limit of 3.03Å. These data had an 
anomalous completeness of 99.9% and anomalous multiplicity of 6.5 but once again a high Rpim of 
0.165 and CC1/2 of 0.531 highlight the low quality of diffraction for these crystals, as well as a low 
mid-slope anomalous probability score of 0.882 which meant the selenium atoms could not be 
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assigned correctly. It is possible that prolonged radiation damage decreased the quality of the data 
over this time course as diffraction data had to be collected to 720o. Also given the nature of the 
small flat square crystals it was difficult to keep the beam line centred down the planar edge, which 
will have contributed to a lower quality diffraction data collection at various oscillations.  
It was surprising to discover that there was a structure of cobyrinic acid a,c-diamide synthase 
(anaerobic CobB equivalent) already available on the PDB (4PSF, 5IF9 and 5IHP). Upon further 
investigation this protein structure appears to only contain the ATP binding domain. The Phyre2 
modelling server did produce a model based on this PDB structure but it was ranked at 54/120 with 
24% sequence similarity and had a confidence score of 99.5%. Despite these available PDB 
structures and the Phyre2 models, molecular replacement phasing was still unable to solve the 
structure of CobB. This structure of cobyrinic acid-a,c-diamide originated from Mycobacterium 
smegmatis. Upon locating this gene from its genome which has locus tag ‘MSMEG_1927’, the 
neighbouring gene sequences did not show the presence of glutamine binding domain with 
‘MSMEG_1926’ a phosphoglycerate mutase (glycolysis protein) and ‘MSMEG_1928’ a 
serine/threonine phosphatase. This could mean that the glutamine binding domain is located 
elsewhere in the genome of M. smegmatis and, in a similar fashion to CbiET, indicate CobB arose as 
a result of a gene fusion event. Alternatively, the amidation steps of cobyrinic acid may occur via the 
neighbouring phosphatase gene, in which this enzyme subsequently removes the phosphate group 
added via the ATP binding domain, highlighting an alternative catalytic mechanism.   
If a structure of CobB had been obtained further studies would mimic those in line with other 
class I glutamine-dependent amidotransferases 76,106–109. These studies typically go on to identify the 
amino acid residues which are involved in the formation of the molecular tunnel required for the 
safe delivery of ammonia from the glutamine binding site to the ATP binding site107,108. Additional 
studies have also attempted to explore how these two binding sites are linked and coordinate their 
respective reactions when both are occupied by substrates to avoid the loss of wasteful 
hydrolysis76,109. The antibiotic acivicin has also been shown to be an inhibitor in glutamine-
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dependent proteins, as it is able to bind to the active site cysteine and has assisted in crystallography 
structure determinations 110,111. But most importantly, it would have been possible to study the 
CobH-CobB pair structurally to better understand product/substrate transfer. 
As discussed above with CobL crystallography and future work in section 3.4.1 continued 
crystallisation screening and optimisation may produce higher quality and larger crystals and result 
in better diffraction data. Again, it could be worth trialling the crystal glue provided by MiTeGen or 
the antibiotic acivicin.  Alternatively, the use of mercury soaks, given CobB contains a readily 
available active site cysteine, would produce a much stronger anomalous signal when collecting 
crystal diffraction data. Finally using a CobB protein from another species may be easier to purify 
and crystallise, yielding a near atomic resolution structure. 
3.4.4 CobH crystallography (CobB co-crystallisation with CobH) 
There is little new information to report on the 1.5Å structure of CobH solved during this 
project. There was a very small improvement on the resolution but otherwise this structure is 
identical to existing product bound structures. CobH was a relatively easy protein to purify in high 
amounts and produced numerous large pink crystals in a variety of crystallography screen conditions 
in the presence of its product HBA.  
The co-crystallisation attempts did not assist in the crystallography of a CobB structure. A 
preliminary thermal melt study of CobH and CobB was carried out to probe if there may be an 
interaction between these enzymes as shown in Figure 45. The presence of HBA did interfere with 
the absorbance measurements of SYPRO-orange used during this technique, meaning a change in 
melting temperature (Tm) of CobH could not be measured. When a thermal melt was carried out on 
CobH and CobB together, with CobB activity being controlled by using either ATP or non-
hydrolysable ATP, the presence of HBA/HBAD signal continued to interfere. However, what was 
interesting to observe is that when PC6B (which does not absorb in the absorbance range of SYPRO-
orange) was converted into HBA and subsequently HBAD in the presence of CobL, CobH and CobB 
together, the HBA signal was lost, Figure 45C. The HBA signal is produced when SAM is added for 
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CobL to convert PC6B into PC8 which can be subsequently converted in HBA by CobH and non-
hydrolysable ATP prevents CobB activity. Yet when this reaction is set up and repeated with ATP for 
CobB to convert HBA into HBAD, the HBA signal is not observed. This may indicate that a protein 
interaction is occurring and blocking the HBA absorbance measurements at lower temperatures. The 
results of Figure 45B could possibly be explained by the fact that thermal melt studies are carried 
out in an excess of substrates, so unbound HBA interfered, whereas in Figure 45C HBA can only be 
produced directly from PC6B and therefore proportional to enzyme activity. There are a lot of 
components in some of these thermal melts and these experiments are very preliminary, so it is 
certainly not a conclusive result that these proteins interact, but it is an interesting observation 
regardless.  
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Figure 45: Real time PCR thermal melt studies of (A) CobH in the presence and absence of HBA (B) 
CobH and CobB in the presence and absence of HBA and where CobB activity is controlled using 
ATP/non-hydrolysable ATP (C) CobL, CobH and CobB where PC6B is converted into HBA using SAM 
and HBAD using glutamine and ATP. 
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3.4.5 Concluding remarks 
Despite numerous efforts to produce and optimise CobL and CobB crystals, it was perplexing 
that the crystals produced and sent off for data collection were of insufficient quality for molecular 
replacement or SeMet anomalous dispersion experiments. Co-crystallisation efforts of the enzyme 
pairs were promising but unfortunately resulted in the crystallisation of only one of the present 
proteins, in which both of these had already had their structures solved and published. The 
structures of CobK or CobH that were solved did not reveal anything substantially new regarding 
how these enzymes function and only really offered a small improvement in the resolution.  
There are certainly plenty of continuing efforts that can be undertaken to produce good quality 
crystals to help solve the structures of CobL and CobB but due to the time constraints of this project 
they could not be acted on. In an effort to explore the enzyme pairs and how the subsequent 
enzyme in the cobalamin pathway receives its substrate it was considered that perhaps other 
techniques to probe the likelihood of a protein-protein interaction could be used as discussed in the 
next chapter.  
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Chapter 4: Investigating product 
binding and release from CobK 
 
4.1 Introduction, aims and objectives 
The crystal structure of CobK with NADPH and its product precorrin-6B (PC6B) was solved by the 
Pickersgill group in 201562, which in fact surprisingly contained PC6B which was additionally 
methylated at C5. As described in section 1.4.2 the structure shows tight binding of the product 
PC6B, via the closure of a flexible loop region over the active site. It is plausible to suggest that 
product binding during the cobalamin biosynthetic pathway prevents off-pathway reactions. To 
explore and confirm product binding activity in CobK the following experiments were carried out: 
 
1. UV-VIS spectroscopy to follow the purification of PC6B and how the absorbance changes 
under different buffer conditions and during the addition of CobK via a titration 
experiment. 
2. Thermal melt studies of CobK and how its stability changes in the presence of the ligands 
NADPH and PC6B by calculating the change in melting temperature (Tm). 
3. 2D nuclear magnetic resonance (NMR) using N15 labelled CobK protein to observe how 
the spectra change in the presence of the ligands NADPH and PC6B. 
4. Isothermal calorimetry (ITC) to quantify the dissociation constant (Kd) for PC6B product 
binding. 
 
After demonstrating that CobK binds its product tightly, the next question tackled is how the 
cobalamin pathway continues and CobL, the subsequent enzyme in the pathway, obtains its 
substrate PC6B. There are two possibilities; either the dissociation constant (Kd) is sufficient for the 
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CobL catalysed methylations to proceed at sufficient rate, or there is some active transfer process 
between CobK and CobL. The latter prevents the possibility of off pathway reactions and wasteful 
loss of intermediates half way through this biosynthetic sequence. An exciting possibility is that a 
protein-protein interaction occurs between CobK and CobL to facilitate the successful delivery of 
PC6B between the two enzymes. X-ray crystallography of the two proteins was attempted and 
discussed in the previous chapter, but this did not lead to a successful co-crystallisation of a CobK-
CobL complex. Therefore, other laboratory-based techniques were used to explore release of PC6B 
to CobL including: 
 
1. Native-PAGE gels, a nickel column pull down and size exclusion chromatography (SEC). 
2. UV-VIS spectroscopy titration to explore if SAM or SAH triggers the release of product 
PC6B. 
3. Kinetics of PC6B turnover in the presence and absence of CobK. 
4. 1D proton NMR to observe if CobK and the CobL C-terminus (CobLc) potentially interact. 
 
Of the four enzymes CobK, CobL, CobH and CobB investigated in these last two chapters, two of 
these, CobK and CobH, have demonstrated visually, experimentally and structurally product binding 
activity53,62,67. Why these two enzymes, which are so close together in the cobalamin biosynthetic 
pathway, do this is unclear and it raises the question as to whether there is a purpose for this? 
Having already discussed the possibility of substrate channelling to prevent the wasteful loss of 
intermediates, in what is a complex and metabolically demanding biosynthetic pathway, it is 
impressive that specificity is maintained given the high degree of similarity between the various 
cobalamin intermediates. In this case substrate channelling may also serve a purpose of controlling 
the order of reactions and prevent out of turn reactions. Failure to methylate C20 via the enzyme 
CobI, alters the chemistry of biosynthesis in such a way that CobJ, only two steps further along, is 
then unable to correctly carry out the corrin-ring contraction, resulting in a dead-end intermediate56. 
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For example it is reasonable to suggest that the cobalamin intermediate PC6B may be able to bind to 
CobB, subsequently missing out decarboxylation and methylation of C12 via CobL and CobH which 
could be why CobK ensures delivery directly to CobL as discussed above via a protein-protein 
interaction. In a similar fashion CobH may deliver HBA to CobB for the successful di-amidation 
reaction. CobQ is an enzyme further upstream in the pathway and also carries out amidation 
reactions in a very similar fashion to CobB, which could therefore interfere with the enzyme 
reactions between these two proteins.45. To explore incorrect/correct binding of cobalamin 
intermediates to CobK the following were carried out: 
1. Fluorescence spectroscopy to demonstrate if hydrogenobyrinic acid (HBA), the product 
of CobH, can bind to CobK. 
2. An attempt to crystallise CobK with PC6B, as the existing structure contains an over-
methylated ligand of C5-methylated-PC6B. 
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4.2 PC6B binding and release to CobK 
 
4.2.1 PC6B purification 
The purification of PC6B fully relies on the product binding activity of CobK, as it is isolated from 
CobK after a nickel column purification step. For this reason, an additional cell pellet containing over 
expressed CobK was added to the PC6B producing cell pellets so that any additional free PC6B can 
be mopped up, given these cell cultures are grown for a 24-hour period. Once the cells have been 
sonicated and the supernatant collected, this is run down a nickel column where CobK with bound 
PC6B binds to the nickel beads via its histidine tag.  
Upon collecting the nickel column elution (which was brown in colour) the pH was dropped from 
pH7.5 to pH4.0. This resulted in a very clear colour change from brown to yellow, accompanied by 
some precipitation which was removed by centrifugation Figure 46. The precipitation was shown to 
be CobK, confirmed via an SDS-PAGE gel and the colour change of brown to yellow was assumed to 
be PC6B changing from a protein bound state to a free state, which was confirmed by UV 
spectroscopy, shown in Figure 46. Interestingly when the pH was subsequently returned to pH7.5 a 
second occurrence of protein precipitation occurred, which again was confirmed to be CobK, via an 
SDS PAGE gel, and this was removed via centrifugation. This second wave of precipitation removed 
most of the remaining CobK protein present, which was important for improving PC6B purification. 
Changing the pH twice proved to be a significant addition to the purification as it ensured the 
removal of all of CobK, when compared to the original purification protocol provided, shown in 
Figure 47. For the reverse phase column step to work it was essential to drop the pH back to pH4.0, 
upon which no further precipitation was observed, to ensure that PC6B would bind to the column in 
its protonated form. The PC6B could clearly be seen binding the reverse phase column, due to its 
yellow colour, and a UV scan was used to confirm the presence of PC6B in the elution, Figure 48. 
Mass spectrometry was also used to confirm PC6B and the m/z agreed with that recorded in Deery, 
et al, 201253, Figure 49. The reverse phase column elution was freeze dried via lyophilization. The 
PC6B powder was weighed out and stock solutions prepared for future use.   
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Figure 46: UV spectroscopy of PC6B purification and the effect when the pH is lowered to remove 
CobK protein.  
 
 
Figure 47: SDS PAGE gels of new (A) and old (B) methods to purify PC6B. A) Shows that an 
additional step changing the pH results in the removal of more CobK (~26kDa) earlier in the 
purification. B) Shows the old PC6B purification method where it can be seen a small amount of 
CobK remains in the final elution step from the RP18 column.   
 
  
 
pH7.5    à    pH4.0 
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Figure 48: UV spectroscopy of PC6B RP18 purification step, showing free PC6B present in the 
elution step. 
 
 
Figure 49: Mass spectroscopy of PC6B purification, showing the correct mass observed at 897.4.  
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4.2.2 PC6B wavelength scans under different buffer conditions 
Initially CobK and CobL were purified in their respective buffers. However, studies involving both 
proteins CobK and CobL sometimes led to confusing wavelength scans relating to bound and free 
PC6B as recorded in section 4.2.1. As CobK was a more stable protein than CobL and therefore easier 
to purify, CobK could also be purified in CobL buffer during a protein purification, when both 
proteins were required for an experiment. Due to the misleading wavelength scans obtained the 
spectroscopy profile of PC6B was investigated by exploring the effects of pH and salt concentrations 
on purified PC6B, based on differences in the protein purification buffers used for CobK and CobL.  
Initially the salt concentration was investigated as CobK is typically purified in 100mM NaCl 
pH7.5, while CobL is purified in 500mM NaCl pH8.0. A PC6B concentration of 30µM was diluted in 
varying concentrations of sodium chloride and a wavelength scan carried out to observe if varying 
the salt concentration altered the spectroscopy of PC6B. The results are shown in Figure 50, where it 
can generally be seen that increasing the salt concentration does not have an effect on the PC6B 
peak position (378nm), despite a general increase in the baseline of each absorbance reading.  
 
 
Figure 50: UV spectroscopy of PC6B in increasing sodium chloride concentrations in line with the 
protein purification buffers used in the laboratory.  
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
340 360 380 400 420 440
Ab
so
rb
an
ce
 (A
U)
 
Wavelength (nm)
PC6B in varying salt concentrations
0mM salt
100mM salt
200mM salt
300mM salt
400mM salt
500mM salt
 120 
However, the pH influenced the absorbance spectrum of PC6B as shown in Figure 51. There is a 
peak shift as pH is changed, with the maximum varying between 348nm and 378nm or a broader 
double peak between the two suggesting two to three different states of PC6B may exist. The yellow 
colour was visibly seen to decrease as the pH was increased. This change is most likely to be due to 
protonation of the nitrogen atoms inside the pyrrole groups, as this would affect the conjugation 
system of the tetrapyrrole. It is unlikely to be due to the carboxyl groups outside the tetrapyrrole as 
these are not directly conjugated to the ring structure. Finally, the brown colour observed in section 
4.2.1 is not observed suggesting this colour is only present when bound to CobK, as observed after 
the nickel elution step during a purification, as shown in Figure 46.  
 
Figure 51: UV spectroscopy of purified free PC6B at different pH. It can also be visibly seen that the 
yellow colour decreases as the pH increases.  
 
 
These results clearly show that pH has a profound influence on the absorbance spectrum of 
PC6B. This meant that all proteins needed to be purified in the same buffer to ensure pH changes did 
not influence the spectrum obtained. To avoid any further irregular PC6B wavelength scans, 
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concentrated stock solutions were subsequently prepared by weighing out a known mass of PC6B 
powder and dissolving this in distilled water to make stock solutions which were stored at -800C.  
 
4.2.3 PC6B binding titration 
The purification of PC6B via a CobK nickel column purification shows product binding activity is 
occurring. To further show that CobK is able to bind its product PC6B, a binding titration was carried 
out and measured using UV spectroscopy. A stock solution of 30µM PC6B was prepared in CobK 
buffer (pH7.5) and an initial wavelength scan carried out to show PC6B is in the free state which 
absorbs at 378nm. CobK both with and without NADPH present was titrated into this PC6B solution 
and a wavelength scan (280-450nm) taken after each addition. The results are shown in Figure 52 
and show a clear peak shift from 378nm to 348nm over the course of the titration, showing PC6B 
absorbance changes from a free state to a CobK-bound state.  
When the titration was carried out in the presence of CobK and NADPH there was a more 
distinct peak shift than when the titration was carried out only in the presence of CobK. An 
isosbestic point was observed around 360nm suggesting that the mixture contains two distinct 
states which are free PC6B and protein bound PC6B. This shows that NADPH assists in substrate (and 
product) binding and is most likely due to CobK loop interactions with both NADPH and PC6 allowing 
the loop to fully close over the active site.  
NADPH does absorb with a peak maximum of 345nm, so a control titration was carried out 
where only NADPH was titrated into PC6B, as shown in Figure 52C. A slight peak shoulder is 
observed as the NADPH is titrated in, however the free PC6B peak maximum at 378nm is still clearly 
the distinct peak, showing that addition of NADPH at these low concentrations is clearly not enough 
to produce a false positive meaning the PC6B peak shift from 378nm to 348nm is due to CobK 
binding PC6B, with PC6B going from a free state to a bound state. 
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Figure 52: UV spectroscopy titrations of CobK and/or NADPH into free PC6B. A) Increasing 
additions of CobK+NADPH titrated into 30µM PC6B, where the free PC6B peak at 378nm 
shifts to 348nm. B) Increasing additions of CobK titrated into 30µM PC6B, where the free 
PC6B peak at 378nm shows a reduced absorbance maximum when the absorbance shifts 
to 348nm. C) Control titration where increasing NADPH was titrated into 30µM PC6B.    
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4.2.4 CobK thermal melt 
To probe the product binding activity of CobK further, a thermal melt study was carried out in 
the presence and absence of NADPH and PC6B. Pure CobK protein was purified and each condition 
was repeated three times so an average could be taken. Each well contained 65µM CobK protein 
with a 5x excess ligand concentration used. A real time PCR thermal melt was carried out across a 
temperature range of 25-950C where the temperature was increased by 10C every minute between 
scans. The results are shown in Figure 53. 
 
Figure 53: A real time PCR thermal melt experiment of CobK in the presence and absence of the 
ligands NADPH and PC6B. Upon the addition of these ligands an increase in Tm can be observed 
inferring an increase in protein stability. The melting temperature (Tm) can be calculated by 
recording the temperature at which the negative first derivative occurs and has been labelled on 
each curve. 
 
CobK had a melting temperature (Tm) of 370C and the presence of NADPH and/or PC6B increased 
the Tm indicating increased protein stability when these ligands are bound. The addition of NADPH 
increased the Tm to 440C while the addition of PC6B increased the Tm to 480C. However, the biggest 
increase in Tm came when both NADPH and PC6B were added together to CobK increasing the Tm to 
530C. This shows that the addition of a ligand to CobK increases the protein’s stability. The increase 
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in Tm when both NADPH and PC6B are present further supports tight product binding activity of 
CobK and the addition of two ligands, NADPH and PC6B, together causes a large increase in stability 
which is most likely due to the loop closure around the active site making the protein more rigid.  
 
4.2.5 NMR of CobK product binding activity 
A 2D NMR HSQC experiment was carried out to show CobK binding NADPH and PC6B. The 
protein was produced by growing E.coli in minimal media supplemented with N15 labelled 
ammonium chloride to produce labelled CobK protein which was purified following the standard 
protein purification described in section 2.7.2.1 down a nickel column followed by a size exclusion 
column. An SDS-PAGE of the successful protein purification is shown in Figure 54. As expected, the 
yields were less than those normally observed, as in section 3.2.4, due to the protein being produced 
in minimal media. There was also a small amount of unlabelled CobK present which was likely to be 
due to the N15 labelling protocol followed, in which initially the cells were grown in LB media to 
produce all the cell machinery required for protein synthesis before being substituted with minimal 
media containing N15. Additional proteins can be seen in the SDS gel, possibly due to stress proteins 
produced by the E. coli resulted in a very broad UV absorbance during size exclusion 
chromatography.  
 
Figure 54: Purification of 15N labelled CobK (~26kDa). A) SDS-PAGE analysis of the protein 
purification process. B) UV profile of the S200 size exclusion column elution where the peak is 
from the fractions 11 to 17mls. 
A B 
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Once purified the N15 labelled CobK was concentrated to a concentration greater than 0.2mM 
for the NMR experiment. The NMR spectra are shown in Figure 55and show native CobK, CobK + 
NADPH, CobK + NADPH and PC6B. All three spectra are different highlighting that CobK is interacting 
with the ligands. Despite the amino acids of the protein not being assigned it does suggest the 
ligands are interacting with CobK. The changes observed in the spectra are most likely due to two 
halves of CobK being flexible around the central active site, which acts similar to a hinge when the 
loop region closes over it. Upon the addition of the ligands NADPH and PC6B peaks shifts are 
observed showing the protein is undergoing a conformation change upon binding.  
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Figure 55: HSQC NMR of N15 labelled CobK with the ligands NADPH and PC6B. A change in 
the spectra can be seen upon addition of ligands to the protein.  A) A comparison of free 
CobK in red and CobK with NADPH present in blue. B) A comparison of free CobK in red 
and CobK with NADPH and PC6B present in blue.  
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4.2.6 Isothermal titration calorimetry (ITC) 
A final experiment to probe the product binding activity of PC6B to CobK was ITC. Initial trial 
runs (data not shown) were undertaken at 200C with 13 injections of 3µl and included titrating; PC6B 
into CobK buffer, PC6B into CobK and PC6B into CobK with NADPH present (also at 30µM). The first 
titration of PC6B into buffer did not yield any change and confirmed no buffer mismatch. The second 
titration trial of PC6B into CobK did result in an endothermic signal but the change was only small. 
The final titration of PC6B into CobK and NADPH again resulted in an endothermic change with a 
larger signal, but saturation occurred too quickly. For future titrations it was concluded that PC6B 
into CobK + NADPH was the experiment to be pursued. As ligand saturation occurred too quickly the 
number of injections was increased to 19 with a volume of 2µl, and the concentration of protein was 
increased to 45µM to increase the signal and the temperature lowered to 150C given the reaction 
observed was endothermic.   
The final titration was repeated three times and all run at 150C which are shown in Figure 56. 
The CobK concentration used in the cell was 45µM and PC6B concentration in the syringe was kept 
at 300µM. The dissociation constant (Kd) measured was 2.97µM with an error of 7.61x10-7 and a 
stoichiometry around 0.85. The binding of PC6B was endothermic giving an enthalpy change of 2.7 
kcal/mol. This Kd value is at the higher limit of moderate binding affinity typically quoted between 
millimolar to micromolar ranges112. Stoichiometry of around 0.85 suggests the PC6B concentration is 
underestimated by 15% or concentration errors in ligand and enzyme combined to produce a 15% 
error. 3µM is significant binding, but not as tight as drug-receptor interactions which may be 1000 
times tighter in the nanomolar ranges112.  
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Figure 56: ITC titration of PC6B titrated into CobK. A) Shows the thermal heat signature 
observed during each injection. B) Shows the change in enthalpy measured throughout 
the experiment. 
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4.3 Probing protein-protein interactions between CobK and CobL 
4.3.1 Native gel studies 
Some experiments were initially carried out to probe whether CobK and CobL interact. The first 
was a native PAGE experiment where CobK and CobL were mixed with ligands to see if an interaction 
could be observed. Figure 57 shows the native page gel of CobK mixed with CobL with the ligands 
NADPH, PC6B and SAH present. As CobL forms a tetramer with four active sites, it is possible four 
CobK proteins may be able to bind to the C-terminal domains. As the binding ratio was not known an 
increase in the ratio of CobK:CobL was made across the gel exploring up to 4x CobK: 1x CobL.  
In the native PAGE gel in Figure 57 SAH was used in replacement of SAM to prevent any PC6B 
turnover and hopefully encourage or prolong a protein interaction. As the concentration of CobK 
increases across the gel its band becomes more apparent when mixed with CobL. The emergence of 
a new band or disappearance of existent CobK and CobL protein bands does not occur, when 
compared to the control lanes suggesting there is no CobK-CobL interaction.   
 
 
Figure 57: Native PAGE gel of CobK mixed at increasing ratios to CobL with the ligands NADPH, 
PC6B and SAH present.  
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4.3.2 Nickel column pull down 
A nickel column pull down experiment was attempted to see if CobK and CobL interacted. This 
involved removing the Histidine tag from one of the proteins via the TEV cleavage site using 
thrombin. The thrombin cleavage was trialled on both proteins at different temperatures shown in 
Figure 58. The trial was successful with both proteins where successful cleavage was shown by a 
smaller molecular weight protein band on an SDS-PAGE gel. Both protein gels show that protein 
treatment with thrombin at 40C overnight was not enough for complete cleavage and 370C overnight 
was too high and caused a high activity of unspecific protein cleavage, destroying the proteins in the 
process. The best CobK thrombin cleavage occurred at 160C and 300C left overnight, while the best 
CobL thrombin cleavage occurred at 300C overnight.   
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Figure 58: Thrombin TEV cleavage temperature trials on the proteins CobK ~26kDa and 
CobL ~42kDa. A) Shows the temperature trials of thrombin activity on CobK at 40C, 160C, 
300C and 370C after one hour, two hours, three hours and left overnight. B) Shows the 
temperature trial conditions as in (A) but on CobL protein. As the temperature and time 
increases the improvement of thrombin activity in removing the Histidine tag can be 
observed by the reduction in protein mass. In both trials 160C overnight is the most 
successful, while 370C is too active and when left for too long destroys the protein via 
unspecific activity.  
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For the nickel column pull down experiment only one protein needed to have its histidine tag 
removed. CobK was selected and thrombin treated overnight. The sample was then passed through 
a nickel column, where the cleaved protein was collected from the nickel column wash step. 100µM 
Cleaved CobK was then mixed with 100µM CobL and ligands SAH and PC6B in a 5x excess. The 
mixture was then passed through a nickel column where the flow through, wash and elution steps 
were collected. The samples were run on an SDS-PAGE gel and the results are shown in Figure 59. 
The results show that the thrombin cleavage was successful, and protein isolated in the wash step. 
When cleaved CobK was mixed with CobL and ligands, if there was an interaction both would be 
present in the final elution step. However cleaved CobK is shown to be present in the wash step, 
with none present in the elution so there is no evidence from the pull down to suggest a CobK-CobL 
interaction.   
 
Figure 59: Nickel column pull down experiment between thrombin treated CobK ~26kDa and 
Histidine tagged CobL ~42kDa.  
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4.3.3 Size exclusion chromatography 
A separate pull-down experiment was attempted using a size exclusion column to observe a 
potential interaction between CobK and CobL by way of monitoring if an earlier elution peak was 
due to the formation of a larger protein complex. The protein elution profiles are shown in Figure 
60, where CobL is observed eluting the S200 column after 14mls, while CobK is observed eluting 
after 17mls. CobL comes off the column earlier as it is a larger protein with a molecular mass of 
~42kDa (tetramer ~168kDa) so it is not retained for as long as CobK which has a molecular mass of 
~26kDa.  
 
  
 
Figure 60: Purification of CobK (~26kDa) and CobL (~42kDa). A) SDS-PAGE analysis of CobK protein 
purification process. B) UV profile of the S200 size exclusion column elution of CobK where the 
peak is from the fractions 13 to 18mls. C) SDS-PAGE analysis of CobL protein purification process. 
B) UV profile of the S200 size exclusion column elution of CobL where the peak is from the 
fractions 13 to 17mls 
 
A B 
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When the two proteins CobK and CobL were mixed in equal concentrations and injected on to 
an S200 size exclusion column, two elution peaks were observed at the volumes CobL and CobK 
normally elute and this was confirmed using an SDS-PAGE gel shown in Figure 61A. The gel did not 
indicate any interaction as each elution aliquot only contained one protein. When the experiment 
was repeated in the presence of the ligands NADPH, SAH and PC6B in a 5x excess an additional 
elution peak was observed at 20ml, Figure 61B, but an SDS-PAGE confirmed this was CobK only. This 
was thought to occur due to the presence of the ligands NADPH and PC6B binding to CobK, making 
the protein more rigid upon product binding resulting in a smaller surface area and longer elution 
time. This was confirmed by injecting a separate sample of CobK with ligands back on to the size 
exclusion column and elution volumes compared in Figure 61C, which again confirms this additional 
peak is CobK.  
The crystal structures of native and ligand bound CobK were overlaid to show that there is a 
change in protein conformation. Native CobK is more flexible around its central active site, where 
the two halves have more freedom to act independently resulting in a faster elution time due to the 
protein flexibility occupying a larger volume on the column. This conclusion is also in agreement with 
the thermal melt study in section 4.3.4, where ligand binding increases CobK stability and a 
conformation change observed by overlaying the native and ligand bound crystal structures of CobK 
highlighted in Figure 61D.  
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Figure 61: SEC pull data of CobK ~26kDa and CobL ~42kDa to see if they interact accompanied with 
SDS PAGE gels of the elution volume aliquots. A) Shows CobK and CobL injected together at equal 
concentrations. B) Shows CobK and CobL injected together with ligands NADPH, PC6B and SAH. C) 
Shows the different elution volumes of CobK in the presence and absence of the ligands NADPH 
and PC6B. D) The crystal structures of CobK (blue) alignment with CobK + NADPH & PC6B (green) 
to show an overall change in protein conformation. Figure D made via PyMOL, the PyMOL 
Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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4.3.4 Thermal melt studies of CobK and CobL 
A thermal melt of 200µM CobK and CobL was undertaken in the presence of 20x ligands NADPH, 
PC6B and SAH or SAM, Figure 62. The melting temperature (Tm) measured with just CobK and CobL 
was 44oC, which was an increase on the previously reported Tm of CobK of 370C and CobL of 380C. In 
the presence of NADPH, PC6B and SAM the Tm increased to 48oC, whereas in the presence of 
NADPH, PC6B and SAH the Tm increased to 51oC. These Tm values do not quite align with previous 
thermal studies of CobK and CobL, possibly indicating a protein-protein complex is forming. 
 
 
 
Figure 62: A real time PCR thermal melt shift of CobK and CobL together in the presence and 
absence of ligands which included combinations of NADPH, PC6B and SAH or SAM. The melting 
temperature (Tm) can be calculated by recording the temperature at which the negative first 
derivative occurs and has been labelled on each curve. 
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4.3.5 Does SAH cause PC6B release? 
With CobK having been shown to bind its product PC6B, this suggested that it might be for 
protection of intermediates in the biosynthetic pathway. Class I amidotransferases, such as CobB, 
have been observed to only degrade glutamine when ATP and HBA are present to prevent the 
wasteful loss of generated ammonia. Perhaps CobK works in a similar fashion. It was noted that 
SAM/SAH both contain an adenine functional group linked to a ribose similar to NADPH. As SAM is 
the ligand required in the next biosynthetic step perhaps it works as a trigger molecule to open the 
loop to facilitate PC6B release. This was investigated using UV spectroscopy to establish if PC6B was 
released. 
A PC6B purification was carried out up to the nickel column elution step to provide a sample of 
PC6B bound to CobK. The protein concentration of this sample was measured so that increasing 
concentrations of both SAM and SAH could be titrated in to CobK protein with PC6B bound. The 
ratio of SAM/SAH to CobK protein was increased from 1:1 to 50:1 where the CobK concentration 
used was 52µM. The results are shown in Figure 63and show that increasing the respective 
concentration of SAH/SAM with respect to CobK with PC6B bound does not stimulate the release of 
PC6B as no peak shift is observed, with only the PC6B bound peak present at 348nm.  
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Figure 63: A) Shows a comparison of the chemical structures of NADPH and SAM. B) and C) Show a 
UV titration of the addition of SAH and SAM respectively, where both are titrated into CobK with 
PC6B bound to see if they trigger the release of PC6B which absorbs at 348nm when bound and 
378nm when free in solution.  
 
4.3.6 Enzyme kinetics 
 
To explore if CobK and CobL interact the turnover of PC6B in the presence and absence of CobK 
was investigated to see if a change in the rate of reaction was observed. PC6B has an absorption 
maximum of 348nm when in the presence of CobK whereas PC8 shows a decrease and shift with an 
absorbance maximum of 390nm. Due to the stronger absorption signal at 348nm this was chosen as 
the wavelength to measure absorption, as shown in Figure 64.  
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Figure 64: A PC6B and PC8 absorbance of kinetic studies to observe the turnover of PC6B by CobL 
in the presence of CobK. PC6B has an absorbance maximum of 438nm and PC8 has an absorbance 
maximum of 390nm.  
 
 
 
The turnover of PC6B was measured at 50µM intervals between 50µM-400µM in the presence 
of 5µM CobL, where the reaction was initiated by the addition of 1mM SAM and A348nm was 
measured every three seconds over ten minutes. The second investigation of PC6B turnover was as 
above but with the addition of equimolar concentrations of CobK & NADPH to PC6B to ensure 
product binding. These PC6B conversions are shown in Figure 65where three runs were recorded for 
each concentration and the data was fitted to Equation 4.  
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Figure 65: Kinetics data collected for varying concentrations of PC6B turnover in the presence and 
absence of equimolar CobK and NADPH using 5µM CobL and 1mM SAM to begin the reaction. (A) 
50µM PC6B (B) 100µM PC6B (C) 150µM PC6B (D) 200µM PC6B (E) 250µM PC6B (F)300µM PC6B (G) 
350µM PC6B (H) 400µM PC6B. 
 
 
From Equation 4 a rate constant k was obtained, and this allowed an initial velocity to be 
calculated using Equation 5.  Based on the residual plot scatter appropriate runs were selected so 
that an average velocity could be plotted against PC6B concentration in Figure 66. These data were 
then fitted using the Michaelis-Menten equation, Equation 6, where the error quoted was ± 
standard deviation between the initial rates measured for each run. This allowed a reciprocal 
Lineweaver-Burk plot to be plotted in Figure 66B allowing the Vmax, KM and kcat to be calculated and 
are quoted in Table 10. Both the Vmax and Km were provided by Prism analysis of the Michaelis-
Menten graph but were crossed checked via the Lineweaver-Burk plot where the y-axis intercept is 
1/Vmax and the x-axis intercept is 1/Km in which they were almost identical.  
 
Equation 4 
𝑦 = 𝑌F 𝑒𝑥𝑝H,I +	𝐶 
Where: y= absorbance (AU), Y0= absorbance at 0s (AU), k= rate constant (moldm-3s-1), t=time (s), 
C= y-intercept 
 
Equation 5 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙	𝑟𝑎𝑡𝑒 = 𝑘	𝑌F 
Where: k= rate constant (moldm-3s-1), Y0= absorbance at 0s (AU) and units of Initial rate are 
moldm-3s-1. 
 
Equation 6 
𝑉 =	
𝑘OPI[𝐸][𝑆]
𝑘U	[𝑆]
 
Where V= enzyme velocity (moldm-3s-1), kcat= enzyme catalytic turnover (s-1), [E]= enzyme 
concentration (moldm-3), [S]=substrate concentration (moldm-3), KM= Michaelis constant           
(mol-1dm3).  
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Figure 66: A) Shows a Michaelis-Menten kinetics representation of PC6B turnover by CobL in the 
presence (red) and absence (blue) of CobK, where initial velocity was plotted against substrate 
concentration. B) Shows a Lineweaver-Burk plot of PC6B turnover by CobL in the presence (red) 
and absence (blue) of CobK. 
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 CobL only CobK present 
Vmax (Ms-1) 784 x 10-6 298 x 10-6 
KM (M-1) 225 x 10-6 48.9 x 10-6 
kCat (s-1) 15.7 6.0 
 
Table 10: A summary of the Vmax, KM and kcat for PC6B turnover in the presence and absence of 
CobK where Vmax is the maximum enzyme velocity.  
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4.3.7 NMR of CobK with CobLc 
1D proton NMR spectra recorded from 0.05 mM CobK with a ligand concentration of 0.15mM 
NADPH and PC6B is shown in Figure 67.  After this solution had been scanned a 0.15mM excess of 
CobLc was added to this solution and a spectrum recorded. Finally, an excess of 1mM SAH was added 
to this solution to mimic the addition of SAM and arrest PC6B turnover during the experiment. Upon 
addition of SAH three new peaks can be observed between 8.5-9.2ppm which are in the region for 
the corrin ring of PC6B, which indicates that in the presence of CobLc SAH is released. Full length 
CobL was not used for this experiment as the tetramer is too large. 
 
 
 
Figure 67: 1D NMR of CobK with PC6B and NADPH bound (green) with a stepwise addition of CobLc 
(blue), followed by SAH (red). Upon the addition of SAH three peaks can be observed 8.5-9.2ppm 
indicating the release of PC6B.  
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4.4 Promiscuous binding of cobalamin intermediates to CobK  
 
4.4.1 Fluorescence studies 
When HBA is placed under a UV lamp it shows fluorescent activity, while PC6B does not. 
However, when HBA is in the presence of CobK the fluorescence changed from orange to green, 
Figure 68. This suggests that HBA binds to CobK. To explore this a UV-VIS wavelength scan was used 
to observe if there was a wavelength shift similar to when PC6B binds to CobK. This result is shown 
in Figure 68 and shows there is no observable absorption change between free HBA and HBA in the 
presence of CobK. 
 
 
 
Figure 68: Wavelength scan of HBA in the presence and absence of CobK to see if there is a change 
in absorbance (as observed with PC6B). It was noticed that under UV light the fluorescence of HBA 
changes from orange (middle tube) to green (left tube) in the presence of the protein CobK. The 
right tube is CobK protein only, showing fluorescence is not due to protein.  
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To further test the potential binding of HBA to CobK a fluorescent spectroscopy experiment 
using nickel beads was undertaken to show if CobK was in fact able to bind HBA. The experiment 
used three separate samples of CobK, HBA and CobK+HBA. These were mixed into separate 
Eppendorf tubes containing 200µl of charged nickel beads and CobK loading buffer (buffer A). The 
solutions were mixed and then spun at a speed of 1000rpm for two minutes to pellet the beads. The 
tubes were photographed under a UV lamp, before the supernatant was collected for fluorescence 
spectroscopy and a sample taken for an SDS-PAGE gel. The process was repeated by adding 
increasing imidazole concentrations using buffer B and buffer C as described in section 2.4.1. Two 
excitation wavelengths were used when scanning HBA samples using fluorescence spectroscopy as 
the spectrum profile contains two absorption peaks at wavelengths 475nm and 525nm. 
The results are shown in Figure 69. The SDS-PAGE gel confirms CobK bound to the nickel beads 
and was not eluted into the supernatant until the final step. The fluorescent lamp photos show that 
there was excess CobK protein with respect to nickel beads as observed in the fluorescent flow 
through supernatant and SDS-PAGE gel. The most intriguing image was the wash step where the 
pelleted nickel beads fluoresce at the bottom of the tube, showing CobK and HBA are bound, while 
for the HBA sample the entire tube is fluorescent showing HBA does not bind to the nickel beads.  
However, the fluorescent spectroscopy spectra do confirm the presence of HBA in the elution 
step when mixed with CobK via a higher excitation signal than the wash step at both wavelengths. 
Combined with the results in Figure 69A, this confirms that CobK retains HBA while binding to the 
nickel beads. The fluorescent spectroscopy profiles of HBA flow through, wash and elution show a 
decrease in the HBA signal at each step, confirming that HBA is not able to chelate to the nickel 
beads. It is also interesting to compare the fluorescent profile of HBA when excited at 475nm, as the 
peak observed at 600nm disappears in the presence of CobK further supporting it is able to bind to 
CobK, as shown in Figure 69Bi. 
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Figure 69: CobK binding HBA nickel pull down. A) Shows an SDS-PAGE gel of the flow through, 
wash and elution steps of the nickel pull down for samples CobK+HBA, free HBA and free CobK 
accompanied with fluorescence observed under a UV lamp. B) Shows a fluorescence wavelength 
scan of CobK+ HBA nickel pull down excited at 475nm (i) and 525nm (ii). C) Shows a fluorescence 
wavelength scan of HBA nickel pull down excited at 475nm (i) and 525nm (ii). 
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4.4.2 NMR of CobK binding HBA 
A 2D NMR HSQC experiment was carried out using N15 labelled CobK to observe if the protein 
was able to bind HBA. Three samples were measured: native CobK, CobK + NADPH + PC6B and   
CobK + NADPH + HBA. The spectra are shown in Figure 70 and all show different conformations of 
CobK, as they do not fully overlap. When the CobK+HBA spectrum is overlaid with the NMR 
spectrum from section 4.2.5 of CobK binding PC6B a very similar spectrum is seen suggesting HBA 
has bound to CobK. This observable peak shifting supports binding of HBA to CobK.    
 
 
Figure 70: HSQC NMR of N15 labelled CobK in the presence of ligands NADPH+ PC6B or NADPH and 
HBA. There is a clear change in spectra between native CobK protein (blue) and ligand bound 
protein (red/green). The spectrum of PC6B (green) and HBA (red) samples are remarkably similar 
showing CobK is able to bind HBA. 
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4.4.3 CobK crystals with ligand binding 
Finally, crystallography was used to confirm visually HBA binding to CobK. CobK protein was 
purified and crystal trays set with both the ligands HBA and PC6B, as the current published structure 
contains C5-methylated PC6B. HBA binding to CobK was inferred during the protein concentration 
step, as the pink pigment remained in the upper half of the concentrator. Pink crystals did not form 
when CobK was mixed with HBA. However large crystals of CobK ranging between 1-4mm in length 
in the presence of 5x excess ligand concentration of PC6B and NADPH were obtained, Figure 71. The 
crystal conditions used were 17-19% w/v PEG 3350 and 0.2M NH4Cl pH8.0, with a protein 
concentration of 20mg/ml. These crystals were picked in a cryo-solution containing 20% glycerol and 
sent off for data collection at Diamond Synchrotron, where the data collection and refinement is 
summarised in Table 11.  
 
Figure 71: CobK crystal optimisation produced in the presence of PC6B and NADPH 
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CobK+ PC6B data collection statistics 
 
Space group P 21 21 21 
Cell edges (Å) 33.857 73.885 103.612 
90.000 93.293 90.000 
Wavelength (Å) 0.97925 
 Overall Inner shell Outer shell 
Resolution (Å) 1.16-60.16 3.15-60.16 1.16-1.18 
Number of observations 486,306 25,482 20,347 
Number of unique reflections 91,042 4,837 4,506 
Multiplicity 5.3 5.3 4.5 
Rmerge 0.074 0.034 1.772 
Rpim 0.035 0.016 0.928 
Rmeas 0.082 0.037 2.007 
Mean I/s 9.1 38.1 0.6 
CC1/2 0.999 0.998 0.328 
Completeness (%) 99.9 99.0 99.8 
Wilson B estimate (Å2) 11.0   
 
Refinement statistics 
 
Resolution (Å) 1.17-60.16 
Number of reflections 88,385 
R-work/R-free 0.20/0.22 
Number of atoms  
(protein chains/ligand/water) 
1/2/441 
rmsd bond length  0.010 
Rmsd bond angle 1.343 
Mol-probability score 1.19 
Residues in most favoured regions 
(%) 
99.19 
Outliers (%) 1.13 
Table 11: Crystal data and refinement statistics for CobK with PC6B and NADPH. Rmerge = 
Σ hkl Σ i |Ii–< I>| /− Σ hkl Σ Ii, where Ii is the intensity of the ith observation, <I> is the mean 
intensity of the reflection and the summations extend over all unique reflections (hkl) and all 
equivalents (i), respectively and Rpim is a measure of the quality of the data after averaging the 
multiple measurements and Rpim = Σ hkl [n/(n-1)]1/2 Σ i |Ii(hkl)–< I(hkl) > |/Σ hkl Σ i Ii(hkl), where 
n is the multiplicity, other variables as defined for Rmerge R-factor = Σ hkl |Fo–Fc |/Σ hkl Fo, 
where Fo and Fc represent the observed and calculated structure factors, respectively. The R-
Factor is calculated using 95% of the data included in refinement and R-free the 5% excluded62,103. 
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Upon solving the structure of CobK with PC6B it was in fact confirmed to be methylated at the 
C5 position, Figure 72A in a similar fashion to the already published structure of product bound 
CobK. Given the crystallisation conditions used were identical to the published structure, the unit 
cell dimensions and space group were identical. When these two CobK structures were compared 
there was little difference between them, with only a small degree of variation within some of the 
loop regions, Figure 72B, with both of these structures having been solved to a similar resolution of 
~1.2Å.  
 
 
Figure 72: A) Electron density map of C5-methylated PC6B clearly showing the presence of a 
methyl-group at the C5 position of PC6B. B) Structural comparison of the product bound CobK 
structure solved during this project (blue) overlaid with the existing published CobK PDB structure 
4X7G (green), showing a degree of flexibility within some of the loop regions. Figure made via 
PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC.This alignment gave 
an RMSD of 0.880 when 240 of 249 alpha carbons were aligned using the Pymol function ‘align 
Prot1////CA, Prot2, object=alignment’.   
A B 
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4.5 Discussion and future work 
 
4.5.1 CobK product binding activity  
It is clear that CobK is able to hold on to its product PC6B and will in fact re-bind it in the 
presence of NADPH. PC6B is structurally very similar to PC6A only differing by a single hydrogen on 
carbon-19. So, it is questioned whether CobK product binding activity is important for some form of 
protection. PC6A is an unstable intermediate and therefore not routinely purified in the laboratory 
whereas PC6B appears much more stable. Perhaps tight binding is to ensure that PC6A is protected 
until NADPH becomes available or it facilitates the safe transfer of product to CobL, ensuring that 
the product is not lost or exposed to off-pathway reactions.  
Product binding was demonstrated using a range of techniques including UV-VIS spectroscopy, 
size exclusion chromatography, thermal melts, 2D NMR and ITC. Through UV-VIS spectroscopy the 
absorption maximum of PC6B was shown to change in the presence and absence of CobK protein. 
This was demonstrated through a titration where a clear shift between free PC6B to bound PC6B 
was observed as CobK was added. An isosbestic point was seen indicating that two states of PC6B 
exist in the solution; PC6B bound to CobK and PC6B free in solution. This titration also demonstrated 
binding of PC6B to CobK was more likely in the presence of co-factor NADPH, as a repeated titration 
carried out under identical conditions with the removal of NADPH resulted in a lower absorption 
maximum for bound PC6B to CobK at 348nm.  
PC6B product binding was further supported through thermal melt assays. These showed that 
the CobK will bind both ligands separately, while the presence of both ligands resulted in the largest 
increase in protein stability, where the Tm of native CobK increased from 37oC to a Tm of 53oC. It was 
interesting to note that native CobK had a Tm of 370C as this meant that the protocol for preparing 
N15 CobK for NMR experiments was altered as the protocol suggested growing cells at 37oC, so this 
was lowered to 18oC 99. This observation could also explain why Fang et al, 2018, struggled to 
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produce de novo biosynthesis of cobalamin in E.coli when grown at 370C as they would have 
denatured at least half of CobK present, greatly hindering the cobalamin production pathway113.  
Size exclusion chromatography also gave a longer retention time of CobK when ligands were 
present suggesting that the protein becomes tighter and therefore more rigid as the flexible loop 
region closes over the active site, pulling the two Rossman domains together. A change in 
conformation can be observed when the crystal structures of native and ligand-bound CobK are 
overlapped. However, the SEC highlights that the native CobK may in fact be quite flexible giving a 
more dynamic picture of the protein that X-ray crystallography cannot provide.  
The incorporation and production of N15 labelled CobK was successful and allowed 2D NMR 
HSQC spectra to be recorded. This demonstrated that CobK was able to bind NADPH and PC6B, both 
of which caused a conformation change indicated via a change in the shift values of the spectra, with 
the most dramatic shift observed when both ligands were present. Despite amino acid residues not 
being assigned it was still apparent that a change in conformation is occurring, which supports the 
flexible loop observed in the ligand bound crystal structure, but which is not present in the native 
crystal structure.  
In an attempt to quantify product binding activity and determine a dissociation constant (Kd), ITC 
was used. It was interesting to observe that PC6B binding was an endothermic process, with binding 
being driven by the release of water molecules from the active site, suggesting this is being driven by 
entropic factors rather than enthalpy. A Kd constant of 3µM was obtained. Despite the similarity 
between PC6A and PC6B it would be expected that CobK has a higher affinity for its substrate than 
product. However, it should also be noted that the stoichiometric ratio where n= 0.85 was obtained. 
This could mean that the product does not fully bind to CobK, however it is more likely that this is 
due to error in determining the concentration of PC6B stocks, as weighing out the powder would 
have introduced a large degree of error. Any error in the stoichiometric ratio n will consequently 
result in greater error in the derived thermodynamic parameter calculated during ITC114. Therefore, 
it does not instil confidence in the Kd value quoted. However, this experiment still demonstrates that 
 155 
CobK exhibits product binding activity, supporting the other techniques used, but further 
experiments could be undertaken to improve these thermodynamic measurements. This could 
include measuring the Kd of each ligand separately, but also extended to probing a potential protein-
protein interaction between CobK and CobL, discussed below. 
 
4.5.2 Probing potential protein-protein interactions between CobK and CobL 
 
Initial techniques to probe a protein-protein interaction between CobK and CobL included using 
native-PAGE gels, a nickel-column pull down and size exclusion chromatography experiments, all of 
which were unable to show that CobK and CobL interact. In these experiments when ligands were 
used NADPH was added to encourage PC6B product binding to CobK and SAH was used in place of 
SAM to prevent the production of PC8, in the hope that it would assist in trapping the proteins 
together rather than PC6B turnover. In the Native-PAGE experiment an equimolar concentration of 
CobK:CobL was trialled, but given CobL is a larger protein and forms a tetramer it is possible that 
four CobK enzymes may be able to bind at once around the region of the first active site located on 
the C-terminus of each monomer, hence why increasing CobK concentrations were explored. The 
nickel-column pull down again did not remotely suggest an interaction may be present, but it did 
demonstrate that the Histidine tag can be successfully removed from both CobK and CobL using 
thrombin at an optimum temperature of 160C overnight. The SEC studies did not show a protein-
protein complex via an earlier elution profile but did surprisingly end up highlighting the dynamic 
nature of CobK upon PC6B product binding which was discussed above in section 4.6.1. When a 
thermal melt study was undertaken on CobK and CobL together with the ligands NADPH and PC6B, 
to encourage product binding, and SAH or SAM, different melting temperature (Tm) values were 
obtained that were not in agreement when individual protein and ligands were used. When only one 
ligand was used in combination with CobK and CobL together (data not shown) the Tm remained at 
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44oC, therefore possibly indicating that a protein-protein complex is being formed with a different 
degree of stability to the individual proteins. 
Having researched around CobB and the action of class I amidotransferases, discussed in chapter 
1 section 1.4.5, and how the two active sites wait for the other to be occupied before carrying out 
catalysis, it was thought a similar action may occur via a CobK and CobL complex. There is a small 
structural similarity between the ligands NADPH and SAM/SAH, which both share an adenine joined 
to a ribose unit. Therefore, PC6B may not be released from CobK until SAM is present for CobL 
activity. This was investigated by measuring the shift in the absorption maximum of bound PC6B at 
348nm and the expected absorption maximum of free PC6B at 378nm. As increasing concentrations 
of SAM and SAH were titrated into a solution containing bound PC6B to CobK, an absorption shift 
was never observed and does not trigger the release of PC6B. Given how buried the binding site of 
SAM is in the crystal structures of methyltransferases, shown in Figure 10 and Figure 15 in Chapter 
1, this result is not too surprising. 
When PC6B is converted into PC8 via CobL there is a shift in the absorption from 348nm to 
390nm. This was used to measure the rate of conversion for CobL. As PC6B has a higher absorption 
maximum the wavelength 348nm was therefore selected to follow the reaction over time. This 
conversion was carried out in the presence and absence of CobK to see whether a change in rate 
was observed and indicate if a potential protein-protein interaction is occurring.  
 Pre- and post-scans confirmed the conversion and whether PC6B was bound to CobK if present. 
The absorption maximum of PC6B in CobL buffer of pH8 did shift to 348nm, Figure 73, but was not 
as pronounced as CobK buffer of pH 7.5. Finally, a large excess of SAM was added to initiate the 
experiment and also provide an almost consistent concentration so that it could be ignored for the 
kinetics analysis. 
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Figure 73: PC6B pre-scan and PC8 post-scan of PC6B conversion with CobL only, in CobL buffer of 
pH8.0 
 
 
The kinetics analysis of PC6B conversion shown in Figure 66 and Table 10 does appear to suggest 
that CobK and CobL do interact. If CobK binds to CobL this would reduce the concentration of active 
CobL to react with substrate which causes a reduction in Vmax. When CobK is present the reaction 
reaches a half Vmax at a lower substrate concentration which changes the km. This may mean that the 
presence of CobK affects the affinity of CobL for its substrate PC6B. CobK may be binding to CobL in 
such a way that it inactivates the active centre, trapping the enzyme-substrate complex, indicating 
that CobK is acting in a similar fashion to an uncompetitive inhibitor, where both the Vmax and Km 
values are changed115. 
 At high CobK-PC6B concentrations the Vmax falls by a factor of approximately two-fold and the 
Km falls by roughly a factor of four. If Km were unchanged there would be no effect on substrate 
binding, however it is interesting that binding appears to be tighter. The kcat for the reaction does not 
dramatically change. Therefore, the results suggest the possibility of higher affinity for substrate and 
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a reduction of the number of active sites available which would be compatible with the direct 
transfer of PC6B from CobK to CobL.  
The 1D proton NMR experiment also supports a CobK-CobL interaction. Protein concentrations 
were at the lower limits of the technique but when SAH was added to a mixture of CobK with PC6B 
bound and CobLc a change in the proton spectra was observed where three new peaks were 
observed between 8.5-9.2 indicating the release of PC6B into solution.  
The kinetics and NMR experiments are both in the early stages of concluding a protein-protein 
interaction but are certainly promising. Improvements for further work would include testing the 
kinetics on CobLc as this is the active site that acts first on CobL. However, the absorption spectrum 
of PC7 would need to be measured so that a suitable wavelength can be selected during the kinetic 
measurements. Also, as the CobL concentration used during the kinetics was quite low it is possible 
that using the same buffer in the presence and absence of CobK at pH7.5 may not cause it to 
precipitate out of solution and would therefore provide a much better comparison between the two 
experiments regarding the initial PC6B absorption spectrum. This may also explain why the residuals 
plot observed when fitting initial absorbance against time for CobL became worse at higher 
concentrations, as the same fitting equation was used for both experiments.  
Structural insights into a possible CobK-CobL complex would allow further study via targeted 
mutagenesis, but co-crystallisation attempts were unsuccessful. Initial NMR studies appear to 
support an interaction but are limited to smaller protein sizes. This limits the technique to CobK-
CobLc studies, which could certainly be repeated at higher protein concentrations. If amino acid 
residues were assigned to a HSQC experiment using N15 or C13 labelled CobK this would allow the 
identification of interacting amino acids to be identified. An interaction between these enzymes 
would most likely be acting on opening the flexible post-b2 loop region of CobK. The orientation of 
PC6B, when bound to CobK, is such that the C15 methylation site is facing outwardly and therefore it 
is plausible to speculate that it is presented to CobL. For example, this could be instigated via a 
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competing arginine on CobL, which out-competes an existing arginine interaction on CobK which can 
be seen acting as a latch for loop closure, as highlighted in Figure 11 in Chapter 1.   
 
4.5.3 Promiscuous binding of cobalamin intermediates to CobK 
HBA is a fluorescent orange/pink cobalamin intermediate and it was observed that the 
fluorescence changes to green in the presence of CobK protein. A UV-VIS spectroscopy wavelength 
scan was initially measured on a sample of HBA with and without CobK present to see if there was a 
change in absorbance, similar to when PC6B is free in solution or bound to CobK. However, spectra 
of HBA did not change when in the presence of CobK. To investigate this further a nickel column pull 
down experiment was carried out to see if when HBA and CobK were mixed, HBA would be present 
when CobK was purified via its histidine tag. A control containing only HBA was carried out in 
tandem to confirm that HBA was not able to chelate nickel, where it would be purified alongside 
CobK rather than through CobK binding. This was tracked using an SDS-PAGE gel and visually 
checking the fluorescence under a UV light. CobK acted as expected during the purification and it did 
appear that CobK was binding HBA, which is best observed in Figure 69 during the wash step and the 
fluorescence is visible on the pelleted nickel beads, which did not occur in the HBA wash step.  
The supernatants from each step during the nickel pull down experiments were collected and 
measured using fluorescence spectroscopy. As HBA has two absorption maximums at 475nm and 
525nm these were both used separately as excitation wavelengths. When HBA was excited at 
475nm in the presence of CobK, an absorption emission maximum around 600nm was not present 
when compared to the HBA control. At both excitation wavelengths the nickel column elution 
measurements contained more HBA than the wash step when CobK was present, where excitation 
at 475nm gave a stronger signal.  
These two experiments do appear to support the idea that CobK is incorrectly binding HBA. 
However, it was found that as the imidazole concentration increased throughout the pull down it did 
appear to interfere with the visual fluorescent profile of HBA, Figure 69 elution profile, which also 
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prevented successful UV-VIS wavelength scans. The volumes in this experiment were very small, but 
if repeated the imidazole should be removed by buffer exchange or a desalting column to provide 
better spectroscopy profiles.  
This was followed up with structural studies using 2D NMR in a similar fashion to section 4.3.5. 
N15 labelled CobK was produced and spectra profiles of native CobK, CobK with ligands NADPH and 
PC6B and CobK with ligands NADPH and HBA were compared. The spectra of native CobK varied 
greatly from the other two which were overall highly similar. This is in agreement with the 
conformation change observed when the flexible loop region of CobK binds ligands and further 
supports incorrect binding of HBA.  
Production of CobK crystals with HBA were also trialled to explicitly confirm binding but failed. 
Native CobK crystals were also attempted in the hope of soaking with HBA, but again failed to 
produce anything. In tandem with these trials CobK crystals with the ligand PC6B were also 
attempted as the current structure solved by the Pickersgill group in fact contains C5-methylated 
PC6B62. This did produce crystals, where further attempts to soak with HBA were also trialled but 
were also unsuccessful. 
The protein structure solved that was put down for crystallography trials was purified directly 
from PC6B producing cells, rather than adding purified PC6B, which has been confirmed by mass 
spectroscopy53. This plasmid contains all the Cob enzymes up to CobK, so multiple methyltransferase 
enzymes are present and may be able to act out of turn and incorrectly methylate C5. Given PC6B 
does not share the same molecular mass with preliminary cobalamin intermediates in the pathway, 
this rules out any out of turn methylation occurring during the prolonged 24hr cell growth, but 
rather after CobK purification. The protein purification was followed using SDS-PAGE gels so it is 
possible a methyltransferase was purified alongside CobK as their molecular masses only differ by 
~1kDa, which may not differentiate on the resolution of a gel. However, none of the Cob enzymes 
before CobK contain a histidine tag and the canonical methyltransferases form dimers while CobK is 
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a monomer. This would have led to two elution profiles which were not obtained during size 
exclusion chromatography making this C5 methylation difficult to explain. 
Regardless the C5-methyl group is clearly shown in the electron density map of the crystal 
structures highlighting that CobK does not only bind its substrate PC6A and its product PC6B but is 
also able to bind two other corrin ring based intermediates; HBA and C5-methylated PC6B. As to 
which methyltransferase has acted out of turn, CobM is initially proposed based on comparison of 
comparing the binding ligands. CobK binds a contracted corrin ring of nineteen carbons narrowing 
the choice to CobF and CobM. CobF acts on removing the ethanone decoration on C1 before 
carrying out a methylation. Further methylation has been identified before by Warren et al, 1990 
where CysG (CobA) was found to bring about a third methylation at a high concentration to C12 of 
PC255.  The quickest method to confirm this would be to purify all the methyltransferases separately 
and add PC6B followed by mass spectroscopy to confirm whether an additional methylation has 
occurred. 
 
4.5.4 Concluding remarks 
A wealth of experimental techniques have been undertaken and reported in this chapter to 
predominantly explore CobK binding interactions. The unusual product binding activity of PC6B to 
CobK has been demonstrated. In an attempt to answer how CobL obtains its substrate PC6B from 
CobK, a potential protein-protein interaction has been explored between these two enzymes. 
Attempts to trap the complex structurally via X-ray crystallography were unsuccessful but NMR and 
kinetics do provide supporting evidence of an interaction. Further kinetic studies and ITC would 
continue to probe this. The lack of a full length CobL structure makes targeted mutagenesis difficult 
to track down key binding residues, but the CobLc structure could assist in initial attempts.  
To conclude preliminary studies support HBA binding to CobK, which is produced further 
upstream in the biosynthesis of cobalamin. This chapter has demonstrated that out of turn HBA 
binding and an additional methylation can occur within the reaction pathway. These observations 
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coupled with the fact that the substrate PC6A is an unstable compound, add weight to the idea that 
product trapping activity of CobK could be important for substrate channelling and protection of out 
of turn reactions within the cobalamin pathway itself. Therefore, CobH may also prevent other out 
of turn modifications to HBA and ensure the safe delivery of HBA to CobB. This has led on to the 
investigation of how specificity of cobalamin intermediates is brought about and is discussed in the 
next chapter, with a particular focus on the canonical methyltransferases. 
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Chapter 5: The Cob 
Methyltransferases 
 
5.1 Introduction, aims and objectives 
Methylation is a key reaction required in the development of the cobalamin corrin ring, 
requiring eight methylations in the transformation of uroporphyrinogen III to hydrogenobyrinic 
acid1,15. These are catalysed by the six so called canonical methyltransferases and CobLc a non-
canonical methyltransferase, as summarised in Table 12. The canonical methyltransferases are 
classified via their tertiary fold, in which the active site is located between two aba domains each 
containing five b-strands116.  
These methylation steps are carried out via the transfer of a methyl-group donor S-adenosyl-
methionine (SAM). It has been discussed in section 4.3.3 that at least two of the cobalamin 
biosynthetic enzymes are prone to mistaking some of the cobalamin intermediates. Therefore, to 
conclude this project it was of interest to focus on exploring how the cobalamin methyltransferases 
have developed their regio- and stereo-specificity. To explore specificity regarding precorrin 
cobalamin intermediates of the canonical methyltransferases the following areas were studied: 
1. A sequence analysis to compare the anaerobic and aerobic pairs leading to a discussion 
of methyltransferase structure studies. 
2. Those methyltransferases which have had their structures solved were further explored 
using docking software and outputs which had already been generated by the Pickersgill 
group but not analysed in depth. This unpublished work contained information on 
different docked precorrin ligands. The analysis involved identifying the most feasible 
models which were further studied through identifying and summarising binding 
interactions and the corrin ring decoration. It is proposed that the decoration groups of 
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the corrin ring of these precorrin ligands may help drive specificity as demonstrated in 
Figure 74. 
3. Having identified loop regions involved in precorrin docking across the canonical 
methyltransferases, their sequences were further explored in an attempt to conclude 
whether conserved residues are important for substrate specificity.  
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CobLc 
 
 
 
 
C15 
 
 
 
 
C12 
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CobLN 
 
 
 
 
C5 
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Table 12: A summary of the aerobic methyltransferases and the reaction(s) they catalyse, which 
are shown in red. 
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Figure 74: A simplified precorrin ligand docking schematic. Methylation is assumed to occur on the 
North edge demonstrating how 1800 rotation in the y-axis would change the decoration of the 
corrin ring.  
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5.2 Sequence analysis of aerobic and anaerobic methyltransferase pairs 
In the first part of this analysis a sequence comparison of the canonical methyltransferases was 
undertaken to observe if any conserved amino acid residues could be identified for binding precorrin 
intermediates. This was initially achieved by comparing the aerobic pathway, using gene sequences 
from Rhodobacter capsulatus, and anaerobic gene sequences from the respective analogues which 
have had their crystal structure solved in the Protein Data Bank. These are summarised in Figure 
75A-F.  
At a glance there is a high degree of similarity between both the aerobic and anaerobic enzymes, 
shown by the colour coding in Figure 75, where identical residues are highlighted red and similar 
residues are highlighted in yellow. The GXGXG motif located just after b1 is present in all these 
methyltransferases except CbiD, and in the case of CobLN and CbiE the final glycine residue is not 
present. An additional motif of GDX, where X is most likely to be a proline, is also observed after b4 
in all the methyltransferases, except again in CbiD. Interestingly this shows an aspartic acid 
backbone interaction in crystal structures which is important for the binding of the methyl donating 
ligand SAM, Figure 76.  
From the sequence alignment of CobF and CbiD, CbiD showed little sequence similarity to CobF. 
Therefore, CbiD was removed from the final sequence alignment summarised in Figure 75G, as it did 
not contain either of the conserved motifs present in the other canonical methyltransferases. From 
this more comprehensive sequence comparison the initial binding motif can be extended from 
GXGXG where a threonine or serine is located five amino acids after this, located just before a1. A 
conserved proline is also present after b4, but was not considered relevant for the study as it is likely 
to be for establishing the link between the two aba domains present in Class III methyltransferases, 
as highlighted by Figure 10 in Chapter 1. 
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                                TT                          SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280    1     L               G V L GAGPG    LTL        AD    D LV     K    V        A L   VIV    N DMIDD FAGLPALE ...... S W DPGL HA NA RQ H A E C
CysG_S.typhi/1-253          1     L               G V L GAGPG    LTL        AD    D LV     R    V        L I   IVV    S D..ER FS.EPLDH ...... E V DAGL KG QQ QQ Y R D I
CobA_R.cap/1-263            1     L               G V L GAGPG    LTL        AD    D LV     R    A        A L   VIL    S EMTQI RTSETQAP RTDHRT H T CADH AV RA AA H R A V
consensus>70 ..#.L...............G.V.L.GAGPG....LTL........AD!!..D.LV..#. 
     TT                                         TT          SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280   55   L    A     GK        Q  I       A  G  V RLK GDP  FGR GEE  L  A     D LV    L      V      AK RPG VLEFA RGGKPSPK R SLR EL RA NR G F G L
CysG_S.typhi/1-253         52   L    A     GK        Q  I       A  G  V RLK GDP  FGR GEE  M  V     E LL    V      I      LN RRD DRVFV RAGYHCVP E NQI RE QK KR G F G E
CobA_R.cap/1-263           61   L    A     GK        Q  I       A  G  V RLK GDP  FGR GEE  L  A     E ML    L      V      LA GPQ EVIET TGFGAHMP E IAL GF QA RN S G L D
consensus>70 $.L....A.....GK........Q.#I...$...A..G..V.RLK.GDP.!FGR.GEE.. 
                                                            SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280  115  L      F   PGITA     A  G   T R         TGH   G       W   A VP IV       V  V L    I  I T VEHQ R GIGGL YA IP H EVNHA TF DSS LVPDR N QG
CysG_S.typhi/1-253        112  L      F   PGITA     A  G   T R         TGH   G       W   A IP VV       L  V V    L  L T CHAG S ASGCS YS IP H DYAQS RL LKT ...GE D EN
CobA_R.cap/1-263          121  L      F   PGITA     A  G   T R         TGH   G       W   A IG VL       L  L I    A  L A EAAG T ASAAA GL QS E GRNRE RL DVA ..FAE D AG
consensus>70 .L....!.F.!.PGITA.....A..G...T.R.........TGH...G......#W...A 
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CysG_S.typhi/1-253        169         YM           L   G     PV  V N       V    L        ALV   A IQ  IA       V  L L AEKQT F GLNQ AT EK F MQADM AL E GTSVKQR HGV T..Q GE
CobA_R.cap/1-263          179         YM           L   G     PV  V N       V    L        AAA   A LQ  MM       I  L A RPGAV I GKKA RF GR H ALATT TL E VSRAEER ATT A..D PA
consensus>70 ........YM...........L...G.....PV..V.N.....#.V....L...#....A 
                                                            SUMT_Sinorhizobium/1-280
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CobA_R.cap/1-263          237    E PA    G                                                L   VIL  A AAR G F L PR AAAQSLEAVI...................
consensus>70 ...E.PA.!..G.................................. 
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                                     TT                     CbiL_M.ther/1-232
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                                                 TT         CbiL_M.ther/1-232
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CobI_R.cap/1-245    59     PV     F   D    L    D  A     EL   RDV     GDP  Y  F  L M     E  Y  L      V L    L S  A EY TTELP DSP YI A ARF EW SR S. SKT V CE F G MH Y
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                                TT                          CbiL_M.ther/1-232
CbiL_M.ther/1-232  116  R        E  PG      C    G     GD  L V                 DA VQ I  MV  V   L   EI  V D L    EDMGFKT TSFTA AATA RT VE L P..RV DRFERV RDV C
CobI_R.cap/1-245   118  R        E  PG      C    G     GD  L V                 DA VT L  VI  I   I   DV  M E M    QGR.AEV PGMVG WWAT TP TW T AGTLP ADLVAH ERS I
consensus>70 .R.#......E.!PG!.....C....G.....GD#!L.V......#......$...DA.V 
                             TT TT                          CbiL_M.ther/1-232
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CobI_R.cap/1-245   177  MKT R             R      V    M      R          Y A  LV    V    KI AL G A  T I      HG NLP KR AVA LDA WL ERG PTQR A LVDVAAEDCP F IV GQG
consensus>70 !MKT.R.............R......V....M..#.!.R..........Y.A..LV.... 
                                                            CbiL_M.ther/1-232
CbiL_M.ther/1-232  231 QS.......                                                   
CobI_R.cap/1-245   237 RRPELGDEA                                                   
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                                              TT            CobJ_R.cap/1-245
CobJ_R.cap/1-245    1 M G   V G GPG     T     A  E   I GY  YV  I           T    E   V  A    D V V  L   V     TL   LS W T L RE L PE TA A ATD IP AR A.PREGL HP DNRV
CbiH_B.meg/1-252    1 M G   V G GPG     T     A  E   I GY  YV  I           T    E   L  I    E I A  I   I     QI   VK K L F SF H QR RE Q SDM KT EL QGLLTNQ IS GMTE
consensus>70 M.G...V.G.GPG..#.!T.....A..E...I!GY..YV..I...........T....E. 
                       TT                                   CobJ_R.cap/1-245
CobJ_R.cap/1-245   60  RA  A   A  G  V V SSGD GV  MA    E L         G E    PGI A    T  L   R  V V      F   ALF A H   I IL   T MD H EM AE R P A S EA ..PEHA T R L
CbiH_B.meg/1-252   61  RA  A   A  G  V V SSGD GV  MA    E L         G E    PGI A    Q  V   K  A I      Y   LVY V K   M VI   S IS E KQ EA T A G G IE GWKKET V E N
consensus>70 .RA..A...A..G..V.V!SSGD.GV%.MA...%E.L.........G.E..!.PGI.A.. 
        TT           TT                                     CobJ_R.cap/1-245
CobJ_R.cap/1-245  118   A   GAP  HD C I LSD L P E  EKR   AA  DF  AFYNP S  R  Q     AA   L     N     F IL   L     AM     R  H VAA A G F A N K RH RG KS P FTR
CbiH_B.meg/1-252  121   A   GAP  HD C I LSD L P E  EKR   AA  DF  AFYNP S  R  Q     LL   V     S     W LI   I     VV     K  R ASC S M A T H T EA QA GR T IVE
consensus>70 ..A...GAP..HD.C.I.LSD.L.P.E..EKR...AA..DF..AFYNP.S..R..Q.... 
         TT        TT TT                 TT             TT  CobJ_R.cap/1-245
CobJ_R.cap/1-245  178   IL     P                     L D       M T V VGN  T          I AR V I V  R A A    L    VLE REECE GRL LF A TTPEQA S VE TPEM D R V AA RRVGPW
CbiH_B.meg/1-252  181   IL     P                     L D       M T V VGN  T          V VK A V M  K M I    V    MQR LKYRS DTP GL S YRDREE V TN LNHE G L T SS FFYDDL
consensus>70 ..IL.....P...!..........#.!...#L.D.......M.T.V.VGN..T....... 
                                                            CobJ_R.cap/1-245
CobJ_R.cap/1-245  238  TPRG                                                       Y    VAP....
CbiH_B.meg/1-252  241  TPRG                                                       I    YQRKYTL
consensus>70 .TPRG....... 
β1 η1 α1 β2 η2 β3 
α2 β4 α3 η3 β5 
α4 β6 β7 α5 β8 
α6 β9 β10 η4 η5 β11 β12 β13 
 
                                     TT          TT      TT CobM_R.cap/1-264
CobM_R.cap/1-264    1 GSHM    IGAGPG  DLIT  G  L     V LYA SLV   L A   PGA    TA M    V           IR  I S         L H    IV   P T HF AA RD A CP C G PEA CP K N
CbiF_B.meg/1-268    1 GSHM    IGAGPG  DLIT  G  L     V LYA SLV   L A   PGA    TA M    L           VK  L Q         I K    VL   G K YI DP LK Q AD V D SQD SK E K
consensus>70 GSHM....IGAGPG..DLIT!.G..L.....V.LYA.SLV.#.L.A...PGA.!..TA.M 
                          TT                                CobM_R.cap/1-264
CobM_R.cap/1-264   61  L     T       G  V R H GD     A  EQ   L          PGV S  AAA D II  IAE   A L S  IW  M   L  R I DV        S A D AHAA QD LS S G RR ALN PY T P FA
CbiF_B.meg/1-268   61  L     T       G  V R H GD     A  EQ   L          PGV S  AAA E MV  MLD   V V T  MY  I   M  K V EI        H E G RMRE KM PA G M VL REG DI V T VF
consensus>70 .L#..!.T..#....G..V.R.H.GD.....A..EQ$..L....!..#!.PGV.S..AAA 
                             TT                             CobM_R.cap/1-264
CobM_R.cap/1-264  121 A   AELT P   Q VILTR  GR    P  E L   A      A  LS      V     L     L V  S       M    R L I   V  VT G G A TS ASA AG T ENF TGAV H VH LDE QKL
CbiF_B.meg/1-268  121 A   AELT P   Q VILTR  GR    P  E L   A      A  LS      V     A     I L  T       V    K I L   L  MA E D T AE T.P EF K TDL HKCT F ST TKK KEF
consensus>70 A...AELT.P...Q.VILTR..GR....P..E.L.#.A......A..LS......V.... 
   .            TT TT                                       CobM_R.cap/1-264
CobM_R.cap/1-264  181       ED PV  V  A WPD   VR T   L            A IL G  L       V Y     AI WR S   RV   L  L L RT L  V  PH. G C Q A AT QTS G.AE E RS ATEDFDE
CbiF_B.meg/1-268  180       ED PV  V  A WPD   VR T   L            A IL G  L       I W     VV YK T   KI   V  M I KQ M  A  NAG S T E T KD DDA RTNG R WA DPATPWL
consensus>70 !.....ED.PV.!V..A.WPD#.!VR.T...L#..$........A$IL.G..L....... 
                                                            CobM_R.cap/1-264
CobM_R.cap/1-264  239 S L      R       H       E                                     L   R YAGDYD RYRP GT PRFPEGS ...
CbiF_B.meg/1-268  240 S L      R       H       E                                     A   G GENPAI AMFV HL QALNMAV EAA
consensus>70 S.L......R.......H.......E... 
β1 η1 α1 β2 η2 β3 
α2 β4 α3 β5 α4 
β6 α5 β7 η3 α6 
β8 β9 η4 η5 β10 η6 
 
C
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                                                            CobF_R.cap/1-258  
CobF_R.cap/1-258      1                I                                  A     A L G M  H Q V AMN I PL  L  R.... SH IELSLIG GTGNPR ITG A D AADL LI KG...... DKSD G
CbiD_A.fulgi/1-298    1                I                                  A     A L P L  K S L ILT L GI  I  KMLID IE YRYPEKW KDRDAE KVR G Y EDGY RR TTGTTASA AVAA S
consensus>70 .......$.......I...#...........$..................A.....A.L. 
          TT                                                CobF_R.cap/1-258  
CobF_R.cap/1-258     51           PA                          D     I E    E      G I AHLTN  ID L V R  A  L  T  RQ CA TKV FA P RDASNPSY KG....V DWHD A TW S I AHVP .
CbiD_A.fulgi/1-298   61           PA                          D     I E    E      G V VKVST  VE V A K  I  V  S  EK EK GVD VE E EKGFARVR FSGDHEF VTNG F AE C T GIFF R
consensus>70 ..!.......PA...!#.....................D.....I.E....E......G. 
                TT                                          CobF_R.cap/1-258  
CobF_R.cap/1-258    106       G  A                             V  G      T            L SL DS LRI PL    L A....LE RV LVWGDP Y T AERLKSRL TTK IP .....I AIQA C AHA
CbiD_A.fulgi/1-298  121       G  A                             V  G      T            V QI EN IKA GV    V IGVGVKA EK SRSAKL L F SREFNFSG RIS PD EEVAKK GNEK G KGG
consensus>70 ......G..A..........#..................V..G......T..#....... 
     TT                        TT                   TT      CobF_R.cap/1-258  
CobF_R.cap/1-258    157 I                V T           A T    A L     F    P         L V  R L       IP NDIG.......AP I TG Q RDHGWP G ETVV M DGECS QSLP DGLT FWG
CbiD_A.fulgi/1-298  181 I                V T           A T    A L     F    P         I L  K A       VS LGTTGFVEPWCKK E KL I MQYHRI I TGRK W YARKK PEYQ FVFG HID
consensus>70 I................V.T......#....A.T....A.L.....F....P....!... 
  TT TT                                                     CobF_R.cap/1-258  
CobF_R.cap/1-258    210      P E  I G                 RA        V                   V   L  V T E L   H  MD L AAC AM E V R P..... AEV D I QA DLRAR GW IY LRRNVP A....
CbiD_A.fulgi/1-298  241      P E  I G                 RA        V                   L   I  I S D I   R  IE M VEA KH G K V FPGLLK WAG R R EE REEGV VV DD DSWVWD QGTDH
consensus>70 .....P.E..I.G......!.....#..#.RA........V.#..$............ 
β1 η1 α1 β2 η2 
α2 β3 α3 
β4 α4 β5 α5 
β6 α6 β7 η3 β8 
β9 α7 β10 
 
               TT                               TT          CbiE_A.ful/1-199 
CbiE_A.ful/1-199     1        I G G               E AEVI G  R L L       RA         I  V  T K II     Y   E A V   L....M W S .TCRGQT ERA E R SR A G VDDS RI RSFKGD
CobLn_R.cap/1-213    1        I G G               E AEVI G  R L L       RA         L  L  S R AL     F   D V A   VMSDPW S L EDGLDGL LAS R T GP H A GGRG WP P....F
consensus>70 .......I.G.G...............E.AEVI%G..R.L#L.......RA......... 
              1 
                                                            CbiE_A.ful/1-199 
CbiE_A.ful/1-199    56 EI       R R   V   GDP   G G  L E     E    P    V    ARL      IME   A I T    L V  A  I  A  QVA    LRR EG E EV S MVA R R I EDV IK E ISS L KVD
CobLn_R.cap/1-213   57 EI       R R   V   GDP   G G  L E     E    P    V    ARL      VLD   V L S    A M  L  A  V  SLL    VAP .C G AT A FWF S A R APG WQ F PGV C SWR
consensus>70 EI..!$#..R.R...V...GDP...G.G..L.E.....E....P....V....ARL.... 
 
                      .                 TT                TTCbiE_A.ful/1-199 
CbiE_A.ful/1-199   116  E A    HA  F   L  L    R    L D                G  R    E L   VV      K  LL   L   VVLL  S V DC KD DAE TE L .Y H I A ........SHFP ERL KR N C
CobLn_R.cap/1-213  116  E A    HA  F   L  L    R    L D                G  R    E L   AL      R  VV   A   MAVA  E T GL AP GRL PV G GQ A T R GAAVADLAGWLV NGF AV R G
consensus>70 .E.A....HA..F...L..L....R....L.D.............#..G..R....E.L. 
                                                           1 
 TT                                                         CbiE_A.ful/1-199 
CbiE_A.ful/1-199   167    E  R   A             V                                    I  D E II  E MEMEG R EGN SI LESDYT F ER V GS.....
CobLn_R.cap/1-213  176    E  R   A             V                                    L  E D LV  D ADGPA M SIA DY FTDVSA A AL G LASGTGL
consensus>70 ...E..R...A#..#.......!.V..#..#....... 
 
β1 α1 β2 α2 β3 
α3 β4 α4 β5 α5 
η1 β6 α6 α7 β7 η2 β8 
β9 β10 
 
E 
F 
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Figure 75: A sequence comparison of the methyltransferase pairs from the aerobic and anaerobic 
pathways, where red shows identical residues and yellow shows similar residues. A) A sequence 
comparison of CobA, CysG and SUMT. B) A sequence comparison of CobI and CbiL. C) A sequence 
comparison of CobJ and CbiH. D) A sequence comparison of CobM and CbiF. E) A sequence 
comparison of CobF and CbiD. F) A sequence comparison of CobLN and CbiE. G) A comparison of all 
the aforementioned methyltransferases with CbiD removed. Figure generated using ESPript 3.0 
web server117. 
                                TT                          SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280    1                           G G                               V LV A PG LT AL A VIVMIDDLFAGLPALEK......GS W DPGL LHAAN RQ D HD.......
CbiL_M.ther/1-232           1                           G G                               L V V PG E LT VL V VI..................MHGK IG DS L LRAVN RS P CAPRSSSER.
CbiH_B.meg/1-252            1                           G G                               L VI  PG E IT AI MII..................MKGK L F SF H QRARE QESD GY.......
CbiF_B.meg/1-268            1                           G G                               L II A PG D IT LL A VVL.................GSHMK Y DP L VKGLK QQ D YAD......
CbiE_A.ful/1-199            1                           G G                               I IV  T II A VI.....................M W S .TCRGQT ERAKE ER E YGS.......
CobA_R.cap/1-263            1                           G G                               V LA A PG D LT AL A VILMTQILRTSETQAPRRTDHRTGH T CA H LAVAR AA D HD.......
CobI_R.cap/1-245            1                           G G                               I A L PG D IS AI A IA...................MGR LC DP L VRSDR RA TD HFRKAGRAG
CobJ_R.cap/1-245            1                           G G                               V VA L PG D VT AL A IV..................MSGW T RE L PEVTA AE TD GY.......
CobM_R.cap/1-264            1                           G G                               V I A PG D IT LI V L.................GSHMT HF AA L IRGRD ASCP C YAG......
CobF_R.cap/1-258            1                           G G                               L LI I G IT AM A LIL................GSHMIE S T NPRH GQAVD NA D IPLKGADKS
CobLn_R.cap/1-213           1                           G G                               L IL L D LS AL A VI.................MSDPW S EDGL G LASRR ET E FGG.......
consensus>70 ..........................G.Gpg..d..t.........a..i.......... 
                          TT                                SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280   48                    D L        L                        LV   ..............ALVNE C KLARPGAV EFAGKRGGKPS....PKQRDISLR  ELA
CbiL_M.ther/1-232          42                    DIL        I                        VA   ..........ESIALSIVE   TERRDGCR LDPVFPMTDDRDELESHWDSAARM  AEL
CbiH_B.meg/1-252           36                    ELI        I                        AV   ...............KTYV   QGLLTNQQ ISTGM..........TEEVSRAQE  KQA
CbiF_B.meg/1-268           38                    DLI        V                        ML   ..............SLVSQ   AKSKPGAE LKTAG..........MHLEEMVGT  DRM
CbiE_A.ful/1-199           32                    ELA                                  I   ...............RRAL   GVVDDSRARILRSFK.............GDEIRR MEE
CobA_R.cap/1-263           54                    EVL        V                        ML   ..............RLVSA   ALAGPQAE IETGKTGFGAH....MPQEEIIAL  GFA
CobI_R.cap/1-245           42                    E A        L                         L   QAR....RIVEGMLRPDVV H MEYPVTTE PFDSPDYIEAL....ARFYDEWASR SEL
CobJ_R.cap/1-245           36                      I        L                        AL   ...............IPYVAR A.PREGLT HPTDN..........RVELDRATH  EMA
CobM_R.cap/1-264           38                     LL        I                        IA   ..............SLVPEA  AHCPPGAK VNTAP..........MSLDAIIDT  EAH
CobF_R.cap/1-258           45                     VI        A                         A   DLAGLRRQICAAHLTNPATK  DFALPVRD SNPSYRKGVDDWHDAIAETWLSEIT HVP
CobLn_R.cap/1-213          37                    DLV                                 A    ...............PRHL   AAGGRGRAWP..................VPFEI PVLD
consensus>70 ...................d........................................ 
             TT                                             SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280   90            GD                              P                G VL L   P VF L V IV GIT LA A I VRA NR R KG F GRGGEEALT VEH......Q PFR AGIGG Y G P
CbiL_M.ther/1-232          92            GD                              P                GR VA I   P IY I MV GVT AA A LED D F TL S STFSYLQQR EDMG......FKTE SFTAC T GRT
CbiH_B.meg/1-252           71            GD                              P                GK VA I   VY L V VI GIS I A L A VEA T V SS AG GMAGLVYEV IEKGWKKETG EME A NSC SL G P
CbiF_B.meg/1-268           74            GD                              P                GK VV V   P MY L V IV GVT V AA A A LRE M R HT A GAIMEQMVL KRE......G DIE S FAA A E E
CbiE_A.ful/1-199           64            GD                              P                R VA I   P V I V I  IS V LA L V LGRE E V ST M AG.LGRVLRE AED....... EIK E A S QVA R K D
CobA_R.cap/1-263           96            GD                              P                GR VL L   P VF L I VL GIT A AA L LQA N R KS G GRLGEELDA EAA......G GFT A SAA G GQS
CobI_R.cap/1-245           94            GD                              P                R VV L   P LY L A VI GI M ISKT D V CE F GSFMHLYTR QGR....... EVE PG VGCWWATGTP
CobJ_R.cap/1-245           70            GD                              P                GR VV V   P VF L IL GIT M AA A A LAE R V SS G AMASALFEA EAH..PEHAGTEIR A LAA A G P
CobM_R.cap/1-264           74            GD                              P                G VA L   IW L I V  GV AA L A LAA QD R HS LS SAMGEQLRR RAL......N PYD T PSFAAA T G E
CobF_R.cap/1-258          105            GD                              P                VA L   P LY L L VI GIT I A I LGLEGR L VW S DSTLRIAER KSR.....LP TTK A QALC AHA P
CobLn_R.cap/1-213          64            GD                              P                GR V L   P F L V GV L L VCR AT V AS FW GAGSMLAER APG......EWQAFP VS LCAR SWR EE
consensus>70 ..g..v.....GDp..y.........l..............v.Pg!.......a...... 
                                               ....         SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280  144 T       V                    IA    VIVM                  I   HREVNHA TFLTGHDSSGLVPDRINWQG  SGSP    YMAMKHIG....AITANL AG
CbiL_M.ther/1-232         146         L V                  L      VIM                  V  VEG..DEI L VPR.......VDDRFERV RDVDAC   KTSRHGRR.......AME VE
CbiH_B.meg/1-252          131           I                  AA    VVA                   L  M....HDACT SLSDHLTPWELIEKRIEA  QADF   FYNPKSGRRTRQIVEAQRI LK
CbiF_B.meg/1-268          128 T       V L                  LA     IAL                  I   IPDLTQT I TRAEGRT.PVPEFEKLTD  KHKCT   FLSSTLTK....KVMKEF NA
CbiE_A.ful/1-199          116 S       A V                  LL    LLIL                      .....EV V DCH.....AKDFDAELTE  KYRH    ADSHFPLER............
CobA_R.cap/1-263          150 T       L L                  LA    VAAI                  M   ERGRNRE R ITGHDVAGFAEA..DWAG  RPGA    YMGKKAAR....FLQGRL MH
CobI_R.cap/1-245          147 T       L V                  M     IVVM                  A   WG..DDV T MAG.....TLPEADLVAH ERSDA    KTGRNLPK.......IKR LA
CobJ_R.cap/1-245          128           I                  AA    AMA                   L  G....HDFCA NLSDNLKPFEILEKRLRH  RGDF   FYNPRSKSRPHQFTRVLEI RE
CobM_R.cap/1-264          128 T       V L                   A    VLAI                  V   LPGVAQS I TRTSGRASAMPAGETLENF RTGA    HLSVHVLD....EVVQKL PH
CobF_R.cap/1-258          160 N       V I                   A    VVAM                      DIG..AP V TTG.......RQLRDHGWP GTET    LDG............ECSFQS
CobLn_R.cap/1-213         118 T       L L                  L     AVV                   L   .....AA G HAA.......PFGRLLPV GRGQR   TLRDGAAVAD.....LAGW VA
consensus>70 ............................................................ 
   TT        TT TT       TTT                                SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280  200        V  V  A      V           V    L      VV              GRSPDEP AF CN ATPQQA LETTLARAEAD AAAG EPPAIV  GEVVRLRAALDWIG
CbiL_M.ther/1-232         190        V  V         V                       LV              SDPRGKD VS ANCSMDDEV ERG.........FASGGGYLATT  RFREQS........
CbiH_B.meg/1-252          187        V  V  A      V           M    I      VV              YRSPDTP GL KS YRDREE VMTNLK....D LNHE GMLTTV  GNSSTFFYDDLMIT
CbiF_B.meg/1-268          183        V  V  A      I           M    I      LA              GWSEDTP VV YK TWPDEK VRTTVKDLDDA RTNG RKQAMI  GWALDPATPWLSGL
CbiE_A.ful/1-199          154        V  L  L      I                I       I              ..LGKRR VL EN CMEGER REG.........NADS ELESDYT IFVEREVMEGS...
CobA_R.cap/1-263          204        V  V  V      V           A    L      L               GALATTP TL EN SRAEER IATTLA..DLP AAAR EGPAVI FGLAPRAAAAQSLEA
CobI_R.cap/1-245          193        A  V         I           V           LV              VAGRLDA WL ERGTMPTQR AR......LVD AAEDCPYFAIV  HGQGRRPELGDEA.
CobJ_R.cap/1-245          184        I  A  V      I           A    A      LV              ECEPGRL LF RA TTPEQA SVVELR....D TPEM DMRTVV  GNAATRRVGPWVYT
CobM_R.cap/1-264          184        V  V  A      V           L    L      LV              .YGEDCP AI WR SWPDQR VRATLATLQTS G.AE ERTALI  GRSLATEDFDESRL
CobF_R.cap/1-258          199        I     V      L           I    A                      LPPDGLT FWGAC AMPEEV IRGPVAEVTDE LQAR DLRARHGWVMDIYLLRRNVPAA
CobLn_R.cap/1-213         161        M  A  L      L           I           AL              NGFGAVR AV ER GGPAEM RS......... AAEDYDFTDVS  VAVALDGADLASGT
consensus>70 .......v..........#.v....................................... 
                                                            SUMT_Sinorhizobium/1-280
SUMT_Sinorhizobium/1-280  260 ALDGRKLAADPFANRILRNPA.....                                  
CbiL_M.ther/1-232       ..........................                                  
CbiH_B.meg/1-252          243 PRGYQRKYTL................                                  
CbiF_B.meg/1-268          243 GENPAIRAMFVAHLHQALNMAVEEAA                                  
CbiE_A.ful/1-199        ..........................                                  
CobA_R.cap/1-263          262 VI........................                                  
CobI_R.cap/1-245        ..........................                                  
CobJ_R.cap/1-245          240 PRGVAP....................                                  
CobM_R.cap/1-264          242 YAGDYDRRYRPLGTHPRFPEGSE...                                  
CobF_R.cap/1-258        ..........................                                  
CobLn_R.cap/1-213         212 GL........................                                  
consensus>70 .......................... 
β1 α1 β2 
η1 β3 α2 
β4 α3 β5 α4 
β6 α5 β7 α6 
β8 β9 α7 β10 η2 α8 α9 
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Figure 76: SAH docked in CobJ (3NUT.pdb). The GDP motif is highlighted showing how the 
conserved aspartic acid interacts with SAH, an unmethylated SAM, through a protein backbone 
interaction. Figure made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 
Schrodinger, LLC. 
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5.3 Docking data of methyltransferases 
To test the AutoDock Vina software the docking of HBA to CobH (4FDV.pdb) was trialled given 
that the pdb file already contains a structure of HBA bound within CobH. The HBA coordinates were 
stripped from 4FDV.pdb and used as an input for docking. The AutoDock Vina software predicted the 
experimental structure very closely. It also correctly predicted the HBA position for both binding 
sites, when the search space was extended and also when the structure of HBA is randomized in 
Autodock. This trial run gave a binding affinity of -13.7kcal/mol.  
An unpublished structure of CbiET, solved by the Pickersgill group, containing Cobalt-precorrin-6 
ligand present was also trialled. Cobalt-precorrin-6B binds to the C-terminal domain in essentially 
the same way as PC6B in the non-canonical methyltransferase CobLc in which in silico docking 
studies gave a binding affinity of -8.5kcal/mol. This is believed to provide a more realistic bench 
mark for less tightly binding precorrin ligands.  
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5.3.1 Docking of PC4 (product) to CobJ (3NUT.pdb) 
Initial docking of PC4 showed that the cleft was too tight for PC4 to penetrate into the right 
depth, so NMA was undertaken using the ElNemo web server. Eleven structures in this mode were 
generated with varying degrees of cleft opening. The widest cleft gave generated models with the 
best binding affinity energies between -7.5kcal/mol and -7.2kcal/mol. These results showed that the 
degree of cleft opening does play a crucial role in binding. Of the nine docked structures generated a 
summary of the distance between the C17 methylation site on PC4 and sulphur atom of SAH, which 
binds the methyl group in SAM, are shown in Table 13.   
Docking model of PC4 
to CobJ 
Distance between C17 
and S atoms (Å) 
1 4.9 
2 4.8 
3 8.2 
4 8.6 
5 6.6 
6 10.8 
7 11.1 
8 9.5 
9 9.9 
Table 13: Summary table of docking models obtained from Autodock Vina for the protein CobJ 
with ligand PC4 and the distance measured between methylation site and sulphur atom of SAH. 
 
 
Models which gave a distance greater than 7Å between SAH and ligand were eliminated as this 
distance is roughly two hydrogen bond lengths and this would normally be occupied by a methyl 
group, which is available for transfer within the active site. This therefore left models 1, 2 and 5 
upon which the polar interaction of the acetic and propanoic decorations of the PC4 corrin ring were 
identified. The amino acids involved in these interactions, hydrogen bond distances and whether 
they came about via an R-group or protein backbone interaction are summarised in Table 14. In a 
few cases this interaction came about via an amino acid on a second protein chain so was underlined 
to signify this. From this summary models 1 & 2 were almost identical and therefore the most 
probable solution generated. The key amino acid interactions from model 1 are shown in Figure 77.  
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Location of PC4 
decoration  
Model 1 
Amino acid 
interactions and 
distance (Å) 
Model 2 
Amino acid 
interactions and 
distance (Å) 
Model 5 
Amino acid 
interactions 
and distance (Å) 
 
C1 
(ethanone) 
Backbone 
S137- 3.4 
R-group 
S137- 3.0 
N164-3.4 
Backbone 
S137- 3.4 
R-group 
S137- 3.0 
N164-3.4 
 
 
- 
 
C2 
(acetic acid) 
Backbone 
S137- 3.4 
N139-3.3 
R-group 
N139-3.2 
Backbone 
S137-3.0 
N139-3.3 
R-group 
N139-3.2 
 
 
- 
 
C3 
(propanoic acid) 
R-group 
S169-3.0 
Backbone 
K168-3.3 
R-group 
S169-3.0 
 
- 
C7 
(acetic acid) 
- - - 
 
 
C8 
(propanoic acid) 
 
 
- 
 
 
- 
Backbone 
S137-3.4 
R-group 
N139-3.2 
S167-2.7 
S169-3.0 
 
C12 
(acetic acid) 
Backbone 
N55-3.1 
R-group 
N55-3.2 
S80-3.0 
R-group 
S80-2.8 
R-group 
D138-3.5 
R241-3.2 
 
C13 
(propanoic acid) 
Backbone 
S80-3.2 
R-group 
S79-3.2 
S80-3.0 
Backbone 
S79-3.2 
S80-3.3 
R-group 
S80-2.9 
Backbone 
A87-3.0 
R-group 
R241-2.9 
 
C17 
(propanoic acid) 
R-group 
R241-3.1 
R-group 
R241-3.0 
Backbone 
S80-2.9 
R-group 
S79-3.0 
S80-2.8 
C18 
(acetic acid) 
 
- 
 
- 
R-group 
N55-3.1 
S80-2.8 
Table 14: From the most feasible model predictions for PC4 to CobJ, the carbon, upon which the 
carboxylate decoration is located to the precorrin ring is summarised, showing the amino acid 
interactions involved.  
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Figure 77: The amino acids which are involved in docking interactions of PC4 to CobJ (3NUT.pdb). 
SAH is coloured purple, PC4 is coloured green. Chain A of CobJ is coloured yellow and chain B is 
coloured blue, which shows R241 contributes from the other chain. Figure made via PyMOL, the 
PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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5.3.2 Docking of PC4 (substrate) and PC5 (product) to CobM (3NDC.pdb) 
Docking of both the substrate PC4 and product PC5 were trialled with CobM. The following 
residues in CobM were permitted flexibility: L36, S81, R137, R141, L165, R218 and Q131 (where 
Q131 was located on chain A, while the rest are located on chain B). The following binding affinity 
energies and distance between C11 and SAH are summarised in Table 15 and Table 16.  
 
Docking 
model of PC4 
to CobM 
Binding affinity 
(kcal/mol) 
Distance 
from best 
model 
rmsd (I.B) 
Distance 
from best 
model rmsd 
(U.B) 
Distance 
between C11 
and S atoms 
(Å) 
1 -7.6 0.000 0.000 5.9 
2 -7.6 2.054 6.067 7.1 
3 -7.4 1.515 2.014 6.2 
4 -7.3 1.742 2.398 6.6 
5 -7.3 2.053 6.137 8.2 
6 -7.1 2.087 6.346 6.3 
7 -7.1 1.395 1.935 5.9 
8 -7.0 3.183 8.682 8.1 
9 -7.0 1.911 6.432 7.1 
Table 15: Summary table of docking models obtained from Autodock Vina for the protein CobM 
with substrate PC4. Binding affinity, distance from best model and the distance measured 
between methylation site and sulphur atom of SAH are all shown. 
 
Docking 
model of PC5 
to CobM 
Binding affinity 
(kcal/mol) 
Distance 
from best 
model 
rmsd (I.B) 
Distance 
from best 
model rmsd 
(U.B) 
Distance 
between C11 
and S atoms 
(Å) 
1 -8.1 0.000 0.000 8.2 
2 -8.0 1.884 7.146 8.3 
3 -8.0 1.319 1.818 8.3 
4 -7.9 2.136 7.346 7.3 
5 -7.7 1.658 2.167 8.4 
6 -7.5 1.875 6.354 4.9 
7 -7.4 2.261 6.245 7.7 
8 -7.3 2.189 6.153 5.3 
9 -7.3 1.774 6.488 7.3 
Table 16: Summary table of docking models obtained from Autodock Vina for the protein CobM 
with product PC5. Binding affinity, distance from best model and the distance measured between 
methylation site and sulphur atom of SAH are all shown. 
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The NMA technique was applied to CobM to check if different degrees of cleft opening would 
facilitate docking. Both a more open and tighter cleft opening using NMA did not help to correctly 
dock PC5 to CobM. All 9 different cleft openings contain one or two correct ligand conformations, 
but C11 is still quite far away from the S-atom of SAH. In a similar fashion to CobJ above, a summary 
of the binding interactions to corrin ring decoration of the ligands PC4 and PC5 is summarised in 
Table 17 and Table 18 respectively. From these tables, model 6 from PC4 docking and model 1 from 
PC5 docking could be paired together based on the similarities of the respective binding energies, 
distance measured and binding interactions. The key amino acid interactions from PC4 model 1 and 
PC5 model 6 are shown in Figure 78. 
 
 
Figure 78: A) The amino acids which are involved in docking interactions of PC4 to CobM 
(3NDC.pdb). B) The amino acids which are involved in docking interactions of PC5 to CobM. SAH is 
coloured purple, PC4 is coloured green and CobM is coloured yellow. Figure made via PyMOL, the 
PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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Location 
of PC4 
decoration 
Model 1 
Amino acid 
interactions 
and 
distance (Å) 
Model 2 
Amino acid 
interactions 
and 
distance (Å) 
Model 3 
Amino acid 
interactions 
and 
distance (Å) 
Model 4 
Amino acid 
interactions 
and 
distance (Å) 
Model 6 
Amino acid 
interactions 
and 
distance (Å) 
Model 7 
Amino acid 
interactions 
and 
distance (Å) 
Model 9 
Amino acid 
interactions 
and 
distance (Å) 
C1 - Backbone 
S88-3.4 
- - Other 
SAH-3.0 
- - 
 
C2 
Backbone 
S35-3.0 
L36-3.3 
Backbone 
A55-3.5 
R-group 
T54-2.8 
Backbone 
A33-2.8 
Backbone 
S35-3.0 
R-group 
S35-3.2 
 
- 
 
- 
 
- 
 
 
C3 
R-group 
T219-2.9 
Backbone 
M57-3.3 
L59-3.2 
R-group 
E92-3.3 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
C7 
 
- R-group 
E92-3.4 
- - R-group 
S81-2.9 
 R-group 
S81-2.6 
 
 
C8 
Backbone 
L165-3.3 
R-group 
R218-2.9 
Backbone 
A142-3.3 
R-group 
R137-3.0 
R-group 
H168-3.2 
R218-3.1 
Backbone 
G140-3.5 
R-group 
H168-3.1 
R218-3.3 
R-group 
H80-3.2 
S81-3.3 
Other 
SAH-3.4 
R-group 
H168-3.4 
R218-3.1 
R-group 
T54-3.1 
R78-3.1 
 
C12 
R-group 
R137-3.1 
R-group 
R218-2.9 
 
- 
Backbone 
A142-3.2 
R-group 
R137-2.7 
 
- 
R-group 
R137-3.2 
Backbone 
W87-3.3 
 
C13 
 
- 
Backbone 
R218-3.2 
R-group 
R218-3.2 
R-group 
Q131-2.5 
R137-1.6 
R-group 
R137-2.6 
R-group 
Q131-3.0 
R137-2.5 
R-group 
E123-3.5 
Backbone 
A142-3.2 
R-group 
R137-2.2 
 
 
C17 
Backbone 
S81-3.1 
 
 
Backbone 
S35-3.2 
L36-3.2 
R-group 
S35-3.2 
Backbone 
S-81-3.1 
Backbone 
S88-3.3 
R-group 
H80-2.9 
R-group 
R218-2.0 
Backbone 
S81-3.2 
R-group 
R218-2.9 
R-group 
H168-3.2 
 
 
C18 
R-group 
T54-2.9 
Backbone 
A33-2.9 
R-group 
S81-2.6 
 
 
- 
Backbone 
A33-3.4 
R-group 
H168-3.3 
R218-3.0 
Other 
SAH-2.9 
 
 
- 
Other 
SAH-2.8 
Table 17: From the most feasible model predictions for PC4 to CobM, the carbon, upon which the 
carboxylate decoration is located to the precorrin ring is summarised, showing the amino acid 
interactions involved. Interactions occurring from the other protein chain are underlined. 
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Location of PC5 
decoration 
Model 6 
Amino acid 
interactions and 
distance (Å) 
Model 8 
Amino acid 
interactions and 
distance (Å) 
C1 
(ethanone) 
- - 
 
C2 
(acetic acid) 
Backbone 
S35-3.3 
L36-3.1 
R-group 
E92-3.4 
C3 
(propanoic acid) 
R-group 
T219-2.7 
Backbone 
T54-3.4 
A55-3.4 
R-group 
T54-2.8 
R78- 3.1 
C7 
(acetic acid) 
R-group 
R218-2.7 
- 
 
C8 
(propanoic acid) 
Backbone 
L135-3.3 
R-group 
R218-2.9 
R-group 
R218-2.9 
Other 
SAH-3.0 
C12 
(acetic acid) 
R-group 
R137-3.0 
R-group 
S80-2.8 
 
C13 
(propanoic acid) 
 
- 
 
- 
C17 
(propanoic acid) 
Backbone 
S81-3.1 
- 
 
 
C18 
(acetic acid) 
R-group 
T54-2.8 
 
- 
Table 18: From the most feasible model predictions for PC5 to CobM, the carbon, upon which the 
carboxylate decoration is located to the precorrin ring is summarised, showing the amino acid 
interactions involved. 
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5.3.3 Docking of PC6A (substrate) to CobF (3ND1.pdb) 
As above, summaries of CobF docking are outlined below in Table 19 and Table 20. The following 
residues in CobF were made flexible: I159 (A-chain), D39 (B-chain), Y118 (B-chain), S120 (B-chain), 
R169 (B-chain), R236 (B-chain), M243 (B-chain). When SAH was set to flexible its position became 
less stable when compared to the other methyltransferases. In general, the docking of PC5 to CobF 
gave fairly unsatisfactory results with only one potentially feasible model, showing much less 
consistency. The key amino acid interactions from model 2 are shown in Figure 79. 
 
 
 
Figure 79: The amino acids which are involved in docking interactions of PC6A to CobF (3ND1.pdb). 
SAH is coloured purple, PC4 is coloured green and CobF is coloured yellow. Figure made via 
PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
  
 183 
Docking 
model of PC5 
to CobF 
Binding affinity 
(kcal/mol) 
Distance 
from best 
model 
rmsd (I.B) 
Distance 
from best 
model rmsd 
(U.B) 
Distance 
between C11 
and S atoms 
(Å) 
1 -8.3 0.000 0.000 7.0 
2 -8.2 2.024 6.450 5.3 
3 -7.7 3.336 8.757 10.0 
4 -7.6 3.021 6.622 7.0 
5 -7.5 1.527 2.045 10.0 
6 -7.4 2.215 6.415 10.1 
7 -7.4 3.039 7.312 10.1 
8 -7.4 1.677 5.976 8.0 
9 -7.4 2.051 6.659 11.4 
Table 19: Summary table of docking models obtained from Autodock Vina for the protein CobF 
with substrate PC5. Binding affinity, distance from best model and the distance measured 
between methylation site and sulphur atom of SAH are all shown. 
 
 
Location of PC5 
decoration 
Model 2 
Amino acid 
interactions and 
distance (Å) 
C2 
(acetic acid) 
- 
 
C3 
(propanoic acid) 
- 
 
C7 
(acetic acid) 
R-group 
D39-1.8 
S41-3.0 
 
C8 
(propanoic acid) 
Backbone 
V242-3.3 
R-group 
R232-3.0 
R236-3.5 
C12 
(acetic acid) 
R-group 
R169-3.1 
 
C13 
(propanoic acid) 
Backbone 
L187-3.4 
R-group 
R169-3.3 
C17 
(propanoic acid) 
R-group 
S120-2.8 
 
C18 
(acetic acid) 
Backbone 
S120-3.0 
R-group 
S120-2.9 
Table 20: From the most feasible model predictions for PC5 to CobF, the carbon, upon which the 
carboxylate decoration is located to the precorrin ring is summarised, showing the amino acid 
interactions involved. 
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5.3.4 Docking of PC6 (substrate) to CbiE (2BB3.pdb) 
  
CbiE is the anaerobic equivalent of the N-terminal domain of CobL. The docking of PC6B to CbiE 
is summarised below in Table 21 and Table 22. The docking models one and two are almost identical 
when comparing binding affinities, distance between C5 and SAH and ligand interactions. H129 can 
also be seen almost directly below the corrin ring and would likely be involved in co-ordinating 
cobalt in the anaerobic equivalent Co-PC6B. The key amino acid interactions from model 1 are 
shown in Figure 80. 
 
 
 
Figure 80: The amino acids which are involved in docking interactions of PC6B to CbiE 
(unpublished). SAH is coloured purple, PC4 is coloured green and CbiE is coloured yellow. Figure 
made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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Table 21: Summary table of docking models obtained from Autodock Vina for the protein CbiE 
with ligand PC6B. Binding affinity, distance from best model and the distance measured between 
methylation site and sulphur atom of SAH are all shown. 
 
 
 
 
Docking 
model of PC6B 
to CbiE 
Binding affinity 
(kcal/mol) 
Distance 
from best 
model 
rmsd (I.B) 
Distance 
from best 
model rmsd 
(U.B) 
Distance 
between C5 
and S atoms 
(Å) 
1 -7.5 0.000 0.000 5.2 
2 -7.5 1.646 2.545 5.2 
3 -7.4 2.443 7.626 9.2 
4 -7.3 1.667 2.129 5.0 
5 -7.1 2.774 4.161 7.2 
6 -7.1 2.207 9.583 7.8 
7 -7.1 1.950 9.545 7.8 
8 -7.0 2.586 3.720 9.8 
9 -7.0 2.113 8.099 10.2 
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Table 22: From the most feasible model predictions for PC6B to CbiE, the carbon, upon which the 
carboxylate decoration is located to the precorrin ring is summarised, showing the amino acid 
interactions involved.  
Location of 
PC6B 
decoration  
Model 1 
Amino acid 
interactions and 
distance (Å) 
Model 2 
Amino acid 
interactions and 
distance (Å) 
Model 4 
Amino acid 
interactions and 
distance (Å) 
 
C2 
(acetic acid) 
R-group 
S82-3.2 
Other 
SAH-3.2 
R-group 
S82-3.2 
Other 
SAH-3.2 
R-group 
S82-3.2 
Other 
SAH-3.3 
 
C3 
(propanoic acid) 
Backbone 
G42-3.1 
L80-3.4 
R-group 
H45-3.0 
Backbone 
G42-3.1 
L80-3.4 
R-group 
H45-3.0 
Backbone 
S82-3.3 
Other 
SAH-3.1 
C7 
(acetic acid) 
Backbone 
I90-3.3 
Backbone 
I90-3.4 
- 
 
C8 
(propanoic acid) 
 
- 
Backbone 
H129-3.3 
R-group 
H129-3.0 
 
- 
C12 
(acetic acid) 
R-group 
E152-3.4 
- - 
 
C13 
(propanoic acid) 
R-group 
E60-3.4 
R-group 
E60-3.5 
- 
 
C17 
(propanoic acid) 
Backbone 
L202-3.2 
R-group 
R44-2.9 
S199-3.4 
R-group 
R44-3.2 
R-group 
R44-3.0 
C18 
(acetic acid) 
R-group 
R44-2.9 
R-group 
R44-3.0 
R-group 
R44-3.2 
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5.3.5 Summary of docking interactions 
It seemed appropriate to summarise the location of the interacting amino acid residues in the 
structure of the protein given that the orientation of the precorrin ligand changes upon binding 
depending on the location of the methylation site and docking orientation of the corrin ring. Due to 
variation observed in the number of alpha helices crystal structures and sequence alignments in 
Figure 75, a summary of the amino acid locations was based upon the beta-strands present in Table 
23, as each methyltransferase contains ten beta strands. CobJ does not quite fit this trend, however 
it has already been suggested that an additional ancillary reaction may account for this deviation 
where it also carries out the ring contraction and removal of C20. This summary begins to narrow 
down the loop regions which are involved in precorrin ligand docking and variations that dictate 
specificity. All the methyltransferases appear to contain a serine residue post b4, which is also 
located next to the conserved GDX motif described in section 5.2. In all four enzymes at least one 
arginine is present and important for ligand docking. 
Cob 
enzymes 
Location of interaction on secondary structure of enzyme 
Post b2 Post b3 Post b4 Post b6 Post b7 Post b10 
 
CobJ 
 
- 
 
N55 S79 
S80 
S137 
 
N164 
S169 
R241 
 
CobM 
S35 
L36 
 
T54 
 
S81 
 
L135 
R137 
L165 R218 
T219 
 
CobF 
D39 
S41  
 
 
- 
S120 
H129 
R169 L187 R232 
R236 
V242 
 
CbiE 
G42 
R44 
H45 
E60 L80 
S82 
I90 
H129 E152 S200 
L202 
Table 23: A summary of where the interacting amino acids are located in each methyltransferase 
 
To further explore the decoration pattern of precorrin binding docking interactions of the 
pyrrole rings A-D are summarised in Table 24. This table shows that all sides of the precorrin ring are 
involved in docking, but to varying extents. CobM has two edges interacting with one residue, while 
CobJ and CobF have only one edge in which this occurs. CbiE shows a large number of binding 
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interactions across two edges via at least four amino acids. Overall each methyltransferase has at 
least one edge interacting with at least four amino acid residues.  
 
Cob enzyme 
Corrin ring edge based upon which pyrrole rings 
interactions occur along 
AB 
(C3/C7) 
BC 
(C8/C12) 
CD 
(C13/C17) 
DA 
(C18/C1/C2) 
 
CobJ 
S169 N55 
S80 
S79 
S80 
S137 
N139  
N164  
R241 
 
CobM 
T219 L135 
R137 
L165 
R218 
S81 S35 
L36 
T54 
 
CobF 
D39 
S41 
 
R169 
R232 
R236 
V242 
S120 
R169 
L169 
S120 
 
 
CbiE 
G42 
H45 
L80 
I90 
H129 
E152 
R44 
E60 
S199 
L202 
R44 
S82 
Table 24: A summary of which amino acids interact with each pyrrole ring for different precorrin 
ligands in CobJ, CobM, CobF and CbiE. 
 
 
Using the most probable docking models for each methyltransferase and keeping the orientation 
of SAH the same allowed the precorrin pyrrole sequence and decoration to be summarised in Table 
25. In the case of CobJ and CbiE the pyrrole docking was anti-clockwise (DàA) whereas the pyrrole 
docking in CobM and CobF was clockwise (AàD). This in turn changes the decoration sequence of 
the precorrin ligands, which may drive specificity.  
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Enzyme 
 
Docking orientation 
Edges of 
precorrin ligand 
read in a 
clockwise fashion 
Clockwise 
decoration 
sequence 
 
 
 
 
CobJ 
(methylates C17) 
 
 
 
 
 
 
 
 
DC-CB-BA-AD 
 
 
 
 
 
PP-AP-AP-AA 
 
 
 
 
CobM 
(methylates C11) 
 
 
 
 
 
 
 
BC-CD-DA-AB 
 
 
 
 
PA-PP-AA-PA 
 
 
 
 
CobF 
(methylates C1) 
 
 
 
 
 
 
 
DA-AB-BC-CD 
 
 
 
 
AA-PA-PA-PP 
 
 
 
 
 
CbiE 
(methylates C5) 
 
 
 
 
 
 
 
 
BA-AD-DC-CB 
 
 
 
 
 
AP-AA-PA-PP 
Table 25: A summary of the docking orientation and decoration sequence of precorrin ligands 
when the architecture of the methyltransferase and SAM/SAH binding site is kept fixed. 
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5.4 Exploring the b-loop sequences and precorrin ligand decoration patterns 
 
Due to the lack of conserved residues in these loop regions, precorrin specificity may be dictated 
more by steric factors based on the decoration sequence of the precorrin ring. For example, an 
acetic acid group is shorter and would therefore allow a longer amino acid R-group to be present, 
which would otherwise clash with a longer propanoic chain. Therefore, these regions could be 
assigned to specific pyrrole interactions. Given the methyltransferase tertiary structure and 
SAM/SAH binding orientation is similar and can remain fixed, a more appropriate method to assign 
these loop regions could be to use compass descriptions, due to precorrin docking orientation 
changing. This is summarised in Table 26 where the only consistency is observed in the post b7 
region which appears to always interact with the south-east pyrrole group upon ligand docking. The 
post b4 loop appears to interact with the west side of the precorrin ligand upon docking.  
 
Cob 
enzymes 
Pyrrole ring upon which docking occurs and description of docking 
orientation using compass points 
Post b2 Post b3 Post b4 Post b6 Post b7 Post b10 
 
CobJ 
 
- 
C-ring 
NW 
C-ring 
NW 
A-ring 
SE 
A-ring 
SE 
 
D-ring 
SW 
 
CobM 
A-ring 
NE 
 
D-ring 
NW 
D-ring 
NW 
B-ring & 
C-ring 
S 
 
B-ring 
SE 
C-ring 
SE 
 
 
CobF 
B-ring 
NE 
 
- 
D-ring 
SW 
C-ring 
SE 
 
C-ring 
SE 
B-ring 
NE 
 
CbiE 
A-ring & D-
ring 
N 
C-ring 
SE 
A-ring & 
B-ring 
W 
B-ring 
SW 
C-ring 
SE 
 
D-ring 
NE 
 
Table 26: Table summarising which pyrrole group of the precorrin these loop regions interact with 
and a compass description of how the ligand is docked (e.g. NW=North-West). 
 
Based on the binding residues described earlier in Table 24 the amino acid sequence ±5 residues 
upstream and downstream were isolated. These sequences were grouped based on where they are 
located in the tertiary structure and aligned using Jalview118. These were aligned to see if any 
similarities or conserved residues were present which is summarised in Figure 81. The two most 
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similar regions were post b4 and post b6 loop regions. The post b4 region contained the 
aforementioned GDX motif, but the interacting serine residue occurs post this in CobF rather than 
before it in the others. The post b6 loop contained at least one basic residue and either a serine or 
threonine. None of the other loops appeared to contain any significant features.  
 
Figure 81: A sequence alignment of post b-strand loop regions across the methyltransferases. The 
sequences were isolated by taking the residues ±5 residues up-and down-stream of interacting 
amino acids identified during docking studies. Blue signifies hydrophobic residues, orange signifies 
a glycine, yellow signifies a proline, green signifies a threonine or serine, red signifies an arginine 
or lysine, purple signifies an aspartate and teal signifies an aromatic residue. 
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5.5 Discussion and conclusions  
5.5.1 Sequence analyses 
The sequence analyses of the canonical methyltransferases did not show any obvious conserved 
amino acid residues which may be involved in precorrin binding or residues which are important in 
differentiating between the different precorrin intermediates. Despite using only two sequences for 
a comparison this was undertaken between enzymes from distinctly different respiratory pathways 
which carry other identical chemical modifications. Structurally these enzymes are very similar and 
so it comes as no surprise at the good sequence similarity (yellow) and identity (red) observed in 
Figure 75A-E. The only pair that did not match well were CobF and CbiD, however this is not 
surprising given Warren et al, 2002 describes them as genetically distinct due to the nature of the 
ancillary reaction they carry out, where CobF removes acetic acid at C1 and CbiD removes 
acetaldehyde2.  
For this reason, CbiD was removed from the more comprehensive sequence analysis shown in 
Figure 75G between all the canonical methyltransferases of the aerobic and anaerobic pathway. Two 
sequence motifs are observed, the first of which is GXGXG located after b1. This is supported by 
Schubert et al, 2003 as a means of identifying this class of methyltransferase, despite not actually 
being involved in SAM binding54. The final glycine residue in this sequence is not fully conserved but 
given it is not essential for SAM binding, some flexibility may be permitted. Also, six residues 
upstream of this motif, there appears to be a threonine or serine which is located at the start a1. 
The second conserved motif present is GDX located after b4, where X is typically a proline. The 
aspartic acid residue is clearly conserved as structurally it can be observed interacting directly with 
SAH in crystal structures and therefore essential for SAM binding. Interestingly this is brought about 
via backbone interactions of the two adjoining amide linkages, rather than the R-group of aspartic 
acid. This might lead one to speculate that the acetic acid R-group is important for a further 
interaction. However, upon exploring the structures further there does not structurally appear to be 
an apparent dependence for this as it is located between the dimer interface and typically interacts 
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with a water molecule bridged to a5-helix on the second protein chain and therefore is possibly 
involved in dimer formation but is clearly not solely responsible for this. However this has not been 
explored using mutagenesis.   
 
5.5.2 Docking analysis 
Initial docking trials using CobH were encouraging as the software was able to correctly identify 
the ligand binding site and dock HBA correctly on to a known enzyme-ligand complex. The binding 
affinity energies for CobH was quite high at -13.7kcal/mol. However, CobH is known to have a very 
high affinity for HBA. A second trial of CobLc in silico docking studies, in which predicted docking was 
matched to the known ligand docking of CbiET, gave a more reasonable binding affinity of -8.5 
kcal/mol providing a more realistic benchmark for less tightly bound precorrin ligands in the 
methyltransferases. The subsequent in silico docking studies of precorrin ligands into different 
methyltransferases all gave similar binding affinities around -7.5kcal/mol in which the SAH ligand 
was docked correctly and in an identical orientation across all the methyltransferases.  
CobJ docking was remarkable in that the binding site of PC4 had very few binding interactions 
from arginines and lysines, despite them being dotted around the precorrin cleft. These are in fact 
not well conserved apart from R241 which interacts with the PC4 pyrrole ring A. This would explain 
why such an extreme C-terminal residue is seen in the electron density map of the crystal structure. 
In the homodimer this R241 interaction occurs from the other protein chain and is important in 
substrate binding and orientation. Unpublished work from the Pickersgill group generated in vitro 
CobJ mutants where it was shown that the methylation and ring contraction reactions are in fact 
uncoupled and their activity is dependent on interactions contributed from each protein chain. 
CobM showed a relatively open substrate-binding cleft. Important contacts defining the binding 
mode are conserved R141 and semi-conserved R/L218 which bind to the C- and D-pyrrole ring 
groups via basic residues. Conservation is greatest around the SAM-binding site and C-ring, which is 
in agreement with the need to position C11 for effective catalysis.   
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CobF gave only one feasible docking model of PC5 based on the distance involved for a 
methylation reaction to occur. A number of arginine residues are involved in binding interactions 
including R169 which binds to the C-ring and R232 and R236 which bind to the B-ring. The lack of 
formally positively charged residues in the proximity of the A-ring could be related to the 
requirements of catalysis where protonation of an aspartate by water could lead to generation of a 
hydroxy-group to attack the C1 acetyl substituent with subsequent methylation from the other side 
of the ring. D39 together with the A-ring acetate may activate a water molecule to attack the C1 
carbonyl-carbon, while conserved D119 on the other side of the ring, close to SAH, may also be 
catalytic. 
CbiE docking can in fact be confirmed by cross-checking with the unpublished structure of CbiET 
solved by the Pickersgill group. This structure confirms that H129 is involved in co-ordinating to 
cobalt in Co-PC6B, which would not be needed in CobLN of the aerobic pathway, but it can be 
assumed the remaining interactions would be comparable. This structure and docking confirm that 
the majority of interactions occur to the A-ring to guide orientation for C5 methylation through the 
basic residue R44, whereas the C- and D-ring are left more exposed, supporting the binding affinities 
recorded for less tightly bound ligands. 
Each docking attempt generated multiple models and by carefully inspecting and comparing 
these, including the distance between the sulphur on SAH with the methylation site, the most 
appropriate model could be selected. This allowed amino acid interactions to be summarised based 
on their position in the protein structure. In the case of CobJ and CbiE the precorrin ligand docked in 
an anticlockwise fashion with respect to the pyrrole groups, while in CobM and CobJ docking 
occurred in a clockwise fashion, as summarised in Figure 82. Therefore, having suggested in chapter 
4 that CobM may be the culprit for additional C5 methylation, observed in the CobK-PC6B crystal 
structure, CobJ may in fact be a more appropriate suspect. This is due to the fact that both precorrin 
ligands bind in an anticlockwise fashion rather than a clockwise fashion seen in CobM docking. In 
both CobJ and CbiE methylation occurs along the west edge of the docked ligand. Again, this could 
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be confirmed as suggested in chapter 4 by mixing purified PC6B with separate methyltransferase 
enzyme solutions and the use of mass spectrometry to confirm if an additional methylation has 
occurred. 
It was surprising to observe that corrin ring decoration sequences did not dictate specificity 
through variation in the length of interacting amino acid R-groups. The amino acid interactions from 
each docking study are summarised together in Table 27. It might have been the case that longer 
amino acid R-groups would be seen interacting with acetic acid chains, whereas shorter R-groups 
would be seen interacting with propanoic acid chains. This trend was not observed so it cannot be 
concluded if order of decoration helps drive specificity upon binding. It is possible that perhaps the 
order and decoration of methylations also assists through London-dispersion forces/hydrophobic 
interactions, however these would be small and unlikely to drive the docking116. It can be concluded 
that the majority of interactions do come about via serine and arginine residues but other amino 
acids and even the protein backbone can assist in docking. CobJ is the only methyltransferase that 
interacts with the C1 ethanone decoration, which faces inwardly towards the active site, whereas 
when a precorrin ligand is bound in a clockwise fashion this faces outwardly as observed in CobM 
and CobF. It would be interesting to probe this decoration further in CobA and CobI, once structures 
are obtained, as this is a more unique decoration component of the corrin ring in the first half of this 
part of the cobalamin biosynthesis pathway.   
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Figure 82: A summary of precorrin ligand docking to show clockwise and anticlockwise orientation 
where the pyrrole rings have been labelled. (A) PC4 to CobJ (3NUT.pdb) (B) PC4 to CobM 
(3NDC.pdb) (C) PC6A to CobF (3ND1.pdb) (D) PC6B to CbiE (2BB3.pdb). SAH is coloured purple, 
precorrin intermediates are coloured green and the methyltransferase protein is coloured yellow. 
Figure made via PyMOL, the PyMOL Molecular Grapics System, Version 2.0 Schrodinger, LLC. 
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Location of 
precorrin 
decoration 
 
CobJ 
 
CobM 
 
CobF 
 
CbiE 
 
 
C1 
(ethanone) 
Backbone 
S137- 3.4 
R-group 
S137- 3.0 
N164-3.4 
 
 
- 
 
 
- 
 
 
- 
 
C2 
(acetic acid) 
Backbone 
S137- 3.4 
N139-3.3 
R-group 
N139-3.2 
Backbone 
S35-3.0 
L36-3.3 
 
 
- 
 
R-group 
S82-3.2 
Other 
SAH-3.2 
C3 
(propanoic acid) 
R-group 
S169-3.0 
R-group 
T219-2.9 
 
 
- 
 
Backbone 
G42-3.1 
L80-3.4 
R-group 
H45-3.0 
C7 
(acetic acid) 
 
- 
 
- 
R-group 
D39-1.8 
S41-3.0 
Backbone 
I90-3.3 
 
 
C8 
(propanoic acid) 
 
 
- 
Backbone 
L165-3.3 
R-group 
R218-2.9 
Backbone 
V242-3.3 
R-group 
R232-3.0 
R236-3.5 
 
 
- 
 
C12 
(acetic acid) 
Backbone 
N55-3.1 
R-group 
N55-3.2 
S80-3.0 
R-group 
R137-3.1 
R-group 
R169-3.1 
R-group 
E152-3.4 
 
C13 
(propanoic acid) 
Backbone 
S80-3.2 
R-group 
S79-3.2 
S80-3.0 
 
 
- 
Backbone 
L187-3.4 
R-group 
R169-3.3 
R-group 
E60-3.4 
 
C17 
(propanoic acid) 
R-group 
R241-3.1 
Backbone 
S81-3.1 
 
 
R-group 
S120-2.8 
Backbone 
L202-3.2 
R-group 
R44-2.9 
S199-3.4 
 
C18 
(acetic acid) 
 
- 
R-group 
T54-2.9 
Backbone 
S120-3.0 
R-group 
S120-2.9 
R-group 
R44-2.9 
Table 27: A summary of all the interacting amino acid residues from the docking studies in section 
5.2.  
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5.5.3 Exploring the sequences of the b-loops and precorrin ligand decoration patterns 
By exploring the sequences of loop regions of the tertiary structure involved in precorrin ligand 
docking, it was thought that the binding interactions could be elucidated further. Given that the 
precorrin decoration does not appear to drive specificity perhaps loop regions interact with a certain 
geometry of the docked precorrin ligand. This only appeared to be the case in the post b7 loop, 
which always interacted with the south-east pyrrole ring. None of the other loop regions showed 
complete unity across the methyltransferase discussed. However, it could be concluded that the 
post b2, b3 and b4 loop were involved with interactions to the west side of docked precorrin ligands, 
whereas the post b6, b7 and post b10 loop interacted with the east side of precorrin ligands. Given 
the architecture of the canonical methyltransferases and similarity in SAM/SAH binding orientation 
this is not surprising, given the location of methylation typically occurred to the west side with SAM 
buried underneath the substrate.  
When these loop sequences were probed further to see if any similarities were present across 
these enzymes only the conserved motif GDX in the post b4 loop was consistent. It is interesting to 
note that the interacting serine residue in this loop is normally before the GDX motif, except in the 
case of CobF, which could be accountable to the ancillary reaction which has to occur before 
methylation can take place. The post b6 loop appeared to always contain at least one basic residue, 
typically an arginine and a serine, which again is not surprising given most of the precorrin docking 
interactions occur predominantly via these residues. These loops varied in length and it appears 
docking is a result of a contribution of interactions rather than one or two key residues. 
 
 
5.5.4 Concluding remarks 
These results show that the aerobic and anaerobic pairs are remarkably similar genetically and 
structurally, except in the case of CobF and CbiD. This is due to a varying ring contraction mechanism 
carried out by the aerobic pathway and completed by the ancillary reaction of CobJ. These docking 
studies show how these enzymes bind the precorrin ligands to be modified by SAM in the correct 
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orientation and geometry for methyl transfer. Some appear to do this without too firm a grip on the 
substrate, such as CobM. Others however have an apparently firmer grip such as CobF and CbiE 
which appear to have conserved basic residues that melt on to the substrate. CobJ was the only 
methyltransferase that required use of a normal mode to open the substrate-binding cleft slightly to 
allow product binding. There are lots of basic residues around to bind the substrate in CobJ, but 
surprisingly these are not conserved across the CobJ family suggesting maintenance of the general 
electrostatic potential is conserved rather than specific residues. The strength of these interactions 
is in contrast to those recently described for the product binding enzymes CobK and CobH which 
have several conserved basic residues that interact with the substrate carboxylates and clamp firmly 
around substrate and further embrace the product. 
In conclusion there are no apparent conserved amino acid residues present in each 
methyltransferase to dictate specificity or, that the length of amino acids may play a role in 
matching to specific decoration components of the precorrin ligands. Exploration of the tertiary fold 
of the canonical methyltransferases was able to narrow down the post b-strand loop regions that 
play a role in docking. There did not appear to be any key defining steric features or similarities 
across these loop regions.  
Furthermore, the methyltransferases of cobalamin biosynthesis may have similar architectures, 
with the exception of the C-terminal domain of CbiET/CobL, but the pattern and characteristics of 
substrate binding form a varied patchwork of interactions within the conserved framework and are 
able to bring about the essential methylations key to producing cobalamin. These specific loop 
regions have been identified and would provide an excellent target site for the creation of new 
cobalamin biomolecules, either through permitting new corrin ring decorations to dock or assist in 
modifying these decorations.  
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Chapter 6: Conclusions and Future 
Work 
 
6.1 Concluding remarks of crystallography 
To explore the product binding activity of CobK and CobH, the structures of the subsequent 
enzymes of the cobalamin biosynthetic pathway, CobL and CobB needed to be solved. These 
structures may have indicated regions for potential protein-protein interactions involved in the 
release of their substrates. Furthermore, the precise way by which these possible interactions are 
facilitated could have been probed further using site directed mutagenesis.  
However, the full-length structures of CobL and CobB could not be solved, even though crystals 
were successfully obtained which resulted in diffraction data being collected. Given that over many 
years numerous structures of the biosynthetic enzymes have been solved in the cobalamin pathway, 
it is of interest to consider why CobL and CobB have not. It is clear from the present work that these 
are not as readily crystallised so as to generate meaningful data. Therefore, one reason that they are 
some of the last cobalamin biosynthetic enzymes to still not have had their structures solved is that 
other research groups may also have tried and also been unsuccessful. This log jam will be resolved 
by finding the enzymes from a species that yields high quality crystals.  
CobL had the advantage that a structure of CbiET, the anaerobic equivalent, has been solved 
providing a very good model for molecular replacement. However, the quality and size of the CobL 
crystals obtained was not sufficient to attain an optimum resolution higher than three angstroms. 
Suitable models from the cobalamin biosynthesis pathway for CobB would have included the 
anaerobic equivalent CbiA, or CobQ, an enzyme further upstream, but neither of these have had 
their own structures solved. Despite confident models of the ATP binding domain and class I 
glutamine-dependent amidotransferase domain, both present in CobB, none of these seemed 
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sufficient during molecular replacement efforts. To tackle this anomalous dispersion using 
selenomethionine was attempted, but in a similar fashion to CobL the crystal quality and the quality 
of the diffraction data collected were not sufficient to solve the structure.  
Co-crystallisation of the enzyme pairs CobK/L and CobH/B was somewhat prematurely 
attempted, as further experimental research should have been carried out to confirm if a protein-
protein interaction may be occurring, indicating the likelihood of this being trapped in a crystal 
lattice. However, co-crystallisation of the enzyme pair CobK/L did result in a higher resolution 
structure of the apo-form of CobK, in a different space group, possible due to a transient interaction 
between CobL and CobK resulting in different protein contacts presenting in the packing and 
growing of the crystal. The structures solved of CobK and CobH did not reveal anything new when 
compared to existing structures. However, the flexible active site loop region of CobK was able to be 
modelled in the apoenzyme, due to crystal contacts present, highlighting how flexible this region is. 
An interesting avenue observed but not pursued due to time constraints of the project did elude to 
the possibility of an interaction between CobL, CobH and CobB. This was when the HBA signal 
recorded during thermal melt studies was not present when all these enzymes had the suitable 
substrates to facilitate the reaction pathway of PC6B to HBAD, in which the HBA signal was lost 
possibly because it was buried and hidden within a protein complex. 
 
6.2 Concluding remarks of CobK product trapping activity and release 
  
The product binding activity of CobK was confidently demonstrated, when in the presence of 
NADPH, through the use of experimental techniques including UV-VIS spectroscopy, ITC and NMR. 
This is in agreement with the existing PC6B purification protocols which rely on the isolation of 
product bound protein, which is subsequently removed after nickel column chromatography. The 
product bound crystal structure of CobK infers tight binding and encapsulation of PC6B however it is 
still not fully clear why CobK may do this. Given the similarity of PC6A and PC6B this could simply be 
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a case of mistaken identity however kinetics data and NMR showed that in the presence of CobL and 
CobLc respectively PC6B is quickly released. Given the orientation of PC6B in the active site of CobK it 
suggests that it is presented to CobL with the C15 methylation readily available. This advocates a 
protein-protein interaction is more likely to be occurring, but this may only be a transient contact 
brought about by encouraging the opening of the active site b2b3 loop rather than full protein 
docking. 
A possible argument for product trapping activity is to protect intermediates which may be labile 
or be lost to off pathway reactions. Given the similarity of the cobalamin intermediates subsequent 
enzymes in the pathway may be able to act out of turn, which would impact on the overall 
cobalamin synthesis. For example, PC6B may also be able to bind to CobB, missing out CobL and 
CobH, or alternatively HBA may be able to bind to CobQ, which carries out an identical chemical 
modification to CobB to different locations of the corrin ring. Therefore, product binding may ensure 
safe delivery of the substrate to the correct enzyme within the biosynthetic pathway of cobalamin.  
This has been highlighted from further CobK studies showing that it does not only bind its 
substrate PC6A and product PC6B, but also the incorrectly C5-methylated PC6B, observed in a crystal 
structure, showing that a previous methyltransferase has acted out of turn, due to a case of 
mistaken identity. This and preliminary observations using NMR and fluorescence spectroscopy 
demonstrate that HBA can also incorrectly bind to CobK. This certainly adds weight to the proposal 
that these enzymes exhibit product binding activity to protect intermediates from other enzymes 
which includes those within the biosynthetic pathway itself. The protein-protein interaction shown 
between CobK and CobL would ensure the safe delivery of PC6B and CobH may also interact with 
CobL to ensure HBA is delivered to CobB. Therefore, the techniques used to probe interactions 
between CobK and CobL could be extended to CobL and CobH, CobH and CobB, and possibly a larger 
multimeric protein complex between three or all four of these enzymes. 
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6.3 Concluding remarks of canonical methyltransferases  
Finally, the in silico docking studies of the canonical methyltransferases contrasts with the 
stronger binding affinities described for the product binding enzymes CobK and CobH, which contain 
several conserved basic residues to clamp and encapsulate their substrate/product. The specificity 
of the canonical methyltransferases, which have a highly conserved protein architecture, but are 
able to differentiate between the various precorrin intermediates has been explored. However it is 
still not clear how such specificity is brought about to differentiate these, given the lack of any 
conserved residues which contribute to the differentiation between these highly similar 
intermediates. The binding orientation of the subsequent pattern of corrin ring decoration also did 
not show a clear way to distinguish between these precorrin intermediates. Finally, the loop regions 
of these proteins were investigated further to determine whether the R-groups were sterically able 
to detect and dictate different precorrin docking orientations. However, it was not possible to 
conclusively show any defining features able to dictate such substrate specificity.  
6.4 Future work 
Regarding crystallography it is encouraging crystals can be obtained, however further work 
needs to be undertaken to optimise the crystal quality of the unsolved enzymes. Heavy metal 
labelling using mercury would increase the signal of anomalous diffraction data and since CobB 
contains an active site cysteine mercury would therefore be an attractive option. Given the time and 
effort already invested in this project, it may be more beneficial to attempt the crystallisation of 
CobB and CobL from different gene sequences, as there is a chance this will lead to crystals more 
readily and which are of better quality.  
A lot more time could be spent refining some of the techniques used in this project such as ITC 
and NMR to continue to probe protein-protein interactions and incorrect substrate binding. Enzyme 
assays to explore cases of mistaken identity for various Cob enzymes would include glutamine or 
ATP assays to track CobB activity and SAH assays to track the activity of the methyltransferases.  
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A further Cob protein that may have been overlooked is CobE. The synthesis of cobalamin does 
proceed without the need of this enzyme, however Deery et al, 201253 provides comprehensive 
evidence to support that CobE is a chaperone for various cobalamin intermediates including PC4, 
PC5, PC6B, PC8 and HBA. It has had its crystal structure solved (2W6K.pdb and 2W6L.pdb), but it is 
surprising that it has not been crystallised with any of these intermediates. Perhaps co-crystallisation 
studies including CobE would provide a better insight into the co-ordination of cobalamin 
biosynthetic enzymes, offering an additional but insightful layer to the complexity of the pathway, 
especially if a multimeric protein complex exists between some of the Cob proteins. 
 The canonical methyltransferases play a large role in the production of cobalamin. Through 
docking analysis, loop regions important for substrate binding have been identified. These narrow 
down the options for mutation sites, which could be coupled with SAH enzyme assays, to further 
explore and identify residues important for dictating specificity. If successful, this would provide the 
grounding to help facilitate the design and synthesis of new cobalamin molecules, where further 
mutagenesis studies could facilitate the accommodation or assist in addition of new components to 
these desired cobalamin-based molecules. 
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